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Cancer is known as one of the most frequent diseases that are responsible for 
morbidity and mortality worldwide. In general, cancer disease is characterized by 
uncontrolled growth of cells. Cancer cells proliferate in an uncontrolled manner and 
may invade the other parts of the body where they can form tumors known as 
metastases. Currently, metastases are the main cause of cancer deaths. (Dillekås et 
al., 2019; Hsu et al., 2019; Owyong et al., 2019; Wang et al., 2018) Though the 
primary cause of why some tumors metastasize and others do not, remains 
undetected. There is a group of cells, which directly bridges the primary tumor and 
metastatic tumor sites in the body. These cells are named circulating tumor cells 
(CTC). CTC are an infinite source of new information on tumor development in 
time. We believe more straightforward characterization of CTC on the molecular 
level could change the way how we think about the cancer in general.  
The universal approach “one drug fits all” has been found to become ineffective in 
the term of toxicity risks and treatment failures for various diseases. Instead, 
individual patient approach in disease management has become more preferred. 
(Matsuzaki et al., 2020; Groisberg et al., 2018; Tsongalis, 2018; Cho et al., 2012) 
The point of view, how to plan patients‘ cure, has been developed to be more 
individual, known as personalized or precision medicine which has been referred 
as “the process of tailoring medical treatment to the individual characteristics of 
each patient; to classify individuals into subpopulations, that differ in their 
susceptibility to a particular disease of their response to a specific treatment, so that 
preventive or therapeutic interventions can then be concentrated on those, who will 
benefit, sparing expense and side effects for those who will not.” along with “The 
molecular methods that make personalized medicine possible, include testing for 
variation in genes, gene expression, proteins, and metabolites as well as new 
treatments that target molecular mechanisms. Test results are correlated with 
clinical factors – such as disease stage, prediction of future disease status, drug 
response, and treatment prognosis – to help physicians individualize treatment for 
each patient.” (Martínez-Jiménez et al., 2020; Maier, 2019; Shalowitz et al., 2019; 
Coleman and Tsongalis, 2017; Rinaldi, 2016; Silbermann, 2016) 
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Application of personalized medicine includes testing of newly developed 
molecules targets from whole molecular pathways through one mutated protein and 
aims to segment heterogeneous subset of patients whose response to therapeutic 
intervention within each subset is homogenous. (Crisci et al., 2019; Wang and 
Deisboeck, 2019; Dugger et al., 2018) Molecular-genetic methods and innovative 
technologies are useful tools to apply these personalized principles in clinical 
oncology, nowadays.  
Tumor classification based on molecular characterization helps guide treatment of 
patients. The philosophy of personalized medicine has found to stop searching for 
one drug to treat all patients with a specific indication. It is necessary to focus on 
differencies in patients with the same disease who need to be treated differently, 
and to identify the best treatment for these patients and appropriate method to 
monitor the disease in a long-term perspective. (Martínez-Jiménez et al., 2020; 
Chen et al., 2019; Goldhammer et al., 2019; Kankeu Fonkoua and Yee, 2018) 
Recently, the most frequently used tests include genetic alterations testing (e.g. 
TP53 gene) (Fortuno et al., 2020; Azzollini et al., 2018; Campo et al., 2018), 
mismatch repair genes  testing (e.g. MLH1, MSH2, MSH6) (Antonarakis et al., 
2019, Xavier et al., 2019; Zhao et al., 2019) overexpression and/or amplification of 
the genes (e.g. ESR, PGR, HER2) (Schaffar  et al., 2019; Gupta et al., 2018; 
Kriegmair et al., 2018) or mutations predicting drug effectivity (e.g. KRAS, BRAF) 
(Bylsma et al., 2019; Midthun et al., 2019; Deshwar et al. 2018). The most updated 
information regarding new genes modifications may be found in The Cancer 
Genome Atlas (TCGA) of the National Cancer Institute (The Cancer Genome Atlas 
Program, 2019) 
Regular testing of these genes’ status could offer real-time monitoring of individual 
tumor development. The way how to reach this target could be connection of 
patients’ liquid biopsy (LB) with molecular-genetic analysis. CTC and cell-free 
tumor deoxyribonucleic acid (ctDNA) are tumor markers obtained from blood of 
cancer patients. Both of them are bringing a new hope into the cancer field how to 
use “liquid” information in the process of therapy choice and therapy effect 
monitoring. Current research has signified combined analysis of CTC and ctDNA 
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increases sensitivity and provides real-time information about individual patients’ 
disease status. (Gorges et al., 2019; McNamara et al., 2019; Ye et al., 2019; Onidani 
et al., 2019; Mohan et al., 2018) 
Thus, CTC represent rare cells which were previously a part of tumor tissue, were 
shedded from it, survived in circulation and are still able to form metastases. Since 
CTC are present in patients’ blood, they are a suitable tool for regular patients 
monitoring. After their enrichment several scenarios are available regarding their 
processing. We are able to observe their consecutive behaviour (growth, division, 
differentiation or ability to be part of/ to create clusters) or compare them with 
known tumor features from biopsy. This information can significantly contribute to 
overall picture of the patients’ disease in real-time. (Amantini et al., 2019; Heeke 
et al., 2019; Chen et al., 2019; Pereira-Veiga et al., 2019; Jakabova et al., 2017) 
Although wide spectrum of tumors has been studied for CTC, this thesis is focused 
preliminary on breast cancer (BC) patients. Population of CTC in blood system is 
very low. Their enrichment from blood is a crucial step which makes their 
characterisation even more challenging. In addition, we hypothesized that viable 
CTC can offer more information about cancer patients’ disease status in comparison 
with the fixed ones. We were able to enrich viable CTC, cultivate them in vitro and 
monitor their behaviour and stage by cytomorphologic methodologies. Additional 
CTC- features could be obtained by gene expression analysis of tumor- and 
chemoresistance-associated genes. These analyses are performed regularly during 
treatment process. Results from these tests are then individually evaluated, 
correlated with current primary tumor characteristics and compared to patients’ 
clinical outcomes. Long-term CTC monitoring enables to study both prognostic and 
predictive potential of CTC. 
Breast carcinoma belongs to the most extensively studied areas within the wide 
spectrum of cancer diseases. Large international meta-analyses have been focused 
on CTC role in this cancer type. Recently, prognostic relevance of CTC in both 
adjuvant treatment and metastatic settings in breast carcinoma diagnosis has been 
determined. Outcome of these intensive researches confirms CTC position in the 
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field of biomarkers to be widely used in clinical practice. (Banys-Paluchowski et 
al., 2019) 
The introduction is consists of chapters that provide insight to current knowledge 
about cancer and CTC. It explains cancer disease in general and then focus on 
process of carcinogenesis, the form of cancer cells. Another chapters are dedicated 
to cancer progression which includes actions needed for tumor growth, cancer cells 
release into circulation and development of metastasis which are essential 
mechanisms for CTC. The next chapter is focused on BC because most of the 
research was focused on this type and therefore more information about this disease 
need to be part of this dissertation work. This part includes risk factors, genes 
contributions, types and their treatment options. The important part in diagnosis and 
monitoring proces maintain biomarkers that can be also obtained from LB, since 
CTC are candidates for becoming biomarkers. The next chapter is subsequently 
dedicated to CTC, their enrichment, identification and value confirmed by research 
studies. The last chapter of introduction discusses resistence to anticancer drug 
because this phenomenon causes chemotherapy failure and continue of tumor 
growth. 
1.1. Cancer diseases 
The World Health Organisation (WHO) reported that cancer is the second leading 
cause of death, nearly 1 in 6 deaths is due to cancer. Lung, liver, colorectal (CRC), 
stomach and BC are the most common causes of death worldwide, respectively. 
(Cancer, 2018) As communicated newly, cancer became the leading cause of death 
in some high- and middle-income countries. Those countries include Sweden, 
Canada, Chile, Argentina, Poland and Turkey. (Dagenais et al 2019) WHO has also 
documented that 30-50% of all cancer events are preventable. Aside pediatric 
cancers, it usually takes decades until cancer develops. (Reiter et al, 2018) Risk 
factors contributing to tumor diseases development have already been revealed and 
need to be omitted for decreasing cancer occurrence. Tobacco use belongs to the 
most dangerous activity which is strongly connected to cause many types of cancer, 
including lung, oesophagus, larynx or mouth. Second-hand smoking has been 
proven to cause lung cancer and smokeless tobacco causes oral, oesophageal and 
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pancreatic cancer. Risk of cancer is also increased by alcohol consumption, often 
combined with tobacco. Alcohol-related tumor diseases include CRC, BC or liver 
cancer. Moreover, imbalanced physical inactivity in combination with dietary 
factor can support development of obesity-related cancers like oesophagus, 
pancreas, CRC, endometrial or kidney cancer. There are also non-modifiable 
factors such as age, race or family history that it is not possible to alter. In addition, 
some harmful environmental factors are also integral part of our lives, which can 
be rarely affected by individuals. Infections, radiation and environmental pollution 
are among the most important ones. (Gomes et al., 2020; Wang and Zhang, 2020; 
McKenzie et al., 2016; Midha et al,2016; Olver, 2016) 
1.2. Cancer cells 
Cancer disease is a result of a normal cell to a malignant cell transformation by a 
process called carcinogenesis. A lot of factors can contribute to this process. It 
includes genetic and metabolic transformation which is necessary for cancer 
initiation. Malignant character and behaviour of cancer cells (growth, proliferation, 
migration, and invasion) requires significant changes in metabolism to provide the 
sufficient energy supply.  
1.2.1. Carcinogenesis  
Carcinogenesis process has been intensively studied for decades. The process may 
be divided into three phases: Neoplastic transformation, Genetic / Metabolic 
Facilitative and Malignant. (Figure 1) These phases cover processes included in 
oncogenic transformation, metabolic transformation and malignancy.   
The relationship between cell’s activity and metabolism has been revealed as 
important part of carcinogenesis mechanism understanding. Costello and Franklin 
referred axioms of cell activity and cell metabolism for defining these principles. 
1. The existing intermediary metabolism of a cell provides the 
bioenergetic/synthetic/catabolic requirements that are essential for the 




2. When the activity of a cell changes, its metabolism must also be altered to 
provide new bioenergetic/synthetic/ catabolic requirements for the cell’s 
changing activity. 
3. Malignant cells are derived from normal cells that have undergone genetic 
transformation to neoplastic cells that have malignant potential. 
4. Manifestation of the malignant potential of the neoplastic cell necessitates 
alterations in its metabolism (i.e., metabolic transformation) to provide the 
bioenergetic, synthetic, and catabolic requirements of malignancy. 
5. In the absence of the metabolic transformation, the neoplastic cell will not 
progress to a malignant cell with its manifestation of malignancy. 
Conversely, the metabolic transformation, in the absence of the genetic 
transformation to a neoplastic cell, will not cause malignancy. 
6. Genetic transformations and proteomic changes have little relevancy if the 
genetic/proteomic alterations are not manifested as changes in cell 
metabolism and function. The absence of identified genetic transformations 
and proteomic changes does not demonstrate the absence of changes in cell 
metabolism and function. 
Cancer initiation, in the term of genetic/metabolic concept defines cancer as a 
genetic disease, requiring series of gene alterations, which produce mutations that 
activate oncogenes, mutations that inactivate tumor suppressor genes and influence 
genes stability (leading to increased mutation rates of other genes) known as 
oncogenic transformation. (Ebron et al., 2019; Böttcher et al., 2015; Volgenstein 
and Kinzler, 2004). Results of these events are neoplastic cells (genetically 
transformed cells which have malignant ability potential). This part of 
carcinogenesis is called a neoplastic transformation phase. (Sewastianik et al., 




Figure 1.: Schematic representation of genetic/metabolic transformation proces of carcinogenesis. 
(adapted and modified from Costello and Franklin, 2012) 
The next step to achieve fully malignant cells includes genetic and metabolic events 
occurred via oncogenic-initiated cascading and progressing signalling pathways 
and factors. Process is illustrated in Figure 1. (Costello and Franklin, 2012)  
This multistep process includes also epigenetic changes which develop in cancer 
cells. The level of epigenetic changes increases with time and the changes are stable 
because despite toxicants’ removal (arsenic exposure) after malignant 
transformation, both malignant phenotype and epigenetic changes remains. 
Epigenetic modification has also been connected to gene expression changes which 
can correspond to malignant phenotype progression. (Futscher et al., 2013; Chang 
et al., 2010)  
1.3. Tumor growth (cancer progression) 
Malignancy is presented by increasing mass of malignant cells which is following 
different oxygen gradient exposure from normoxia through hypoxia to anoxia. 
Under these limited conditions of lacking nutrients and limited removal of wasteful 
metabolic products are quiet and direct necessary activities. (Costello and Franklin, 
2012; Hanahan and Weinberg, 2011; Alqawi et al., 2007; Dang and Samenza, 1999) 
In fact, tumor growth is essential for successful invasion and spread of disease 
through body. Both angiogenesis and lymphangiogenesis belong to the most 




Figure 2.: Schematic representation of potential metastatic routes via lymphatic vasculature and 
lymph nodes (yellow) and blood vessels (red). (adapted from Achen and Stacker, 2008)  
1.3.1. Angiogenesis 
Growth of blood vessels, known as angiogenesis, belongs to one of the most 
important processes in our body. These capillaries are used for nutrients and 
metabolites exchange by diffusion mechanism. In general, angiogenesis can be 
affected by our life style habits. Therapeutic influences of this mechanism have 
been found to be effective in many diseases (cardiovascular diseases, wound 
healing, rheumatoid arthritis, etc.).  (Ondrovics et al., 2017, Bartolucci et al., 2014)  
Assumption that angiogenesis process is essential also for tumor growth and 
metastasis was proposed many years ago. Group of Folkman in collaboration with 
his colleagues (Sherwood et al., 1971) performed several experiments to 
demonstrate dependency of tumor invasive growth on neovascularization, 
including tumor angiogenesis in rabbit eye. They observed angiogenesis is used by 
tumors from 1-2 mm3 of size for their growth and development. From the avascular 
environment of cornea, the slow growth of tumor at a linear rate was reported but 
after vascularization exponential development was observed. Moreover, concept of 
tumor dormancy caused by neovascularisation prevention was revealed. Viable and 
mitotically active tumor cells were in the aquaneous fluid of the rabbit eye up to 6 
weeks. They were avascular and limited size. After their implantation into 
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environment full of blood vessels, they induced neovascularization and rapid 
growth. In addition, tumor cells can also survive in the form of dormant population 
which is characterized as a balance between proliferating cells near the surface of 
the spheroid and dying cells in the centre. (Ribatti, 2008) Pre-cancerous neoplasm, 
such as “carcinoma in situ” or “intraepithelial neoplasia” lesions can be surgically 
removed as benign tumors. These ones are localized, do not spread and necessary 
nutrients and oxygen are delivered from capillaries placed under the basement 
membrane of the epithelial layer via diffusion. If cell proliferation and apoptosis 
are relatively balanced the cells can be dormant for years. In the case of prostatic 
intraepithelial neoplasia (PIN) diagnosis, tumors may be dormant for years or 
progress. Activity of those lesions types is found to remain questionable. 
(Bielenberg and Zetter, 2015) 
In tumor, angiogenesis is regulated by different types of regulators in the affected 
tissue. Hypoxia’s environment has been considered as a critical factor in this 
process. Tumor is able to overcome oxidative stress and deficiency of oxygen-
dependent energy production caused by this condition. Tumor and its 
miroenvironment is capable to stimulate new blood vessels formation which is 
attributed to vascular endothelial growth factor (VEGF). It has been found out 
hypoxia-inducible factor, (HIF)-1α, is the main compoment of molecular hypoxia-
induced angiogenesis initiation. It has been observed HIF-1α is the critical element. 
While HIF-1α is continuously synthetized and degraded during normoxic condition, 
its stabilization, accumulation and dimerization with HIF-1β in the cytoplasm has 
been observed during hypotoxic conditions. This dimer is capable to control 
expression of many genes, including VEGF. Other important supporting 
components resulted from hypoxia conditions are cytokines (such as interleukin IL-
8) or other growth factors (such as Platelet Derived Growth Factor - PDGF). 
Together with VEGF-A then contribute to angiogenesis by stimulation of Vascular 
Endothelial Growth Factor Receptor (VEGFR) on the endothelial cells surface. 





Lymphatic system is essential part of our body responsible for tissue pressure 
regulation and as important component of the immune system. Lymphatic 
capillaries go through most of our tissues apart from e.g. cartilage, epidermis, nails, 
hair, retina or cornea which belong to avascular group of tissues. (Cueni and 
Detmar, 2008) Lymphatic vessels consist of lymphatic endothelial cells, opened 
into tissue periphery which attach to the extracellular matrix by filaments. (Gerli et 
al., 2000) Drained lymph fluid is passed through lymphatic capillaries into 
collecting vessels or it is released into the blood stream through lymph nodes 
cascade. (Mumprecht and Detmar, 2009) Lymphagiogenesis does not occur in 
adults just in exception of endometrium changes during pregnancy or pathological 
state such as repair processes, chronic inflammation or tumor growth. (Cueni and 
Detmar, 2008; Proulx et al., 2007; Red-Horse et al., 2006) 
For successful lymphagiogenesis action, several growth factors are required. This 
group includes vascular endothelial growth factor-C (VEGF-C) and vascular 
endothelial growth factor-D (VEGF-D) which bind to vascular endothelial growth 
factor receptor-3 (VEGFR-3) on lymphatic endothelial cells, hepatocyte growth 
factor which binds to c-met receptor or angiopoietin-1 which binds to Tie2 receptor 
(Mumprecht and Detmar, 2009; Morisada et al., 2005; Kajiya et al., 2005; Tammela 
et al., 2005) VEGF-C have become the most studied lymphagiogenesis factor in the 
manner of BC, melanoma, CRC, endometrial or ovarian cancers. Expression of 
VEGF-C in tumor or tumor-associated cells correlated with lymph node metastasis 
and poor prognosis. (Mumprecht and Detmar, 2009; Rinderknecht and Detmar, 
2008; Pepper et al., 2003) 
Lymphagiogenesis is a serious problem in cancer patients because it is associated 
with tumor invasion and metastasis. It occurs in tumor periphery and the inner-
tumor cell mass. Tumors often metastasize to their regional lymph nodes via 
lymphatic vessels. Lymph node status is used to estimate survival and to choose 
appropriate clinical management strategy. (Mumprecht and Detmar, 2009; Van der 




1.3.3 Stem cells and their role in cancer 
One of the current questions which have to be answered is where are the cancer 
cells coming from. Therefore, the role of stem cells dispered in the adult tissues still 
remains a matter of debate.  
Stem cells are characterized by preserved ability to divide thanks to self-renewal. 
They are able to generate mature cells of appropriate tissue through differentiation 
process. Their incidence differs between tissues but as reported earlier they are rare. 
(Geraili et al., 2018; Reya et al., 2001) They need specific environment, factors and 
cytokines to survive. (Aponte and Caicedo, 2017; Guo et al., 2016; Wu and Izpisua 
Belmonte, 2016; Ouspenskaia et al., 2016) Stem cells have an important mission in 
keeping homeostasis within organism. They are responsible for replacing cells and 
maintaining functions of organ by self-renewing and regulating their quantities in 
environment of physiological and abnormal conditions. (Aponte and Caicedo, 
2017; Shenghui et al., 2009; Alison et al., 2002) Adult stem cells present in tissues 
have partially limited differentiation potential. (Lane et al., 2014; Scadden et al., 
2014; Morrison and Spradling, 2008) Despite different locations, all stem cells 
share similar characteristics such as long cell cycling, self-renewal capacity, 
microenvironmental protection, genome repair abilities or undifferentiated status 
combined with differentiating potential. (Aponte and Caicedo, 2017; Alison et al., 
2002) These cells are one of the main members of hierarchical organization known 
as Stem Cell Systems (SCSs) which are the part of almost all major organs in 
different quantities. (Aponte and Caicedo, 2017; Gage and Temple, 2013) 
Following sections are present in SCSs: the basal, the transmit-amplifying and the 
differentiation. (Alison et al., 2002) Basal compartment of this system is a residence 
of stem cells. This environment, together with other factors (extracellular matrix, 
oxygen, etc.) contributes to the stem cells survival and maintenance. (Lane et al., 
2014) Stem cells progenies then fill transit-amplifying compartment. Cells which 
are part of this section are in transient state. They have shorter cells cycle and divide 
rapidly. The differentiation compartment is residence of differentiated cells that are 
ready to perform normal tissue or organ function. Under specialized conditions, 
these cells can also dedifferentiate and add into stem cells pool. SCSs thus have 
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become highly regulated parts where balance between self-renewal and 
differentiation activity is maintained. (Aponte and Caicedo, 2017)  
Genes responsible for self-renewal have been found to work as oncogenes in 
comparison with differentiating ones. Tumors consist of heterogeneous cells. 
Normal stem cells and cancer / tumorigenic stem cells are able to create 
phenotypically different cells. Cancer cells heterogeneity is also partly caused by 
tumor environment. Tumors mass may be increasing also due through mutations 
that upset normal pathways and then culminate in circulating stem cells (CSCs) 
formation. (Clarke and Fuller, 2006; Reya et al., 2001). According to evidence the 
progenitor cells pools in the tumors are able to revert back to CSCs state by various 
ways, such as epithelial-mesenchymal transition. (Aponte and Caicedo, 2017) 
1.3.4 Epithelial-mesenchymal transition  
Epithelial-mesenchymal transition (EMT) is a process of biochemical modification 
to achieve mesenchymal phenotype of epithelial cell. Character of mesenchymal 
phenotype cells is presented typically by enhanced migration, invasiveness, 
increased resistance to apoptosis and elevated secretion of extracellular matrix 
(ECM) components. (Lee and Nelson, 2012; Kalluri and Neilson, 2003) Final step 
of EMT consists of underlying basement membrane degradation so that the 
mesenchymal cells can migrate from the epithelial layer of its origin. (Angadi and 
Kale, 2015; Kalluri and Weinberg, 2009; Lee et al., 2006)  
The term “epithelial-mesenchymal transformation” meaning a conversion from 
epithelial to mesenchymal state was used by Elisabeth Hay as first. She used a chick 
primitive model to determined dramatic phenotypic changes performed. (Kalluri 
and Weinberg, 2009) Because of the reversibility process and prevention to 
neoplastic transformation confusion, “transformation” was renamed to “transition”. 
A reverse process of mesenchymal-epithelial transition (MET) aims to achieve 
epithelial phenotype of cells. (Angadi and Kale, 2015; Lee and Nelson, 2012; 
Kalluri and Weinberg, 2009) Epithelial cells have apicobasal polarity, they held 
together by intracellular adhesion complexes on the basement membrane. They are 
not able to migrate and express epithelial markers. On the contrary, mesenchymal 
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phenotype is associated with absence of stable cell junctions, anterior/posterior 
polarity, increased matrix degradation and expression of mesenchymal markers. 
(Vergara et al., 2016; Kalluri and Weinberg, 2009) EMT process initiation requires 
the loss of cell-cell adhesion, alteration in expression of cell-surface protein, 
production of ECM degrading enzymes, transcription factors activation or 
expression and reorganisation of cytoskeletal proteins. (Thiery, 2003; Thiery, 2002) 
Reorganisation of cytoskeleton, loss of epithelial cell proteins such as E-cadherin, 
claudins or occluding and elevation of mesenchymal markers such as N-cadherin, 
vimentin or fibronectin belong to main characteristics of EMT process. (Trimboli 
et al, 2008; Huber et al., 2005) (Figure 3) 
 
Figure 3: Schematic representation of functional transition from epithelial cells through intermediate 
phenotypes into mesenchymal cells. Characteristic epithelial and mesenchymal markers are shown 
below the corresponding phenotypes. Intermediate phenotype of EMT defines cells with both 
dinstict markers expression. ZO-1, zona occludens 1; MUC1, mucin 1, cell surface associated; 
miR200, microRNA 200; SIP1, survival of motor neuron protein interacting protein 1; FOXC2, 
forkhead box C2. (adapted from Kalluri and Weinberg, 2009) 
EMT process is divided into three different subtypes according to biological context 
in which they occur (Figure 4). The first type, known as type 1 EMT, is performed 
during embryo implantation and initiation of placenta formation. Primitive streak 
is generated in the epiblast layer. Epithelial cells in this tissue express E-cadherin 
and exhibit apical-basal polarity. The epithelial-like cells undergo programmed 
changes governed by specific expression of proteins linked with cell migration and 
differentiation. This form of EMT is presented during embryo implantation, 
placental development, gastrulation and organ development. (Lee and Nelson, 
2012; Kalluri and Weinberg, 2009) 
The second form of EMT, type 2 EMT, is associated with wound healing and organ 
fibrosis. Role of this mechanism is repairing tissue after trauma and inflammatory 
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damage by generating fibroblast and other cells necessary for reconstruction. This 
type of EMT can also lead to organ damage in the case of primary insult persistence. 
(Lee and Nelson, 2012; Kalluri and Weinberg, 2009)  
 
Figure 4.: Schematic representation of three types of EMT – development, wound healing and cancer 
invasion. (adapted from Angadi and Kale, 2015) 
The last EMT subtype is known as Type 3 EMT. This one is associated with cancer 
progression and metastasis. Researchers have proposed EMT activation is critical 
mechanism for malignant phenotype acquisition. This process is believed to be 
responsible for cancer dissemination. Observation of EMT activation in human 
tumors is often related to disease progression and drug resistance. It also causes 
morphological and genetic changes result from elevated migratory and invasive 
capabilities. The cancer cells are not equal in tumor mass. Epithelial and 
mesenchymal subtypes can coexist and cooperate with each other. These changes 
alter the tumor suppressor genes and oncogenes which regulate EMT system. It is 
followed by basement membrane invasion, metastasis to other locations introducing 
the terminal step of carcinogenesis process. Cancer cells derived during EMT 
process are then establishing secondary colonies which are histopathologically 
similar to original tumor. These cells have not longer mesenchymal phenotype 
which is the result of MET mechanism. (Vergara et al, 2016; Angadi and Kale, 
2015; Kalluri and Weinberg, 2009) 
Regulation of transcription factors activity and expression that induce EMT are 
dependent on signalling pathways. Signal is transmitted though intracellular kinase 
cascades to induce transcription factors that include e.g. transforming growth factor 
β (TGF-β), bone morphogenic protein (BMP), fibroblast growth factor (FGF), 
PDGF, epidermal growth factor (EGF), Wnt, Notch, Sonic Hedgehog (Shh) and 
integrin signalling. Signals tend to be cell- and tissue type-specific. Different state, 
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type or environment of cells may result from different reactions with diverse 
sensitivities. (Gonzalez and Medici, 2014; McCormack and O’Dea, 2013; Espinoza 
and Miele, 2013; Heldin et al., 2012; Thiery et al., 2009) Signaling pathways which 
are involved in EMT are showed in Figure 5. 
 
Figure 5.: Schematic representation of signalling pathways involved in EMT. ECM, extracellular 
matrix; TGFβ, transforming growth factor-β; FZD, frizzled; SMO, smoothened; SHH, sonic 
hedgehog; PTCH1, patched 1; IL-6, interleukin-6; ILK, integrin-linked kinase; GSK3β, glycogen 
synthase kinase-3β; mTORC2, mammalian TOR complex 2; TRAF6, TNF receptor-associated 
factor 6; TAK1, TGFβ-activated kinase 1; MKK, MAPK kinase; JNK, JUN N-terminal kinase; 
SHCA, SRC homology 2 domain-containing-transforming A; GRB2, growth factor receptor-bound 
protein 2; SOS, son of sevenless; NFκB, nuclear factor-κB; TCF, T cell factor; LEF, lymphoid 
enhancer-binding factor 1; GLI1, HH signalling, glioma 1; STAT3, Janus kinase (JAK)–signal 
transducer and activator of transcription 3; HIF1α, hypoxia-inducible factor 1α. (adapted from 
Lamouille et al., 2014) 
1.3.4.1 Epithelial-mesenchymal transition markers with clinical relevance 
It turns out, that markers associated with EMT may have impact on cancer patients. 
Lower level of E-cadherin expression is one of the typical signs of the ongoing 
EMT transition. Secretion of β-catenin into the cytosol and nucleus, possibly, is 
often connected with reduced E-cadherin expression. This association was found in 
triple-negative and basal-like types of BC samples by immunohistochemical 
analysis. (Vergata et al., 2016; Geyer et al., 2011; Jeanes et al., 2008) On the other 
hand, high expression of E-cadherin can be a positive indicator for disease-free and 
overall survival in squamous cell lung carcinoma patients but abnormal expression 
of this marker is also associated with poorer differentiation degree in the case of 
esophageal cancer. (Xu et al., 2014; Zhang et al., 2013)  
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Decreased level of E-cadherin is often associated with elevated N-cadherin 
expression. Its overexpression has been associated with poor differentiation, 
reduced overall survival and advanced Tumor, Nodes, Metastasis (TNM) stage in 
numerous cancer types. (Hiu et al., 2013; Di Domenico et al., 2011; Lascombie et 
al., 2006) Snail, Slug and Twist proteins have been found to be correlated with poor 
survival, worse outcome and advanced stages in more types of cancer. In the case 
of BC, Snail, Twist and Twist/Snail ratio have been revealed as predictive for 
metastatic and distant relapses. (Vergata et al., 2016; Muenst et al., 2013; Tran et 
al., 2011; Jouppila-Mättő, 2011) 
Expression of vimentin (VIM) is related to EMT, too. Aggressive behaviour, 
metastatic potential, chemoresistance, high histological grade and poor prognosis 
can be predicted by determination of its expression alone or in combination with 
other markers in several cancer types. In BC, higher expression of VIM was 
detected in triple-negative BC in comparison with other BC types and correlated 
with high Ki67 expression, nuclear grade, poor prognosis and younger age. 
(Vergata et al., 2016; Karihtala et al., 2013; Satelli and Shulin, 2011) 
1.4 Metastatic models  
In the majority of the cancer cases, tumor-associated deaths are caused by 
metastasis. Overall, metastatic process is not very effective; it is driven by sequence 
of mechanical and molecular obstacles. Most of the cancer cells are not able to 
create tumors at the distant sites. Although period to new distant tumors 
establishment is individual, certain cancer types exhibit organ specific metastatic 
potential. (Figure 6) Solid tumors are likely to metastasize to preferred sites. BC 
often metastasizes to lung, liver, bone and brain; CRC to liver and lung; or lung 
adenocarcinoma likely metastasize to bone, liver and brain. It has turned out that 
the most frequent metastatic sites are found in lungs, liver, bones or brain. (Chen 
and Ahmad, 2019; Li et al., 2019; Qiu et al., 2018; Azevedo et al., 2015; Erez and 
Coussens, 2012) Mostly, initial delivery and arrest of tumor cells to specific organs 
is expected to be mainly based on blood flow circulation and/or lymphatic drainage. 
Some of the belligerent cancers spread high numbers of tumor cells to the 
circulation every day. Both streamlines of blood circulation, arterial and venous, 
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can contribute to tumor cells delivery differently. Although arteries are usually 
flexible which allows them to regulate the blood flow indirectly, veins are not 
shaped by high pressure and act as a blood reservoir. Tumor cells, located in 
circulation, are guided by blood circulation while they pass through specific organs. 
(Azevedo et al., 2015) 
 
Figure 6: Common sites of metastasis for different primary sites and cancer types. (adapted from 
Liver Metastases, 2019) 
Metastatic model known as “seed and soil” hypothesis was suggested by Stephen 
Paget based on BC patients with specific metastasis. Cancer cells, as seeds, colonize 
specific distant organs, as soil, where they are able to survive and proliferate. 
(Paget, 1989) The development process of these metastatic “seeds” into larger 
volumes is controlled by specific conditions of organ and its microenvironment. 
The majority of CTC will finally die in distant organs or before landing at distant 
organs. (Paterlini-Bréchot, 2014; Nguyen et al., 2009) Mechanical factors have 
been revealed to be a key determinant of cancer cells settlement and survival. 
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(Chambers et al., 2002) Five leading metastatic sites (lung, bone, lymph node, liver 
and pleura) are the most seeded organs for disseminating tumor cells during 
colonisation because of the “mechanical” circulation patterns. (Azevedo et al., 
2015) 
A relatively new model of metastasis considers blood flow in combination with 
organs filtering effect. In general, the model stresses the role of organs with high 
capillary vasculature that purify and filter blood. (Scott et al., 2014; Scott et al., 
2012) It is hypothesized that initial delivery and arrest of tumor cells is primarily 
regulated by physical parameters of cells. Cancer cells circulation trapping because 
of their size is proved by practical experiments. (Azevedo et al., 2015; Steinbauer 
et al., 2003; Mook et al., 2003) E.g. live imaging of brain revealed “big” tumor cells 
(mean diameter: 12-20mm) trapped by capillaries (diameter: 3-8mm). (Kienast et 
al., 2010) These mechanisms also depend on location and blood vessels diameter 
in particular areas. Although size-based restriction is an important event, active 
adhesion between metastatic cells and vascular wall is required for arrest and 
metastasis establishment. Most probably, physical arrest in combination with active 
adhesion result from metastatic cells stabilization. (Azevedo et al., 2015; Glinskii 
et al., 2005; Enns et al., 2004) 
Survival and metamorphosis of tumor cells after entering to circulation depends on 
their physicochemical interactions with other parameters that contribute to their 
successful arrest and metastasis establishment. Three of them, blood constituents, 
vascular walls and broader vascular flow pattern, play essential role in this mission. 
Tumor cells have developed various strategies to overcome problems with their size 
which is larger in comparison with other cells. Shear stress and flow velocity have 
found to be toxic for cells. Cancer cells located in the circulation preferentially 
arrest in the small blood vessels with curved, branched and stretched 
microvasculature that are usually found in lungs, liver, brain or bone (Guo et al., 
2014; Disibio et al., 2008) They may also use their deformability to move through 
capillaries and clog them. Coagulation with platelets has found to become helpful 
because they are able to surround tumor cells, protect them from immune system 
and alter shear stress. Result of agglomerate formation is its rolling on the 
endothelial surface which favours interaction between carcinoma and endothelial 
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cells through specific adhesion types. (Azevedo et al., 2015; Amini et al., 2014; 
Burdick et al., 2004) 
1.5 Breast cancer 
BC diagnosis belongs to the most frequent oncologic diseases and the most 
common cancer in women worldwide. BC risk has an increasing trend, but survival 
rates improved, in general. Main reasons include earlier and localised diagnostics, 
medical care access and progressive treatment strategies improvement. (Siegel et 
al., 2016) 
1.5.1 Risk factors for breast cancer 
Although high numbers of risk factors have been found to be partly responsible for 
BC manifestation in patients, their exact contribution is individual. They may be 
divided into those which cannot be modified (age, gender, family history) and those, 
that can (diet, smoking, physical activity). (Table 1) According to case-control 
studies provided in the Czech Republic, eight risk factors for manifestation of BC 
modification were revealed: the number of first-order relatives with breast 
carcinomas, the number of first- and second-relatives with any malignant disease, 
menarche age, the first birth age, number of breast biopsies, atypical ductal 
hyperplasia presence in biopsy sample, body mass index, and breast inflammation. 
(Novotný et al., 2016; Yang et al., 2011; McPherson et al., 2000 
Table 1: Modifiable and non-modifiable risk factors of BC manifestation in patients. (adapted from 
Breast density: over 700,000 UK women living with ‘hidden’ breast cancer risk, 2014)  
Non-modifiable risk factors Modifiable risk factors 
Age Body weight 
Gender Physical activity 
Personal cancer history Alcohol use 
Family cancer history and genetics Smoking 
Early menstruation and late menopause Exposure to hormones (Pills, in vitro 
fertilisation, hormone replacement therapy) 
Breast density Pregnancy and breastfeeding 




Standard determinants of BC contribution try to help women who may benefit from 
more intensive cooperation with clinicians to decide their personal risk. Not all of 
the women with risk factors have to develop tumor. Indeed, ordinary woman has 
about 10-15% chance of BC development but with cancerous family history the 
probability may be over 50%. (Chen et al., 2017) 
Increasing age belongs between the most important non-modifiable risk factors in 
most cancer types, including breast. Incidence is usually rising until menopause. 
Then the increase is slowlier and it starts to decline with age. BC affects 100 times 
more women in comparison with men. Surprisingly, studies have supposed that tall 
stature can be associated with increased risk. Women taller than 175 cm have bigger 
risk to develop BC in comparison with those who are shorter than 160 cm. 
(Giovannucci, 2019; Chen et al., 2017; McPherson et al., 2000) 
Relation between reproductive and hormonal factors and BC was firstly suggested 
by Bernadino Ramazzini more than 300 years ago when he noticed higher 
frequency of this disease in nuns compared with other women. (Horn and Vatten, 
2017; Chen et al., 2017) According to new studies, both the first menstruation age 
and time when menopause starts influence BC risk. Similarly, pregnancy and 
breastfeeding can be also partially involved in developing BC. It has been found 
that women who give birth multiple times and have full-term pregnancy in younger 
age have lower risk of this disease in comparison with women who have never given 
birth and were pregnant in older age, respectively. Protective effects have also been 
found in breastfeeding. (Chen et al., 2017; Yang et al., 2011; McPherson et al., 
2000) 
Other modifiable factors are usually associated with peoples’ lifestyle. Both 
physical inactivity and obesity result in unbalanced of energy between consumption 
and expenditure. Excessive amount of adipose tissue increases the risk of BC 
development and progression that is accompanied by overall and BC mortality. 
(Chan et al., 2014; Demark-Wahnefried et al., 2012; Friedenreich et al., 2010) 
Physical activity is usually connected with improved survival. (Hardefeldt et al., 
2018; Ballard-Barbash et al., 2012; Ellsworth et al., 2012) Mortality risk of young 
women patients with BC was reduced in young inactive women. Specialised 
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mechanisms have been suggested for beneficial effects of physical activity in this 
disease. (Brenner et al., 2016; McPherson et al., 2000) 
Dietary factors are strong candidates to influence BC process but evidence has not 
been clear, yet. Connection between diet and BC process has been the main subject 
of research, worldwide. Although the mortality risk is supposed to decrease with 
post-diagnostic fruit, vegetable, whole grain or protein consumption, it is to be 
increased with animal fat. Higher dietary fat consumption seems to influence BC 
risk, progression and recurrence through promotion of oxidative stress, hormonal 
dysregulation or inflammatory signalling. (Brenner et al., 2016; Makarem et al., 
2013) Recent studies suggest dietary interventions such as caloric restriction or 
fasting-mimicking diet may be used not only as a prevention strategy but also help 
during BC treatment. (Caffa et al., 2020; de Groot et al., 2020; Laudisio et al., 2020; 
Shin et al., 2020) 
1.5.2 Clinicopathological and molecular features of breast cancer 
BC is usually divided into several subgroups based on clinicopathological 
parameters that include nodal status, tumor grade, tumor size or menopausal status 
in combination with markers determinating prognosis, prediction and treatment 
selection. (Castro et al., 2019; Vallejos et al., 2010; Cheang et al., 2009; Sotiriou et 
al., 2003) 
1.5.2.1 Tumor staging and grading  
BC presence is usually revealed through breast lump examination or mammography 
screening. Results of atypical mammogram contain micro-calcification; breast 
masses or architectural distortions and suspicious masses are usually painless and 
settled in neighbouring tissue. These discoveries are then undergoing biopsies or 
ultrasound survey to determine of pathological diagnosis and more accurate 
localization. Additional information about breast tumor can be achieved by 
additional medical tests such as breast and/or chest imaging, blood count, analysis 
of liver function, magnetic resonance imaging or computer tomography scan. 
(Kuppusamy et al., 2019; Telloni et al., 2017)  
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TNM classification system is used as common nomenclature of disease. It 
categorizes BC into several subgroups by analysis of primary tumor (T), regional 
lymph nodes (N), and distant metastasis (M). The TNM results stage groups which 
provide more on prediction of patients’ outcome reflecting patients’ tumors 
heterogeneity. Additional tumor characteristics are needed to complete more 
specific information but TNM classification remains the basis of BC diagnostic 
(Table 2). (Oluogun et al., 2019; Giuliano et al., 2017) 
Pathological examination of tumors usually includes determining the rate of its 
differentiation. Similarities between normal breast cells and those of tumor are 
microscopically examined. Pathologists are focused on 3 factors – tubular 
formation, nuclear pleomorphism and mitotic activity, all of them are reflected in 
final grade decision. According to the signs, score from 1 to 3 (1-closer to normal; 
3-different from normal) are assigned to each group. These values are then summed 
up and final number defines the grade. Tumors with final score 3-5 belong to grade 
1 (well differentiated); score 6-7 are in grade 2; and score 8-9 means grade 3 (poorly 
differentiated). (Guiliano et al., 2017; Komaki et al., 2006) Lymph node status, 
tumor grade and tumor size parameters can be considered using the Nottingham 
prognostic index for invasive BC or Van Nuys prognostic index for ductal BC 
patients to survival or relapse risk estimation. (Novotný et al., 2016) 
Table 2: TNM classification and stage in BC patients. (adapted from Giuliano et al., 2017) 
Stage TNM Stage TNM 
0 Tis; N0; M0 IIIA T1; N2; M0 
T2; N2; M0 
T3; N1; M0 
T3; N2; M0 
IA T1; N0; M0 IIIB T4; N0; M0 
T4; N1; M0 
T4; N2; M0 
IB T0; N1mi; M0 
T1; N1mi; M0 
IIIC Any T; N3; M0 
IIA T0; N1; M0 
T1; N1; M0 
T2; N0; M0 
IV Any T; Any N; M1 
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IIB T2; N1; M0 
T3; N0; M0 
  
TX - primary tumor cannot be assessed 
T0 – no evidence of primary tumor 
Tis (DCIS) - Ductal carcinoma in situ (DCIS) 
Tis (Paget) - Paget disease of the nipple NOT associated with invasive carcinoma and/or 
carcinoma in situ (DCIS) in the underlying breastparenchyma. Carcinomas in the breast 
parenchyma associated with Paget disease are categorized based on the size and charac-teristics 
of the parenchymal disease, although the presence of Paget disease should still be noted 
T1 - Tumor ≤ 20 mm in greatest dimension 
T2 - Tumor > 20 mm but ≤ 50 mm in greatest dimension 
T3 - Tumor > 50 mm in greatest dimension 
T4 - Tumor of any size with direct extension to the chest wall and/or to the skin; invasion of the 
dermis alone does not qualify as T4 
pN0 - No regional lymph node metastasis identified or ITCs only 
pN1 - Micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative 
internal mammary lymph nodes with micrometastases or macrometastases by sentinel lymph 
node biopsy 
pN1mi – Micrometastases (up to 200 cells from 0.2mm to 2mm) 
pN2 - Metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph 
nodes by imaging in the absence of axillary lymph node metastases 
pN3 – metastases in 10 or more axilliary lymph nodes; or in infraclavicular lymph nodes; or 
positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more 
positive level I and II axilliary lymph nodes; or in more than 3 axilliary lymph nodes and 
micro/macro metastases by sentinel lymph node biopsy in clinically negative ipsilateral internel 
mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes 
M0 - No clinical or radiographic evidence of distant metastases 
M1 - Histologically proven metastases larger than 0.2 mm (pM) 
*for more detailed criteria see Giuliano et al., 2017: “Breast Cancer—Major changes in the 
American Joint Committee on Cancer eighth edition cancer staging manual”; Lymph nodes are 
defined as pathological (pN), definition of clinical is not viewed here. ITC – isolated tumor cell 
1.5.2.2 Molecular markers of breast cancer  
The basic BC molecular subtypes are standardly evaluated by 
immunohistochemical diagnosis of hormonal and growth receptors. Estrogen 
receptor (ESR), progesterone receptor (PGR) and human epidermal growth factor 
receptor 2 (HER2) are used for primary tumor subtypes classification. In the cases 
of more precise characterization, other markers (e.g. Ki67, mammaglobin (MGB), 
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VEGFR, p53, Phosphatase and Tensin Homolog (PTEN)) are also used. (Baker et 
al., 2019; Firouzabadi et al., 2019; Guestini et al., 2019; Dai et al., 2016; Reigosa 
et al., 2016; Fulford et al., 2006)  
ESR has become one of the most accepted biomarkers for classification of BC. This 
marker is usually present in 75% of BC tumors, which are likely well-differentiated, 
less aggressive and connected with better outcome after surgery in comparison with 
ESR negative ones. (Dunnwald et al., 2007; Putti et al., 2005) Predictive value of 
ESR is important in relation to the hormonal therapy receiving. Patients with ESR 
negative tumors rarely benefit from endocrine therapy but approximately 50% of 
patients with ESR positive tumors respond to anti-estrogen or aromatase inhibitors 
therapy. (Dowsett et al., 2006; Esserman et al., 2005) Together with ESR, also PGR 
status has been widely used for routine diagnosis of BC tumors. PGR positive 
tumors are positive in 65% - 75% of BC. PGR have found to be a helpful marker 
usually due to its relation to ESR. Although PGR positive tumors are rarely ESR 
negative, approximately 40% of ESR positive tumors are PGR negative. (Dai et al., 
2016; Regan et al., 2006) 
ESR and PGR are used for dividing tumors into four subgroups according to their 
expression: ESR+PGR+; ESR-PGR+; ESR+PGR- and ESR-PGR- (plus (+) 
represents positive; minus (-) represents negative). (Rakha et al., 2007) Defining of 
these categories belongs to first steps after diagnosis determination because of 
prognostic and predictive forecast. Both markers positivity occurs in 55%-65% BC 
tumors and their successful responsiveness to endocrine treatment has been 
observed in 75%-85% of these cases. ESR+PGR+ BC subtypes are usually 
associated with lower mortality rate, older age, smaller tumor size and lower grade. 
(Dunnwald et al., 2007; Rakha et al., 2007; Anderson et al, 2001) In contrast, ESR-
PGR- tumor types represent 18%-25% of BC tumors and are often associated with 
heterogeneity, higher grade, lower overall survival, higher recurrence rate and 
though do not respond to endocrine treatment, but anthacycline and/or taxane-based 
preoperative therapy has usually shows a good response. (Bardou et al., 2003 
Anderson et al, 2001; Ravdin et al., 1992) In addition, single positivity of one of 
the receptors, either ESR or PGR, comprises up to 17% of BC cases. They are more 
likely to be aneuploidic, of larger size, higher histological grade, and usually show 
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increased expression of genes associated with proliferation in comparison to 
ESR+PGR+ tumors. Their response to endocrine treatment is worse than in 
ESR+PGR+ BC tumors. (Rakha et al., 2007; Dunnwald et al., 2007; Arpino et al., 
2005; Anderson et al, 2001) 
Beside hormone receptors, a HER2 examination is routinely provided to classify 
BC subtypes. According to studies, HER2 positivity is usually associated with poor 
prognosis and better response to anthacycline-related regimens, taxane-combined 
regimens in comparison to HER2 negative tumors. (Gianni et al., 2009; Tubbs et 
al., 2009; Pritchard et al., 2008; Hayes et al., 2007) HER2 marker represents a target 
for new cancer drugs, in parallel. It has been also reported that tumors with HER2 
positivity likely benefit from paclitaxel addition after adjuvant therapy (doxorubicin 
+ cyclophosphamid) in node-positive BC irrespective of ESR status but 
ESR+HER2+ tumors have usually little profit from this treatment. (Dai et al., 2016; 
Hayes et al., 2007) 
Based on immunochemical results, 4 main subgroups are classified using ESR 
and/or PGR in combination with HER2. Patients with hormone receptors negative 
tumors have generally worse prognosis than ESR and/or PGR positive types. 
Current studies report that  ESR+/PGR+ HER2+ tumors have the best prognosis 
and also the best response to hormone treatment but ESR-PGR-HER2+ and ESR-
PGR-HER2- tumor types often show aggressive behaviour, poor differentiation and 
poor outcome, as next response to hormonal treatment is rare. Other markers are 
newly used for getting more information on BC tumors. (Dai et al., 2016)  
Beside HER2 also androgen receptor (AR) has been used in clinical diagnostic. 
This receptor is expressed in 90% of ESR+ and 55% of ESR- tumors. (Hu et al., 
2011; Ogawa et al., 2008) Analysis of ESR-PGR-AR- (receptors negative) and 
ESR-PGR-AR+ (molecular apocrine) groups revealed that molecular apocrine 
tumors cover 13.2% of all BC cases and are usually marked by Ki67 positivity. 
These tumors have relatively good outcome, often comparable with ESR+PGR+ 
tumor type, generally in therapy including taxanes (Dai et al., 2016; Lakis et al., 
2014; Farmer et al., 2005).   
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Ki67 is the most widely used marker of proliferation that is used mainly for 
neoadjuvant response or adjuvant therapy outcome prediction in BC. It is evaluated 
in combination with ESR, PGR and HER2. Classification of tumors into 
ESR+/PGR+HER2-Ki67+ and ESR+/PGR+HER2-Ki67- has revealed that 
subgroup with Ki67 positivity has been connected with poor outcome regardless of 
systemic therapy. (Dai et al., 2016; Miglietta et al., 2009; Cheang et al., 2009; 
Jacquemier et al., 2009; Viale et al., 2008) 
1.5.3 Molecular subtypes of breast cancer 
Various methods have been used to determine BC subtypes. In general, four main 
subgroups were defined through extensive studying of deoxyribonucleic acid 
(DNA), ribonucleic acid (RNA), microRNA and protein levels: Luminal A, 
Luminal B, HER2-enriched, and Basal-like types (Table 3). (Koboldt et al., 2012) 
Each tumor subgroup exhibits individual features, such as prognosis, incidence, 
therapy response, preferential metastatic organs or disease-free survival outcomes 
(Figure 7). (Cho, 2016; Parker et al., 2009) It has been also found out coexistence 
of more that one tumor subtype can be detected in the same patient. (Verma et al., 
2016) 
Table 3: Molecular subtypes of BC tumors. (according to Novotny et al., 2016; Cho, 2016)  
 
Subtype Characteristics Therapy 
ESR PGR HER2 Ki67 
Luminal A (grade < 
3) 
+ + - Low 
Endocrine 





Endocrine  ± CHT 
Luminal B (HER2+) + Any + Any CHT + anti-HER2+ endo 
HER2 (non-luminal) - - + NA CHT + anti-HER2 
Basal-like (ductal) - - - NA CHT 
NA, not applicable; CHT, chemotherapy; endo, endocrine therapy; plus (+) represents positive; 
minus (-) represents negative 
1.5.3.1 Luminal subtype 
Luminal tumors are the most common subtypes of all BC cases. Luminal A and 
Luminal B types make up 90-95% of ESR and/or PGR positive and HER2 negative 
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tumors. (Prat et al., 2015) It has been found that Luminal A types usually show 
higher expression of ESR-related genes, lower expression of proliferation-related 
genes and are tent to be of lower grade in comparison with luminal B tumor types. 
(Sørlie et al., 2003) Prognostic analysis revealed relatively good prognosis in the 
case of luminal subtypes but Luminal B tumors have significantly worse prognosis 
and reccurence-free survival regardless of adjuvant systemic therapy than Luminal 
A even though Luminal B tumors show higher pathological complete response 
(pCR) rate following neoadjuvant therapy. (Cho, 2016; Ng et al., 2015; Prat et al., 
2015; Sørlie et al., 2003) Various methods have been used to determine BC 
subtypes. In general, four main subgroups were defined through extensive studying 
of Anti-angiogenic approach works effectively for this tumor types based on 
progression-free survival improvement in metastatic BC (mBC) patients after 
receiving bevacizumab (anti-VEGF antibody) therapy in combination with 
paclitaxel. Although luminal tumors often poorly response to standard therapy, they 
response well to hormone medicine. Treatment response thus differs also between 
luminal tumors. (Brenton et al., 2005; Paik et al., 2004) Luminal A types may be 
treated with hormonal therapy only, a combined treatment including chemotherapy 
and endocrine therapeutics could be more effective in BC patients with luminal B 
subtypes. (Xiaofeng et al., 2015) 
1.5.3.2 Human epidermal growth factor receptor 2-enriched subtype 
Tumors with HER2 over-expression profile have been found in 15-25% of invasive 
BC cases. 40-80% of these subtypes harbour TP53 mutation and are more likely to 
be of grade 3. Hormone receptors (HR) can also play a significant role in HER2+ 
cancer cells behaviour. Among HER2-enriched subtypes, both increased disease-
free and overall survival have been rather associated with HR+ tumors in 
comparison with HR- subtypes. (Cho, 2016; Xiaofeng et al., 2015; Arteaga et al., 
2011; Perez et al., 2011) Similarly, for HR- /HER2+ group of patients significantly 
more cancer recurrences were observed. In HR-/HER2+ women, more first relapses 
in the brain and less in the bone occurred. (Iwamoto et al., 2012; Vaz-Luis et al., 
2012) Although tumors with HER2 over-expression display poor prognosis, their 
pCR is higher than in luminal tumors after anthracycline and taxanes-based 
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neoadjuvant therapy regimens. (Xiaofeng et al., 2015; Brenton et al., 2005; Sørlie 
et al., 2003; Sotiriou et al., 2003) Possibility of pCR increase to over 70% may be 
reach also by double-HER2 blockade therapy (trastuzumab + lapatinib or 
trastuzumab + pertuzumab) additionally to the anthracycline/taxane-based 
treatment. (Coates et al., 2015) Surprisingly, pCR rate is higher in HR-/HER2+ in 
comparison with HR+/HER2+ BC tumors. (Cho, 2016; Gianni et al., 2014) 
1.5.3.3 Basal subtype (triple negative breast cancer)  
Tumors of basal subtypes are characterized by absence or low expression level of 
HR and HER2, high expression of basal markers (keratines 5, 6, 14 or 17 and 
epidermal growth factor receptor (EGFR)) and genes responsible for proliferation 
in cells. It is also usually associated low breast cancer genes 1 (BRCA1) expression, 
TP53 mutation and probability of grade 3. The primary tumors are usually larger 
than ones in other groups and show very quick growth, too. (Xiaofeng et al., 2015; 
O'Brien et al., 2010; Abd et al., 2005; Paik et al., 2004; Sotiriou et al., 2003; Sørlie 
et al., 2001) Basal-like tumors have the worst prognosis from all BC types, on the 
contrary Luminal A have the longest life expectancy. (Figure 7)  
Set of triple negative breast cancer (TNBC) includes tumors of 6 main subtypes: 
two of them are basal-like, immunomodulatory, mesenchymal, mesenchymal and 
stem-like and luminal androgen receptor subtype. From these 6 subgroups, 
immunomodulatory subtype shows the best outcome while mesenchymal type 
shows the worst. (Prat et al., 2015; Lehmann et al., 2011) 
Basal tumors are often associated with several important aspects. Younger age and 
earlier menarche, high waist-to-hip ratio, lack of breast-feeding belong to risk 
factors for this subtype. Lower disease-specific survival, higher risk of local and 
regional reccurence is associated with this tumor type. (Ho-Yen et al., 2012; Carey 
et al., 2006) Chemotherapy remains the only option of treatment. Patients achieving 
pCR rates after anthacyclines/taxanes therapy are accounted for 25-35% and have 
better outcome in comparison with those, who do not. (Cho, 2016; Xiaofeng et al., 




Figure 7: Patient outcome based on breast tumor various subtypes. ER, estrogen receptor; PR, 
progesterone receptor; HER2, Human Epidermal Growth Factor Receptor 2; BRCA1, Breast Cancer 
1. (adapted from Xiaofeng et al., 2015) 
1.5.4 Genes’ contribution in breast cancer 
Family history belongs to the most relevant risk factors in the case of BC 
manifestation. If an individual has a parent or a sibling with BC, relative risk for 
BC is doubled but if one has parent and a sibling with BC, relative risk 
quadruplicates. (Keeney et al., 2017) It is generally believed that up to 10% of all 
BC and 5% to 12% of this cancer appeared in women with age less than 45 years 
old and have been developed based on genetic predisposition. (Mehrgou and 
Akouchekian, 2016; Ottini et al., 2011) The others are usually caused by somatic, 
genetic and epigenetic alterations acquired during life. Whereas inherited mutations 
are usually as loss-of-function type, they affect genes linked to cell cycle checkpoint 
activation or DNA repair. These genes, which stimulate cell growth, survival and 
division, are altered in the terms of amplifications, deletions, rearrangements and 
gain-of-function mutation, epigenetic deregulation and micro RNAs and may 
contribute in abnormal genes expression which can result in BC development. (Lee 
and Muller, 2010; Stephens et al., 2009; Croce, 2009; Esteller, 2007)  
The occurrence of germline mutations is usually rare. Frequencies of these heritable 
traits are different. The most important of hereditary mutations are found in breast 
cancer (BRCA), TP53, PTEN, Serine/Threonine Kinase 11 (STK11), Partner and 
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Localizer of BRCA2 (PALB2), E-cadherin (CDH1), Ataxia-Telangiesctasia 
mutated (ATM) or Checkpoint Kinase 2 (CHEK2) genes. (Figure 8) Although a 
degree of their penetrance can vary between high and low, lifetime risk of BC 
manifestation with these susceptibility genes is estimated to be 15-65%. (Kwong et 
al., 2016; Shiovitz and Korde, 2015; Apostolou and Fostira, 2013) (Table 4) 
 
Figure 8: Representation of breast cancer predisposition genes. CHEK2, Checkpoint Kinase 2; 
ATM, Ataxia-Telangiesctasia mutated; BRCA1, Breast Cancer 1; BRCA2, Breast Cancer 2, 
PALB2, Partner and Localizer of BRCA2; FANCA, Fanconi anemia complementation group A; 
BRIP1, BRCA1 interacting protein 1; RAD51C, RAD51 homolog C. (adapted from O'Donnell et 
al., 2018) 
On the contrary, acquired alterations result from a multistep process and include 
mainly genetic (such as copy number variations, etc.) and epigenetic (such as 
promoter methylation, etc.) changes. These modifications affect crucial cellular 
systems containing DNA repair, control of cell cycles mechanisms, adherence, 
differentiation, or normal cells metamorphosis into their malignant counterparts. 
Both proto-oncogenes’ activation (such as phosphatidylinositol-4,5-bisphosphate 
3-kinase catalytic subunit alpha (PIK3CA), c-myc (MYC), etc.) or tumor 
suppressor genes (such as TP53, BRCA1, etc.) inactivation are partly responsible 
for cells transformation and also marvellous breast cancer heterogeneity. Somatic 
alterations have been usually associated with specific tumor characteristics and can 




Table 4: Detailed description and characteristics of genes whose mutations contribute to BC manifestation. 
Gene Gene name Protein 
name 
Mutations outcome Relative 
BC risk  
Reference 
BRCA1 Breast Cancer 
susceptibility 
gene 1 
BRCA1 Microcephaly and grown disorder, 
Ovarian cancer 
tenfold Kurian et al., 2018; O'Donnell et al., 2018; Kwong et al., 2016; 
Mehrgou and Akouchekian, 2016; Mahdi et al., 2013; Stratton 
and Rahman, 2008 
BRCA2 Breast Cancer 
susceptibility 
gene 2 
BRCA2 Fanconi amemia type D1; 
Ovarian, prostate and pancreatic 
cancer 
tenfold Kurian et al., 2018; O'Donnell et al., 2018; Kwong et al., 2016; 
Mehrgou and Akouchekian, 2016; Apostolou and Fostira, 2013; 
Mahdi et al., 2013; Stratton and Rahman, 2008 
TP53 tumor protein 
53 
P53 Li-Fraumeni syndrome; sarcomas, 
leukemia, brain tumors, 
adrenocortical carcinoma, lung 
cancer 
At least 10-
fold (18 – 
60-fold) 
O'Donnell et al., 2018; Kwong et al., 2016; Wang et al., 2013; 




PTEN Cowden syndrome or PTEN 
hamartoma tumor syndrome; 
Thyroid and endometrial cancer 
At least 5-
fold 
Kurian et al., 2018; O'Donnell et al., 2018; Mahdi et al., 2013; 
Apostolou and Fostira, 2013; Tan et al., 2012; Pilarski, 2009 
PALB2 Partner And 
Localizer Of 
BRCA2 
PALB2 Pancreatic cancer 3 to 5-fold Kurian et al., 2018; O'Donnell et al., 2018; Kwong et al., 2016; 





CHK2 Li-Fraumeni and Cowden 
syndrome; colorectal and bladder 
cancer 
2 to 3-fold Kurian et al., 2018; O'Donnell et al., 2018; Apostolou and 




ATM Ataxia telangiectasia syndrome, 
ovarian cancer 
2 to 3-fold Kurian et al., 2018; O'Donnell et al., 2018; Choi and Kurzrock, 
2016; Mahdi et al., 2013; Thompson et al., 2005) 
STK11 Serine/threoni
ne kinase 11 
STK11 Peutz-Jeghers syndrome; ovarian, 
cervical, uterine, testicular, small 
bowel, and colon cancer 
At least 5-
fold 
Jiang et al., 2019; Kurian et al., 2018; O'Donnell et al., 2018; 
Apostolou and Fostira, 2013; van Lier et al., 2010; Beggs et al., 
2010 




Hereditary diffuse gastric cancer, 
colorectal cancer 
5-fold Lo, et al., 2019; Kurian et al., 2018; O'Donnell et al., 2018; 




1.5.5 Treatment selection and drug resistance strategies for different breast 
cancer types  
Therapy choice belongs to critical parts of BC treatment process. Although wide 
platform of therapeutics is available for treatment of this diagnosis, picking out the 
most appropriate drug requires detailed examination of target tumor features 
because of BC’s highly heterogeneous character. Key role in the selection process 
plays immunohistochemical analysis of HR and HER2 status which divides this 
disease into 3 basic groups as HR+, HER2+ and TNBC. (Kadam and Chaun, 2016; 
Tang et al., 2016; Tomao et al., 2015) 
Despite correct initial treatment decision, development of drug resistance is not rare 
phenomenon in BC patients. It has been concluded disease resistance is hardly 
specified to one drug type. Instead, non-responding and progressive tumors may 
behave independently regardless therapy received, such as both chemo and 
monoclonal - antibody resistant. (Bianco and Gévry, 2012; Chen and Sikic, 2012; 
Wang et al., 2012; Vu and Claret, 2012; Musgrove and Sutherland, 2009) 
1.5.5.1 Luminal types of breast cancer 
Most of the BC patients have been included in HR+ HER2- group with often good 
clinical outcome. (Kumar et al., 2018; Viale et al., 2015; Prat et al., 2015) 
Recommended treatment strategies within this group are slightly different. Patients 
with rapidly progressive disease and key organs thread have often received 
chemotherapy to disease stabilization or it can be terminated from other reason 
(unbearable toxicity, as best as possible therapeutics effect achievement). Indeed, 
both BC patients with slowly progressive disease and after chemotherapy regimens 
have usually received endocrine therapy. (Novotny et al., 2016; Tang et al., 2016) 
Mechanism of action of these drugs type can differ. (Figure 9) Therapeutics used 
in this BC types are usually able to block ESR and estrogen binding (tamoxifen, 
toremifene), interfere with ESR synthesis (fulvestrant) or inhibit estrogen synthesis 
(anastrozole, letrozole, exemestane) and are also known as selective ESR 
antagonists/response modulators, ESR expression modulators/downregulators and 
aromatase inhibitors, respectively (Figure 9). Other strategy can represent ovary 
influence to stop them estrogen production (goserelin, leuprolide, triptorelin). 
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Ovarian function can be restored after stop taking medication. (American Cancer 
Society, 2017; Breastcancer.org, 2017) 
Despite great success of endocrine therapy in BC patients’ outcomes, usually up to 
30% cases appeared to be resistant. (Tang et al., 2016) Mechanisms of this 
phenomenon need to be understood for better treatment effect achievement. It has 
been generally believed this behaviour of disease is caused by de novo or acquired 
resistance where both genetic and epigenetic changes contribute to tumor 
independent performance regardless of one and/or several therapies received. (Nass 
and Kalinski, 2015; Merenbakh-Lamin et al., 2013; Bianco and Gévry, 2012) 
Different mechanisms may take role in the case of non-responding therapy status 
occurs in BC patients. Several mutation types have been revealed in estrogen 
receptor alpha (ESR1) gene and have been found to play key role in resistance 
contribution. One of these known genetics modifications, D538G or Y537S/C/N, 
causes conformation modification of ESR1 ligand binding domain which results in 
not only tamoxifen lower affinity and ineffectiveness but also cell proliferation and 
tumor progression without hormone stimulation. Other known dangerous event 
based on fusion has been discovered. Patients with ESR1-CCDC170 mutation 
identified demonstrated more aggressive progression of tumor and higher endocrine 
treatment resistance. (Lei et al., 2019; Tang et al., 2016; Li et al., 2013) Different 
mechanism can be based on alternative pathways evolution which usually does not 
require genetic contribution. Tamoxifen resistance may be achieved by adaptive 
responses development for tamoxifen induced estrogen signalling blockage bypass. 
Examples of this situation are tumor suppressors’ downregulation (PTEN) or drug 
resistance drivers’ upregulation (protein kinase B (AKT)). (Figure 9) Other known 
resistance mechanism is active drug concentration reduction through metabolism in 




Figure 9: Schematic presentation of drugs and their signalling target used in endocrine BC treatment. 
CDK, cyclin-dependent kinase, E2, oestradiol-17 beta, EGFR, epidermal growth factor receptor, 
ER, oestrogen receptor, HDAC, histone deacetylase, HER2, human epidermal growth factor 
receptor, IGF-1R, insulin-like growth factor-1 receptor, MAPK, mitogen-activated protein kinase, 
mTOR, mammalian target of rapamycin, PI3K, phosphoinositide-3-kinase, SERD, selective 
oestrogen receptor degrader, SERM, selective estrogen receptor modulator, T, testosterone, VEGF, 
vascular endothelial growth factor, VEGFR, VEGF receptor. (adapted from Selli et al., 2016) 
1.5.5.2 Human Epidermal Growth Factor Receptor 2 - enriched subtype  
Despite relatively poor prognosis of BC patients with HER2 overexpression, these 
tumors usually respond well to HER2-receptor targeting therapies. (Cho, 2016) 
Trastuzumab, as humanized monoclonal antibody, targets HER2 extracellular 
domain and has been connected to BC patients’ survival enhancement. Since more 
than half of the treated patients with trastuzumab either develop relapse or do not 
respond, essential part of resistance mechanisms have been found out and have led 
to discover effective alternatives to current treatment options. (Butti et al., 2018) 
Detailed research has described several mechanisms such as changed drug binding 
property, downstream pathways modification or alteration HER2 status have been 
revealed to significantly contribute in BC patients de novo or acquired resistance. 
Altered binding property of trastuzumab can be achieved by both enzymatic 
cleavage of target site or epitope masking where mucin 4 (MUC4) and 
CD44/hyaluronan polymer activation has been associated with considerable 
reduced binding efficiency. Other defends of cancer cells can be modified 
regulation of downstream pathways. Elevated heterodimer formation or other ErbB 
family members activation can results from trastuzumab induced signalling 
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blockage bypass. Another mechanism includes receptor status change where lack 
of HER2 can cause trastuzumab inefficiency (Figure 9). (Tang et al., 2016; Gelmon 
et al., 2015; von Minckwitz et al., 2011; van de Ven et al., 2011)  
1.5.5.3 Triple negative type of breast cancer 
Despite TNBC is generally characterized based on negative expression of ESR, 
PGR or HER2, it has been identified at least 7 different TNBC subtypes 
characterized by particular biology features (Figure 10). Since no targeted treatment 
has been officially accepted for this diseases type treatment, traditional cytotoxic 
chemotherapeutics, anthracyclines and taxanes have been commonly used. 
Resistance occurred event in the TNBC patients is not rare, emergence of novel 
treatment strategies is essential. (Tang et al., 2016; Novotny et al., 2016; Abramson 
et al., 2014; Mayer et al., 2014) 
Newly, immunotherapy regimens have been officially approved for TNBC patients. 
If tumors show Programmed death-ligand 1 (PD-L1) positivity of at least 1% on the 
tumor infiltrating immune cell, response was observed. (Bayraktar et al., 2019; 
Mina et al., 2019; The Cancer Genome Atlas) Immunotherapy opens a completely 
new bright field of the TNBC treatment. It has been also reported objective response 
was observed in the pre/treated chemoresistant TNBC patient. (Ponomarenko et al. 
2020) As expected, the tailoring of the patients into the grous of immunotherapy 
receivers and non-receivers is quite challenging, whereby there are no strict rules 
how to decide in this very specific TNBC cases.  
Traditional and new therapeutics have been examined alone or in combination with 
other drugs. Platinum agents (cisplatin, carboplatin) belong to the conventional 
medications and cause DNA crosslink strand breaks. Patients with this medication 
combination have reached higher pCR rate without anthracyclines in 
transformation-related protein 63 (p63) positive tumor patients. Several studies 
have confirmed favourable pCR rate of cisplatin in TNBC patients. (Silver et al., 





Figure 10: TNBC subtypes distribution from The Cancer Genome Atlas (TCGA) with enriched gene 
ontology and potential therapeutic targets. TNBC, triple-negative breast cancer; BL1, basal‐like 
subtype 1; BL2, basal‐like subtype 2; IM, immunomodulatory subtype; M, mesenchymal subtype; 
MSL, mesenchymal stem cell‐like subtype; LAR, luminal subtype expressing androgen receptor; 
PARP, poly‐AD‐ribose polymerase; TP63, tumor protein 63; EGFR, epidermal growth factor 
receptor; MET, MET proto‐oncogene receptor tyrosine kinase; mTOR, mammalian target of 
rapamycin; EMT, epithelial‐mesenchymal transition; Wnt, Wnt proto‐oncogene; TFGβ, 
transforming growth factor β; IG1FR, insulin‐like growth factor 1 receptor; MAPK, mitogen‐
activated protein kinase; Rac, ras‐related family of proteins; PI3K, phosphatidylinositol 3‐kinase; 
PDGF, platelet‐derived growth factor; MEK, mitogen‐activated protein kinase kinase; FOXA1, 
forkhead box protein A1; ERBB4, v‐erb‐a erythroblastic viral oncogene homolog 4; AR, androgen 
receptor; UNC, unclassified. (adapted from Abramson et al., 2015) 
Poly-ADP ribose polymerase (PARP) inhibitors have seemed to become another 
promising approach that exhibited favourable results in BC patients carried BRCA 
½ mutation. (Robson et al., 2017; Telli et al., 2013) Target of this therapeutics is 
PARP enzyme which is essential in DNA repair pathways.  
Another possible treatment strategy in TNBC has seemed to be 
phosphatidylinositol-3-kinase (PI3K) pathway inhibition. It has been observed 
TNBC cells sensitization to DNA-damaging agents after PI3K inhibition. 
Combination of PI3K inhibitors which interact with homologous recombination 
complex followed by DNA-damaging agents has been believed to become efficient 
approach. (Mayer et al., 2014; Ibrahim et al., 2012; Juvekar et al, 2012; Wong et 
al., 2010) 
TNBC is heterogeneous disease which should not be treated uniformly. A therapy 
setting is one of the most challenging tasks in this diagnosis. Although one of the 
strategies is potential targets identification, TNBC biology may allow the disease 
multiple mechanisms development to survive and spread. Events of selective 
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inhibition one pathway followed by compensatory pathway activation are not rare. 
Approach using two or more targeted medications has seemed to have more success 
than single one. (Figure 10) (Novotny et al., 2016; Mayer et al., 2014) 
Currently, if applicable, neoadjuvant therapy in the form of combined 
anthracyclines and taxanes regimens is usually prescribed to TNBC patients. 
Results of this medication administration have revealed at least 40% of patients do 
not reach pCR. These patients have usually recurrence within upcoming 36 months. 
Approximately 30% of patients achieve pCR after neoadjuvant treatment. After 
neadjuvant chemotherapy a surgical removal of the resting tumor residuum is 
planned. In the case there is no clinical evidence of metastatic disease after tumor 
excision; patients stay in the observation without any other treatment. Although it 
is generally believed TNBC patients who have pCR achievement show favourable 
long-term outcome, applying no additional adjuvant treatment strategy has not been 
recommended by latest research data. However there are some similarities in the 
character of pre- and post- treatment tumor. Suitable post-neoadjuvant therapy is 
needed and may be personalized according to individual patients‘tumors subtypes. 
(Mayer et al., 2014; Balko et al., 2012; Guarneri et al., 2009; Jones et al., 2009) 
1.6 Biomarkers  
Personalized medicine, in the oncology field, relies on individual differences in 
patients gained from biomarkers screening. It also provides opportunities and 
impacts included in four aspects, known as P4: Preventive, Predictive, 
Personalized, and Participatory. (Kalia, 2013; Cho et al., 2012) Preventive 
represents ability to prognosticate disease risk or presence before any clinical 
symptoms appear. Role of predictive part of the P4 group is to help with optimal 
therapy choice for defined subgroup of patients. (Cho et al., 2012). Personalized 
section is focused on targets with positive effects on disease following by safe and 
effective development treatment based in this information. Participatory part is 
interested in patients‘treatment adherence. Useful effects and minimal side effects 




If speaking about the personalized medicine, we have to define the term precision 
medicine as well, as they both relate together. Precicion medicine is the medicine 
part where all of the treatment decisions are made based on the precise knowledge 
of the patients’ genom, in tumor biology - tumor genom in addition. A big increase 
of next generation sequencing applicability in daily clinical routine has enabled to 
combine the knowledge of the genotypes and phenotypes into an evidence - based 
decision, which is valued pretty much in the current oncology approach. 
Biomarkers sources are reliable and accurate measurements that indicate a normal 
biological process, a pathogenic process, or a pharmacological response to a 
therapeutic intervention. It includes clarifying parameters such as molecular and 
cellular measures from biological fluids (blood, plasma, serum, etc.), 
histopathological analysis of tissue samples or measurements by magnetic 
resonance images. (Cho et al., 2012) Biomarkers can be divided into standard and 
molecular biomarkers. Standard biomarkers have been already established into 
routine analysis which includes morphologic and functional characteristics 
(histology and grading of tumor, invasion presence, etc.). Molecular biomarkers are 
consisted of compounds and molecules that are part of the genome, epigenome, 
transctiptome, etc. Their classification is then depending on specific 
characterisation (nucleic acids, proteins, hormones, etc.). Molecular markers can be 
divided into prognostic, predictive or diagnostic according to their function. 
Diagnostic biomarkers‘occurence is associated with particular diagnosis and 
contribute to accurate diagnosis determination, prognostic biomarkers are 
connected with survival prediction, and role of predictive biomarkers is to forecast 
a probability of disease response to specific treatment. (Foretova et al., 2014; 
Williams and Stoeber, 2012; Ong et al., 2012; Reis-Filho and Pusztai, 2011)  
In the context of cancer, molecular alterations that have been used as biomarkers 
occur in DNA (gene replication, rearrangements/translocations, point 
mutations/deletions or insertions), RNA (changes in transcription and post-
transcriptional modifications) and protein (changes in translation and post-
translational modifications). Newer approaches are also using miRNAs which are 
small nucleotides (19-25bp) and take an attention by their regulation activity. 
(Goldstein et al., 2013; Demidyuk et al., 2013; Sethi et al., 2013; Ahmed et al., 
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2012; Kong et al., 2012; Bao et al., 2011) As next, exosomes and circulating free 
DNA can be tested in the circulating body liquids, too. 
1.6.1 Diagnostic biomarkers 
One of the requirements for molecules to be used in cancer diagnostic processes is 
their presence in various clinical specimens such as blood, fine needle aspirates or 
fresh frozen and paraffin embedded tumor tissue. Some of these diagnostic 
biomarkers can also act as targets for therapies. Number of this cancer biomarker 
portfolio is still growing. Molecules which are proven to be useful have already 
been incorporated in the clinical patients’ management. (Gall et al., 2013; Sethi et 
al., 2013; Ali et al., 2012; Liu et al., 2012; Liang et al., 2007)  
Diagnostic biomarkers also contribute to revelation of cancers of unknown primary 
origin (CUPs). It is very important because almost one of three cancer patients have 
already distant metastasis at the time of diagnosis. These types represent diagnostic 
of 150000 new cases of this type in the USA and the European Union. CUPs are 
found to be related to poor prognosis and non-selective empirical therapy treatment.  
Protein serum - based markers have been already introduced to the clinical practice 
and contribute to the determination of proper diagnosis, but most of them are not 
often specific enough. For example carcinoembryonic antigen (CEA) levels are test 
in gastrointerstinal tumors of epithelial origins, prostate specific antigen (PSA) is a 
leading marker in the diagnosis and treatment of prostate cancer in men, increased 
cancer antigen 125 (CA-125) levels may point on ovarian cancer in women. 
(Tomuleasa et al., 2017; tothill et al., 2013; Handorf et al., 2013) 
Performing molecular profiling of CUPs tumors is mainly based on the DNA, 
messenger RNA (mRNA), microRNA or epigenetic changes evaluation. 
Commercially available tests (often works based on mRNA and microRNA 
evaluation) are dependent on RNA quality and much more expensive in comparison 
with immunohistochemistry. Due to the CUPs diagnosis difficulty, both 
immunohistochemistry and molecular methods should be used to reveal correct 
diagnosis of diseases. (Tomuleasa et al., 2017; Oien and Dennis, 2012; 
Economopoulou et al., 2015; Golfinopoulos et al., 2009; Lazaridis et al., 2008)  
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1.6.2 Prognostic biomarkers 
Information on clinical outcomes of patients (overall survival, recurrence-free 
survival), independently of treatment, are provided based on prognostic biomarkers. 
A clinical useful prognostic biomarker must be an independent, significant factor 
that is easy to be determined and interpreted and that has some therapeutic impact. 
It can be used for patients’ treatment selection without treatment response forecast. 
(Cho et al., 2012; Ong et al., 2012; Buyse et al., 2011) However, therapy progress, 
evaluation of the tumor stage and its malignancy potencial or disease remission 
prognosis can be monitored through levels and concentrations of the prognostic 
biomarkers, too. (Nalejska et al., 2014) In the case of BC, adjuvant systemic 
treatment choice is usually based on nodal status, tumor size, tumor type/grade, 
lymphatic and vascular invasion, age, and ethnicity. Patients are classified into 5 
molecular subtypes according to immunohistochemical expression detection of 
ESR, PGR, HER2 or mindbomb E3 ubiquitin protein ligase 1 (MIB1) antibody 
(Cheuk et al., 2017; Brouckaert et al., 2012; Cho et al., 2012)  
Prognostic biomarkers are evaluated according to specific tumor types by proven 
presence of single nucleotide polymorphisms, specific mRNA molecules or CTC, 
mutations, DNA methylation changes or altered gene expression. (Nalejska et al., 
2014)  
Some of the genes responsible for normal cells growth can mutate which may 
results in increased risk of cancer diseases in individuals. These abnormal genes 
can be transferred from one generation to the next together with higher risk of 
developing cancer although majority of cancer patients have no family history of 
this disease.  
Genetic testing is recommended to reveal possible mutation presence based on the 
tumor type. Abnormal BRCA1, Breast Cancer 2 (BRCA2) and PALB2 genes 
contribute higher than average risk of developing breast and/or ovarian cancer. 
Changes in these genes may account for up to 10% of all breast cancers. (Nalejska 
et al., 2014; Genetic testing: Breastcancer.org). In addition to these mutation 
analyses, expression profiles of breast tumors are an important part of tumor 
outcome determination. Based on all the information, BC tumors are then divided 
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into several subgroups with different prognosis and treatment options. (Foretova et 
al., 2014) 
1.6.3 Predictive biomarkers 
Information about probability to react on administered treatment can be helpful in 
therapeutics regimens decision processes. It could be provided by predictive 
biomarkers. Screening of tumor specific features is important for several purposes, 
such as, reducing unnecessary treatment, avoiding toxic effects of therapeutics 
regimens or decreasing morbidity. These markers are supposed to reach overall 
health care cost reduction and may enhance quality of patients’ life. (Nalejska et 
al., 2014; Cho et al., 2012; Ong et al., 2012; Voon and Kong, 2011; Duffy et al., 
2011; Walther, 2009; Suter et al., 2007)  
BC belongs to diseases that have been cured by first monoclonal antibody known 
as trastuzumab. It belongs to target therapy regimens because this humanized 
monoclonal antibody is directed against extracellular domain of HER2. Expression 
of HER2 is a critical indicator of multiple downstream pathways activations, which 
are required for the uncontrolled proliferation of cancer cells. (Foretova et al., 2014; 
Vu and Claret, 2012) It has been found out that HER2 overexpression (tumors 
known as HER2-positive subtypes) is present in 20-30% of breast cancers. These 
tumor subtypes are associated with lower disease-free survival and overall survival 
rates in comparison with other subtypes of BC. (Vu and Claret, 2012; Browne et 
al., 2009) 
Numbers of clinically valuable predictive biomarkers are still growing. Changes in 
genes which are reflecting therapy responses are likely to be caused by point 
mutations and chromosomal aberration. One of the most studied gene alterations, 
screening mainly in the cases of CRC, are mutations in KRAS gene. Presence of 
this type of mutation is the most common in codons 12 and 13 and less common in 
61 and 146. (Nalejska et al., 2014; Loupakis et al., 2009) Results of this screening 
are helpful during therapy decision process for monoclonal antibody treatment 
(cetuximab) against EGFR extracellular domain. (Figure 11) KRAS is an important 
player in several signalling pathways in cells and its mutations lead to abnormal 
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growth, proliferation and differentiation actions. (Nalejska et al., 2014; Ong et al., 
2012; Walther, 2009) 
 
Figure 11: Representation of ligand binding to the EGFR and it triggers signaling through the 
Ras/MAPK pathway to multiple targets that may regulate ligand levels (A). Monoclonal antibodies 
to EGFR (cetuximab and panitumumab), prevent ligand binding and deactivate EGFR signaling (B). 
Mutation in KRAS can result in dysregulation of the MAPK pathway and downstream signaling in 
the absence of ligand-dependent receptor activation (C). MAPK, mitogen‐activated protein kinase; 
EGFR, epidermal growth factor receptor. (adapted from Eng, 2010) 
1.7 Liquid biopsy 
Additional testing to classical biopsies has been intensively discussed for decades. 
In ideal situation, the new test should be an easily approachable alternative to the 
relatively complicated process of tissue biopsy. Taking this fact into account, one 
would consider examination of bodily fluids. This is how the liquid biopsy (LB) era 
officially started.  
Nowadays, information obtained from classical tissue biopsy is to be compared and 
completed by LB, which includes testing of CTC and ctDNA in the most of the 
cases. Additionally, testing of circulating exosomes or/ and microRNA may be 
added. The term LB is used for sampling method of non-solid biological tissue 
which usually includes blood, salina, urine, pleural effusion, cerebrospinal fluid and 
other body fluids. Patients’ blood, as LB, is widely used in oncology. (Figure 12) 
LB is a minimally invasive or non-invasive alternative to surgical biopsies which 
provide data on tumor cells from simple blood sample. LB is used for patients’ 
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stratification, screening, tumor development and real-time treatment response 
monitoring and also to detect minimal residual disease after surgery or in era of 
possible recurrence. (Brock et al., 2015; Crowley et al., 2013) 
Patients with metastasis have often micrometastasis or macrometastasis in their 
organs but not all of them are always clinically detectable. These tumor foci often 
represent risk of disease progression due to several reasons. Direct biopsy of tumor 
or metastatic tissue is not always possible due to invasiveness or hard access. (Table 
5) Significant cost of these biopsy examinations is one of the arguments which 
prevent repeating and following tumor changes through time. For completion of 
diagnosis sufficient amount of tumor sample is necessary to obtain which is not 
always possible. Classical biopsies analysis is not usually achievable without 
conservation techniques which often lead to false positive genetic tests. (Brock et 
al., 2015; Gkountela et al., 2016) 
 
Figure 12: Schematic representation of liquid biopsy – withdrawal from blood veins of cancer 
patient. (adapted and modified from Wyatt and Gleave, 2015) 
There is also growing evidence on negative biopsy impact regarding mechanical 
tumor integrity. Cancer cells are known for their uncontrolled growth and 
proliferation which is connected to lack of cohesiveness. The cancer cells are not 
coherent enough to resist dislodging biopsy, surgical intervention or needle 
aspiration and result in migration and colonization. This theory is supported by case 
studies where patients developed cancer or exhibited tumor cells presence in their 
bloodstream after diagnostic biopsy or surgery in various cancer types. (Alieva et 
al., 2018; Yu et al., 2018; Kaigorodova et al., 2017; Marshall and King, 2016; 
Shyamala et al., 2014; Kuo et al., 2012) 
Samples from classical biopsies hardly reflect cancerous population of individual 
patients. (Table 5) Tumors and metastasis are usually consisted of cells with 
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heterogeneous profiles and evolutionary process of metastasis often forms new 
metastatic sub-clones with high heterogeneity degree whose results from critical 
differences between both primary tumor and metastasis and also metastasis 
themself. Despite these facts, patients are often treated based on information 
obtained from their primary tumors. (Aaltonen et al., 2017; Turajlic and Swanton, 
2016; Gkountela et al., 2016; Valastyan and Weinberg, 2011)  
Table 5: Comparison of biopsy, CTC and cell-free tumor DNA characteristics in patients with solid 
tumors. (according to Schaffner et al., 2020)  






Invasive, more difficult to 
obtain 












More difficult to control 
(sample processing, such 
as time to fixation, may 
cause artifacts) 








Sensitivity Abundance of cells (106-
108 cells per biopsy) 
Low cells number (⁓ 1-
1000 cells per 7.5 ml 
whole blood) 







(e.g. ESR, PGR, HER2) 
Immunohistochemistry 





feasible (whole genome, 
exome, transcriptome, 
copy number analyses) 
NGS feasible for 
candidate genes (n = 10-
100) depending on 
volume of CTC/nucleic 
acid content 
NGS feasible for 
candidate genes (n = 
10-100) depending on 





Only represents one tumor 
site 
May represent more 
comprehensive tumor 
assessment 
May represent more 
comprehensive tumor 
assessment 
Represents biology of 
tissue-based cancer at that 
site 
May not represent 
biology of “tissue-based” 
cancer 
Unknown 
Represents “live” cancer 
cells 
Represents “live” cancer 
cells 
Represents apoptotic 
cells or secreted 
exosomes 
ESR, estroger receptor; PGR, progesterone receptor; HER2, Human Epidermal Growth Factor 
Receptor 2; CTC, circulating tumor cells; NGS, next-generation sequencing; N/A,not applicable 
In general, blood as LB is an attractive concept to overcome limitations of classical 
biopsy and also allows measuring other human blood components status. CTC and 
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ctDNA are widely used as circulating blood-based biomarkers in oncology. Both of 
these analytes can significantly contribute to improve cancer diagnosis, therapy 
guidance or disease monitoring. Despite both of them are easy to obtain from 
patient, their frequency is very low so proper characterisation is challenging. 
(Schaffner et al., 2020; Bidard, 2019; Neumann et al., 2018; Calabuig-Fariñas et 
al., 2016) (Table 5) Moreover, their lifetime has been found to be similar. Half-life 
of single CTC, CTC cluster and cell-free tumor DNA is between 0.5 – 2.4 hod, 6-
10 min and 16 min - 2.5 h, respectively. (Bronkhorst et al., 2019; Kustanovich et 
al., 2019; Lozar et al., 2019; Ye et al., 2019; Chen et al., 2017)  
One of the most important difference between these two markers is their origin. 
CTC are shed from tumor tissue and most of them undergo apoptosis as a result of 
adhesion to the extracellular martix loss, hemodynamic shear forces, body immune 
system attack or drugs target. On the other hand, ctDNA is derived from apoptotic 
and necrotic tumor cells which released their DNA into blood circulation. CtDNA 
is a small fraction of cell-free DNA which is non-cancerous origin and its detection 
relies on tumor-specific detection of cell-free DNA. In general, significant 
deficiencies in cell-free DNA approach are (1) the lack of defining details of tumor 
heterogeneity; (2) only relative copy number rather than absolute one can be 
obtained; (3) establishing in vivo and in vitro models (such as cells lines, organoids 
or animal xenograft modelling) is not possible; and (4) lack of transcriptomic or 
proteomic assays. (Schaffner et al., 2020; Ye et al., 2019) 
Thus, blood withdrawal, included in sampling known as LB, is less invasive for 
patients in comparison with classical biopsy and can be performed during medical 
examination in every ambulance. (Figure 12) Information from patients’ blood is 
gained using biomarkers presence, quantity and characteristics. There are several 
assays types which can be implemented for complex characterisation of tumor 




Table 6: Schematic overview of assays types and value of obtained information. (taken and adapted 
from Schaffner et al., 2020) 
Type of analysis Information 
Enumeration Prognostic value (OS, PFS), cancer recurrence detection, 
real-time monitoring of tumor sensitivity and acquired 
resistance, algorithm for treatment to huide the use of 
marker levels over the treatment course 
Gene expression Mechanism underlying tumor metastasis understanding, 
identification of gene markers (disease progression and 
treatment response prediction) and tissue of origin 
Mutation assays Recognition of actionable targets and acquired resistance via 
acquired mutations 
Sequencing Novel targets for potentional therapies identification 
OS, overall survival; PFS, progression-free survival 
LB’s investigation allows us to evaluate tumor-specific genetic alterations, to 
influence the therapy and to reflect resistance development. One of the most 
primising biomarkers is CTC which enable scientists a real-time diseases 
monitoring. Their obtaining is minimally invasive for patients and they can be 
widely used for microscopy or both phenotypic and genomic assays. (Table 5) They 
offer information obtaining directly from intact malignant cells. (Schaffner et al., 
2020; Müller Bark et al., 2019; Soda et al., 2019; Bai and Shao, 2018; Buder et al., 
2016; Brock et al., 2015) 
1.8 Circulating tumor cells  
Metastases are still the most common reason of death in the cases of oncological 
disease. New methods for real-time disease‘monitoring have been developed 
nowadays. One of the most promising approaches uses CTC which may become 
indispensable in future. CTC are shed from tumor tissue, circulate through body of 
cancer patients and might proliferate and set up metastasis. (Figure 13) They belong 
to rare cell group placed in peripheral blood of cancer patients. They can be useful 
in real-time disease monitoring mainly due to their short half-life in circulation. 
CTC reflect actual diseases status and have been shown to be more accurate than 




Figure 13:  Schematic illustration of tumor cells spread through blood circulation. (adapted from 
Circulating Tumor Cells VS Tumor Biopsies, 2019) 
CTC as biomarkers can offer several valuable information about cancer patients’ 
tumor but the information depends very much on their separation process, detection 
and characterization. Although frequency of CTC in patients’ peripheral blood is 
often very low, enrichment methods can be introduced for successful CTC 
separation.  
1.8.1 Circulating tumor cells enrichment 
Separation of CTC has been included in CTC characterization process to capture as 
much CTC as possible for following analysis. Heterogeneity of these cells has 
forced scientists to apply new methods to reach pure and representative CTC 
population typical for individual oncological patients. Nowadays, the most used 
enrichment methods are based on differences in physical and/or biological 




Table 7: Schematic list and description of CTC enrichment methodologies. (taken and adapted from 
Bankó et al., 2019; Chen et al., 2017) 




y based filtration 
Easy and fast method 
High throughput 
High CTC and CTC 
clusters capture efficacy 
Downstream analysis of 
enriched cells 
Label-free CTC 
Unmodified and viable 
cells 
Short enrichment time 
Less cost due to lack of 
labels 
Loss of CTC with size 
equal to and smaller than 
pore size of filter 
CTC damage due to 
hemodynamic stress 
Flow pressure 
Possible interference with 
other cells (leucocytes) 
Validation issues 
(difference in size between 




Easy to use 
High throughput 






High CTC viability Loss of CTC with electrical 










Easy to scale up 
Automated systems 
Downstream analysis 
Loss of CTC 
subpopulations including 
EMTed CTC, clusters, and 
CTC cloaked by blood 
cells (no universal CTC 
antigen have been 
identified) 
Tumor-specific assays may 
be required since CTC 
phenotype varies by cancer 
type and over disease 
progression and treatment 
course 
CTC bound to the surface 
of a device can cause 








Potential to enrich all CTC 
subpopulations 





CTC, circulating tumor cells 
1.8.1.1 Physical properties used for isolation of CTC 
Isolation methods based on physical properties of CTC have become popular 
nowadays. They depend on characteristics such as size, deformability, density or 
electric charge which allow capturing of heterogeneous cells with various gene 
expression and protein profiles. (Table 7) Some of these methods enable to isolate 
viable CTC which may be helpful in their further functional characterization. 
(Ferreira et al., 2016; Zhang et al., 2016) 
Physical parameter which is often used as typical for CTC is their size. It has been 
reported that the majority of CTC is usually bigger than blood cells in various 
cancer diagnosis, although it is dependent on cancer cell fitness, different stages of 
cell cycle, media composition or fixation process. Size is utilized in the size-based 
separations technologies where filters are used to remove the most of the blood cells 
from blood samples. It has been also observed that there is enormous size 
heterogeneity between CTC in a patient. CTC have sometimes irregular shape, 
irregular nuclear membrane, multiple nucleoli and also form aggregates - in these 
aggregates CTC are smaller than non-aggregated CTC. (Bobek and Kolostova, 
2018; Zhang et al., 2016; Cho et al., 2012; Lecharpentier et al., 2011; Tan et al., 
2010) 
Deformability is another physical property used in the CTC separation 
technologies. Several studies have suggested connection between deformability, 
tumor cells and metastatic potential. In most of the studies higher deformability in 
tumor cells in comparison to nonmalignant cells has been observed. According to 
Osmulski et al., CTC isolated from castrate-resistant prostate cancer patients were 
about 7 times more adhesive and 3 times more deformable and softer than castrate-
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sensitive specimens. (Vazquez et al., 2015; Osmulski  et al., 2014; Zhang et al., 
2012; Gossett et al., 2012) 
Cancer cells can be enriched also based on their density which usually differs 
among cells present in blood stream. Based on different density a centrifugation 
process is followed by layers creation, layers are represented by cells with particular 
density typical for specific layers. It had been found that density of mononuclear 
cells and CTC is <1.077 g/ml and other blood cells and granulocytes is >1.077g/ml. 
This principle of CTC isolation is considered to be quick and simple but there is a 
risk of CTC loss by their aggregation. (Zhang et al., 2016; Rosenberg et al., 2002) 
Dielectrophoresis uses cell separation approach based on electrical properties of 
CTC applying non-uniform electric field. Cells with diverse dielectric properties 
can be manipulated or transported or separated by dielectrophoresis. Although this 
method is relatively slow, it enables to isolate cells with high accuracy and 
precision. (Zhang et al., 2016; Ferreira et al., 2016; Harouaka et al., 2014)   
1.8.1.2 Biological properties used for isolation of CTC 
CTC enrichment based on biological characteristics of cells works usually based on 
affinity reactions. Antigens which are present on the target cells surface are 
captured by antibodies.  There are two types of this immunologic selection, positive 
and negative. (Table 7) Positive selection procedure consists of pulling CTC out 
from other blood particles via antibodies against tumor-associated antigens (usually 
anti epithelial cellular adhesion molecule (EpCAM)). On the other hand, negative 
selection is removing other blood particles to “concentrate” CTC in resting 
specimen (usually anti-CD45 is applied). Although these types of separation may 
be highly specific and automatized, the newest studies are expressing concern about 
capture and analysis of heterogeneous CTC population in blood. Samples of cancer 
cells may undergo EMT and CTC of mesenchymal character are usually lost by 
applying anti-EpCAM approach. Moreover, cells with EpCAM expression has been 
also found in individuals with benign disease. (Gabriel et al., 2016; Ferreira et al., 
2016; Pantel et al., 2012) 
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CellSearch® system is the only FDA (US Food and drug Administration) approved 
technology for CTC enrichment. Principles of this immunomagnetic enrichment are 
represented by ferrofluid particles with an EpCAM antibody which separate 
EpCAM positive cells from other blood particles. As next, immunostaining 
procedure to prove cytokeratin-8 (KRT8), cytokeratin-18 (KRT18) and 
cytokeratin-19 (KRT19) expression is applied together with fluorescent nuclear 
staining by 4',6-diamidino-2-phenylindole (DAPI) and lack of CD45 expression 
confirmation determined by negative CD45 staining. As the historically first 
accredited CTC separation system, it is used as a gold standard in comparison to 
other separation methods. (Su and Nieva, 2017) 
AdnaTest® (Adnagen AG, Germany) is also using immunomagnetic separation for 
CTC enrichment and detection. Separation of CTC is provided by magnetic, 
antibody-coated beads. Unlike Cellsearch®, in AdnaTest® a cocktail of 3 various 
cancers type specific antibodies are used. Tests for BC, prostate, ovarian and colon 
cancer have been already prepared and tested. Detection of captured cells is based 
on multiplex PCR reactions, where an expression of tumor-associated markers is 
determined. (Ferreira et al., 2016)  
These two methods, CellSearch® and AdnaTest® have already been tested in 
parallel resulting in positivity rate for CTC in metastatic CRC patients (33% 
patients positivity when using CellSearch® (≥3 CTC); 30% positivity when using 
the AdnaTest®; 50% if both assays were combined) but unfortunately 50% of 
patients were evaluated as negative despite of clinically detectable metastasis 
presence. (Gorges et al., 2016) 
Other relatively flexible methods have been developed for CTC enrichment by 
magnetic separation. They are based on magnetic beads connected with antibodies. 
Magnetic cell sorter (MACS) captures cells labelled with magnetic nanoparticles 
conjugated to antibodies for purposes of cell separation, enrichment and depletion. 
(Giordano et al., 2012; Pluim et al., 2012) Similarly, Magsweeper® technology is 
able to use unfractionated blood to isolate viable cells, based on immunomagnetic 
strategy. (Powell et al., 2012)   
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1.8.2 Circulating tumor cells identification 
Some of the CTC enrichment methods mentioned earlier applies a CTC 
determination step immediately after enrichment. Enumeration and characterization 
of CTC have found to represent a critical step of monitoring. Various technologies 
have been developed for their analysis but the most used ones are based on simple 
principles.   
1.8.2.1 Evaluation of enriched cells 
Detection of CTC based on cytopathologic characteristics is one of the direct 
analysis methods. It is relatively fast and offers specificity, simplicity and low cost. 
It may bring significant value in identification of oncological patients with high 
recurrence or metastasis risk and invasive tumors. It has been also reported that 
experienced pathologists are able to recognize circulating non-hematologic cells 
(CNHC) without malignant characteristics and identify CTC according to 
cytopathologic criteria. (El-Heliebi et al., 2013; Hofman et al., 2011) 
Based on the ISET filtration enrichment of CTC, blood samples were filtered 
through 8µm pores (isolated by size – ISET technology) and CNHC were evaluated 
separately according to their states. Clusters (cellular aggregates) or single cells and 
were divided into 3 classes, malignant features (CNHC-MF), uncertain malignant 
features (CNHC-UMF) and benign features (CNHC-BF) according to 
cytopathologic criteria fulfilment.  
Single CNHC has been usually considered as malignant as per following criteria: 
1. Nuclei larger than 24µm (3 times higher than 8 μm pore size) (Kamal et al., 
2019; Paterlini-Bréchot, 2014; El-Heliebi et al., 2013; Hofman et al., 2011 
2. Cell size at least 1.5 times larger than white blood cells (Kang et al., 2018; 
Nam et al., 2016; Paterlini-Bréchot, 2014) 
3. Irregular nuclei and nuclear membrane (Kamal et al., 2019; Kang et al., 
2018; Nam et al., 2016; El-Heliebi et al., 2013; Hofman et al., 2011) 
4. Anisonucleosis (ratio >0.5) (Kamal et al., 2019; El-Heliebi et al., 2013; 
Hofman et al., 2011) 
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5. High nuclear/cytoplasmic ratio (Kamal et al., 2019; Kang et al., 2018; Nam 
et al., 2016; El-Heliebi et al., 2013; Hofman et al., 2011) 
6. Presence of 3-dimensional sheets (Kamal et al., 2019; El-Heliebi et al., 
2013; Hofman et al., 2011 
 
Although these criteria are usually taking into account, all of them are rarely present 
in the malignant cells. Cells with malignant features are characterized by presence 
of certain amount of these features. (Kamal et al., 2019; El-Heliebi et al., 2013; 
Hofman et al., 2011) 
Incorporation of morphological CTC testing to routine cytological laboratories has 
seems to be the next step in this area. This field includes identification based on 
established criteria of cells structure in combination with labelling markers. These 
institutions perform these activities on cytology specimen therefore intergration of 
CTC identification into clinical practice can be easily applied. (Lowe, 2018) 
Studies have suggested cytomorphologic examination is relevant in the field of 
CTC detection. Although it may improve CTC presence, other molecular or 
immunological methods should be added into evaluation process to confirm 
existence and features of CTC. (El-Heliebi et al., 2013; Pantel et al., 2012; Hofman 
et al., 2011) 
Using nucleic acids for CTC characterization has become popular in last decades. 
(Table 8) Several innovative methods became a standard diagnostic tool nowadays, 
e.g. mutations, rearrangements or amplification by PCR, fluorescence in situ 
hybridization (FISH), sequencing, massive parallel sequencing, comparative 
genome hybridization (CGH), or gene expression analysis. (Cortés-Hernández et 
al., 2020; Rossi and Zamarchi, 2019; Watanabe et al., 2018) (Table 8) 
To examine RNA, gene expression analyses provided by quantitative real-time 
polymerase chain reaction (qPCR) belongs to the most commonly used methods. It 
enables researchers to identify expression of genes (tumor-associated; 
chemoresistance-associated) in particular cancer types’ samples, enabling their 
identifications. (Table 8) New genes have been found to be expressed as increased 
or decreased in differently advanced oncological diagnoses; the most researched 
58 
 
are BC, CRC, prostate and lung cancer samples. Changes in the expression degree 
of tumor-specific or tumor-associated genes may be then monitored throughout 
whole treatment process. (Krebs et al., 2014; Yu et al., 2013; Chen et al., 2013; 
Dotan et al., 2009) 
To examine DNA, PCR has been also used for detection of known DNA mutations 
in tumor cell samples. (Table 8) Particular gene mutations are often associated with 
worse survival, cancer behaviour or therapy resistance which may bring a valuable 
information for clinicians to support the choice of the most suitable way of 
treatment. In CRC some patients’ specific mutations in KRAS and PIK3CA genes 
have been detected through specific PCR reactions. (Harouaka et al., 2014; Gasch 
et al., 2013) 
Next generation sequencing (NGS) has brought a completely new insight into 
molecular characterisation of CTC and tumor disease themselves. It enables 
researches to demonstrate tumor cells and CTC heterogeneity; it enables disease 
monitoring in time and stresses the possibility of adapting treatment strategies for 
an individual patient in a process of personalized and precision medicine. (Table 8) 
CTC may provide a better way how to understand an actual real-time status of 
disease. In several research publications some important mutations detected in 
primary tumor and metastasis tissue were found to be present in CTC, too. 
Moreover, mutations which were detected in CTC first, have been also confirmed 
in the primary tumor and metastases of the patient. NGS may be also helpful in the 
process of identification of resistant cancer types which could significantly increase 
number of patients responding to administered therapies. (Heitzer et al., 2013; 
Lianidou et al., 2013; Powell et al., 2012; Gerlinger et al., 2012) 
FISH is a cytogenetic method based on nucleic acid complementarity. Labelled 
probes specifically bind to the particular part of RNA and DNA sequences in 
heterogeneous population of cells. It is an appropriate technique for detection of 
several types of mutations (amplifications, deletions, etc.) in cytological samples. 
(Table 8) It is one of the most known and used approach is examination of HER2 
status in BC CTC where different HER2 status in primary tumor and CTC within 
one patient has been reported. (Zhang et al., 2016; Harouaka et al., 2014) 
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Table 8: Presentation of laboratory methods used in molecular-genetic assays. (taken and adapted 
from Soekojo  et al., 2018; Tomac et al., 2017; Cote and Datar, 2016; Khodakov et al., 2016; The 
Bench Staff, 2015; Furrer et al., 2015) 




Method based on 
exponencial 
amplification of target 
DNA; relative 
quantification of target 
DNA sequences through 
real-time monitoring of 
the PCR amplification 
process 
Rapid and quantitative 
analysis of gene 
amplification; small 
quantities of DNA 
fragments are required; 
flexible, cost- and time-
efficient technique; dynamic 
range and an accurate 
quantification; high 
molecular sensitivity 
Not possible to gain 
information regarding 
morphology; accurate 
CTC number can not be 
estimated; RNA 
fragmentation; nability 
to perform highly 
multiplexed assays 
NGS High-throughput 
sequencing followed by 
mapping and counting 
the sequence of interest 
to determine absolute or 
relative copy number 
Identification of both large 




suitable for nucleic acid 
analysis and diagnostic 
requiring multiplexed 
analysis of many genes and 
their variants 





complicate the calling of 
variants, especially low 
frequency ones 
(F)ISH Hybridization of labelled 
nucleotide sequence to a 
complementary RNA or 
DNA target sequence 
Can be applied to DNA and 
RNA; study of specific 
gene amplification, 
deletion, CNVs and/or gene 
rearrangements; ability to 
vizualize genomic 
alterations, same sample 
could be used for repeated 
imaging for different genes 
behing; high sensitivity 
Time-consuming; 
expensive equipment for 
signal detection and 
recognition; difficult to 





can be missed; observers 
discrepancies 
CGH Comparision of 
specimen of interest and 
reference samples – 
ability to provide 
Large aberations detection; 
ability to assess genome-
wide copy number changes; 
Expensive, requirement 
of educated personnel, 
not standard 




information of copy 
number variations along 
each chromosome 
whole genome analysis; 
high resolution 
PCR, polymerase chain reaction; RT-PCR,reverse transcriptase polymerase chain reaction ; qPCR, 
quantitative real-time polymerase chain reaction; CNVs, copy number variations; NGS, next-
generation sequencing; (F)ISH, (fluorescence) in situ hybridization; CGH, comparative genome 
hybridization 
This availability of advanced technologies enables to analyse genomes of individual 
CTC derived from clinical samples. Tumor heterogeneity assess is clinically 
important for proper management of cancer patient and novel and efficient 
treatment concept development. (Schaffner et al., 2020; Cote and Datar, 2016) 
1.8.2.2 Immunohistochemistry 
Immunostaining is one of the most widely used techniques mainly because of its 
easy integration within standard immunohistochemistry in pathology departments. 
Similarly, immunostaing used by CellSearch® system enables appling simple 
criteria for CTC identification, e.g. positive expression of cytokeratins, negative 
expression of CD45 and positive nucleus staining by fluorescent DAPI dye qualifies 
captured cells to be evaluated as a CTC. (Cristofanilli et al., 2004) 
Clinically important markers may be also examined by immunostaining 
technology. Their prospective expression is crucial in therapy decision. This 
method can be used in HER2 and EGFR expression status of CTC evaluation, in 
BC and prostate cancer, respectively. Also, expression of keratins (e.g. KRT19) in 
CTC has been connected to worse patient outcomes. (Harouaka et al., 2014; Lazar 
et al., 2012) 
Stem cells markers status has been also examined in enriched CTC fractions by 
immunostaining/immunohistochemistry. Proteins known as associated with stem 
cell characteristics such as CD44+/CD24-, CD133+ or aldehyde dehydrogenase 
(ALDH)+ have been present in CTC, during immunostaining procedure. Except of 
stem cells markers, expression of mesenchymal markers such as TWIST, vimentin 
or N-cadherin has been investigated due to their role in EMT and metastatic process. 
(Poruk et al., 2017; Bacelli et al., 2013; Hou et al., 2013; Armstrong et al., 2011; 
Kallergi et al., 2011; Lecharpentier et al., 2011) 
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1.8.2.3 Functional assays 
Invasion capacity of CTC is one of the most important information on tumor cell 
behaviour. These cells can be studied from functional point of view mainly due to 
considerable progress in both in vitro and in vivo CTC expansion. Several 
technologies have been developed for functional CTC testing. (Alix-Panabières et 
al., 2016; Pantel and Alix-Panabières, 2016) 
The principle of functional assays is enrichment of viable CTC and ability of their 
following cultivation. Our group is using MetaCell® device for size-based 
enrichment of CTC. This technology is enabling to enrich CTC without any 
modifications on polycarbonate membrane. After enrichment, these cells are 
cultivated on the membrane for long-time. This approach allows other analysis to 
be performed. (Klezl et al., 2020; Kiss et al., 2018; Kolostova et al., 2017; Jakabova 
et al., 2017) 
EPISPOT (EPithelial Immuni SPOT) assay have been developed to distinguish 
between apoptotic and viable CTC isolated from peripheral blood of cancer 
patients. In the EPISPOT assay cells undergo short-time cultivation on a membrane 
coated with antibodies that capture secreted/released/shed proteins and those are 
then detected by secondary antibody labelled with fluorochromes. This assay has 
been already used for different tumor types including BC, prostate, ovarian, colon 
cancer or melanomas. (Alix-Panabieres, 2018; Zhang et al., 2016; Alix-Panabières 
and Pantel, 2015; Ramirez et al., 2014) Published results regarding EPISPOT assay 
concluded this technique allows establish permantnent cells lines from CTC of 
cancer patients. Kuske et al. studies CTC of high-risk prostate cancer patients. CTC 
detection by EPISPOT before radical prostatectomy correlated with PSA serum 
values and clinical tumor stage. (Kuske et al., 2016) Group of Cayrefourcq et al. 
studied circulating melanoma cells (CMCs) in patients with metastatic melanoma. 
CMCs were detected by EPISPOT assay based on their secretion of S100 protein 
(S100-EPISPOT) and compared with CellSearch®. Although more CMCs-positive 
patients were detected in S100-EPISPOT assay, results from CellSearch® showed 
association with overal survival (OS). (Cayrefourcq et al., 2019) 
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Fluoro-EPISPOT has been optimized for single CTC and its name was changed to 
EPIDROP. This technology is expected to be more reliable and sensitive in 
comparison with EPISPOT and can significantly contribute to personalized 
“oncogram” that might help to improve clinical management of patients with tumor 
disease. (Cayrefourcq et al., 2019; Alix-Panabieres, 2018)  
CTC-derived xenograpfts or CTC derived cell lines are methods to explore 
vivacious characteristics of CTC obtained from cancer patients at relevant time 
during disease development. These assays types can clarify functional features of 
CTC along with in vivo and in vitro pharmacological testing. Lab of Girotti et al. 
studied tumorigenic potential of melanoma CTC by injecting enriched CTC from 
47 patients’ blood samples into mice with success rate of 13% (6/47). It was also 
reported CTC retained metastatic, histopathologic and immunohistochemical 
features after injection to mice. The assay can be consider as new tool to study of 
melanoma biology in patients with advanced stages. This group could also suggest 
potential way of overcoming the cases when tumors are inaccessible. (Girotti et al., 
2016) Group of Pereira-Veiga developed CTC-derived xenograft from advanced 
TNBC patient. This study demonstrated tumorigenic potential of TNBC CTC and 
suggested CTC-derived xenografts as attractive in vivo model to obtain a detail 
understanding of tumor biology. (Pereira‐Veiga et al., 2018) Recent study of 
Vishnoi et al. published establishment of TNBC model with liver metastasis by 
CTC-derived xenograft method. This model recapitulated CTC biology for four 
sequential generations of mice and helped to reveal 597 genes specific to the TNBC 
liver metastasis. One of the outcomes was prediction of 6 biomarkers with clinically 
available drugs. This approach has a great potential in improvement of TNBC 
patients’ outcome. (Vishnoi et al., 2019) 
1.8.3 Prognostic value of circulating tumor cells 
CTC have been considered as prognostic biomarker in various cancer types. 
Prognostic significance has been established using immunohistochemistry and 
qPCR detection methods. Prognostic value of CTC load was studied in patients with 
metastatic carcinomas by CellSearch® technique as first.  
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A breakthrough study was organized by Cristofanilli et al. in 2004 (Cristofanilli et 
al., 2004), 177 patients with mBC were tested before a new line of treatment and at 
the first follow-up visit. 7.5ml of blood was taken and threshold was established to 
5 cells. This research work confirmed an independent character of CTC as a 
biomarker in progression-free survival (PFS) and OS in patients with this diagnosis. 
The same approach was also applied for other diagnosis.  
In a hormone-refractory prostate cancer study, 64 patients were analysed. It was 
confirmed that 5 and more CTC in 7.5ml of blood were independent predictors of 
OS. (Okegawa et al., 2009) In another study, CTC were enumerated in 430 patients 
with metastatic CRC by the same approach before and during therapy. Threshold 
for CTC level was estimated to 3 CTC/7.5ml of peripheral blood. It was found CTC 
count before and during treatment was an independent predictor of PFS and OS in 
patients with this diagnosis. (Cohen et al., 2008) 
In the case of BC metastatic diseases, many studies have been performed for CTC 
prognostic value confirmation by CellSearch® approach, similarly for metastatic 
diagnosis of lung, bladder, pancreas, ovarian, head and neck or hepatocellular 
cancer. (Andree et al., 2016; Balic et al., 2013; Krebs et al., 2011; Miller et al., 
2010; de Bono et al., 2008) CellSearch® system was also used for CTC counting 
in non-metastatic diagnosis including BC, CRC, oesophagus or bladder cancer, it 
has been found that amount of CTC was much lower. To overcome the obstacle of 
the low CTC number in non-metastatic patients, bigger volumes of blood for CTC 
examination could be considered. (Andree et al., 2016) 
Other CTC detection methods have also suggested prognostic significance of CTC 
monitoring among oncologic patients. PCR-based methods without immune-based 
pre-enrichment step have found to be helpful and sensitive tool in their 
identification. For peripheral blood mononuclear cells fraction and enriched CTC 
fraction, qPCR analyses have been used to confirm CTC presence as well. qPCR 
data were compared in the patients’ groups of both early and metastatic cancer 
diagnosis. (Skerenova et al., 2017; Tewes et al., 2015; Andreopoulou et al., 2012) 
One of the genes tested by qPCR quite exetensively is KRT19. KRT19 mRNA 
analysis was provided by Stathopoulou et al., in 77 patients with early BC after 
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surgery and 47 previously untreated patients with mBC who were tested before and 
after chemotherapy. Study data confirmed CTC as promising marker reflecting 
response to adjuvant chemotherapy. (Stathopoulou et al., 2003) Studies with similar 
approach have been performed where additionally gene expression of other markers 
have been examined such as HER2, MGB in patients with early stage BC. Poor 
clinical outcome and reduced disease-free survival (DFS) and OS have been 
associated with higher level of KRT19 alone or in combination with other markers. 
(Xenidis et al., 2009; Ignatiadis et al., 2007) Immunomagnetic separation methods 
followed by qPCR have confirmed that patients with CTC are displaying poor 
prognosis. (Molloy et al., 2011; Reinholz et al., 2011)  
Other markers have been used for CTC characterisation using qPCR before, during 
and after follow-up period in studies of CRC patients. The studies confirmed 
prognostic significance and clinical utility in response monitoring. (Balic et al., 
2013; Matsusaka et al., 2011; Iinuma et al., 2011; Rahbari et al., 2010; Papavasiliou 
et al., 2010) Studies of metastatic CRC have revealed CTC presence is associated 
with decreased OS in patients with liver metastasis. 
Recent studies have also support idea of CTC as prognostic marker. Cristofanilli et 
al. performed retrospective analysis of 2436 patients with mBC. Patients with ≥ 5 
CTC and < 5 CTC were divided into „aggressive“ and „indolent“ group based on 
CTC results, respectively. Patients in indolent group had longer OS (36.3 months 
vs. 16 months) regardless of disease subtype than patients in aggressive group. 
(Cristofanilli et al., 2019) In addition to CTC count, prognostic significance was 
demonstrated also in molecular field. Strati et al. studied prognostic significance of 
EMT-associated and stem-cell markers in EpCAM+ CTC. Significantly lower DFS 
and OS was found in patients with HR- primary tumor and those with more than 3 
positive lymph nodes that overexpressed TWIST in EpCAM+ cells. The group also 
revealed overexpression of TWIST1 and stem-cells (CD24, CD44, aldehyde 
dehydrogenase 1 (ALDH1)) transcripts present prognostic information in early BC 
patients. (Strati et al., 2019)  
Various methods used for CTC prognostic value establishment associated higher 
number of CTC with worse prognosis of both disease development and patients’ 
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survival. (Fabisiewicz et al., 2020; Hugenschmidt et al., 2020; Xun et al., 2020; 
Qiao et al., 2016; Andree et al., 2016)  
1.8.4 Predictive value of circulating tumor cells 
CTC detection has become tool to monitor real-time state of disease without the 
need of an invasive biopsy. Deeper investigation of CTC enumeration has revealed 
their presence may provide more information about treatment response in 
comparison with standard radiologic techniques, including computed tomography 
(CT) or positron emission tomography (PET). CTC have found to allow earlier non-
responsiveness detection during treatment course and avoid interreader variability 
for evaluation of radiographic scans, so they have been considered to become 
helpful in monitoring and treatment. (Alama et al., 2014; Usiakova et al., 2014; 
Balic et al., 2013; Budd et al., 2006) This predictive potential approach has been 
drawing attention. Early relapse detection might provide to spare patients the 
adverse effects of ineffective therapy and also treatment costs may be decreased by 
way of earlier ending of failed therapy. (Balic et al., 2013; Budd et al., 2006)  
1.8.4.1 Circulating tumor cells enumeration 
Patients with various BC diagnosis types have been tested for a potentially 
predictive role of CTC as a part of their therapy monitoring. Nolé et al. used the 
CellSearch® system for long-term detection of CTC in 80 mBC patients. The study 
hypothesis suggested clinical response may be indicated by changes in CTC 
enumeration and they can work as surrogate parameters during targeted therapies 
for response evaluation. (Nole et al., 2008) Another study analysed 235 mBC 
patients with various therapy regimens by CellSearch® approach. Their results 
showed little survival benefit from first-line endocrinne treatment and small benefit 
of chemotherapy alone in the cases of women with higher CTC counts. (Guiliano 
et al., 2011) Recently, Ma et al. evaluated 187 BC patients receiving chemotherapy 
by flow cytometry. Peripheral blood was withdrawn in several time points (before 
chemotherapy, a day before the third cycle of chemotherapy and a 1 week after the 
third cycle of chemotherapy). CTC numbers was examined for short- and long- term 
indicator of therapy effectiveness. Higher CTC numbers presented worse prognosis 
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after chemotherapy and shorter overall survival in tested BC cohort of Ma et al. 
(Ma et al., 2017) 
Similarly, a predictive role of CTC in patients with lung cancer has been thoroughly 
investigated. Hirose et al. investigated CTC by CellSearch® method in 33 
metastatic non-small cell lung cancer (NSCLC) patients. This study found much 
higher rate of tumor progression in patients with CTC than in CTC negative ones. 
(Hirose et al., 2012) Punnoose et al. have showed predictive significance of CTC 
during treatment in connection to radiological response and clinical outcome. In 
this study 41 patients with advanced NSCLC treated with erlotinib and pertuzumab 
were attended. An informative role of CTC cancer prediction has been suggested 
by study which noticed dramatic decrease in CTC counts at the second cycle of 
chemotherapy. (Punnoose et al., 2012) Shen et al., have studied 80 patients with 
small cell lung cancer (SCLC). This group has shown reduction of CTC numbers 
after two cycles of chemotherapy as a potential predictor of chemotherapy response. 
CTC could become indicators of treatment efficiency monitoring in patients with 
lung cancer. (Shen et al., 2017; Muinelo-Romay et al., 2014; Alama et al., 2014) 
1.8.4.2 Molecular characterization of circulating tumor cells 
Except of CTC enumeration, their molecular analysis represents a significant 
contribution to suitable strategy choice towards treatment process. Detection of new 
therapeutic targets and resistance mechanisms could be usually provided at the 
DNA, RNA and protein levels.   
At the DNA level, important mutations in key genes have been already described. 
Many various mutations have been already assigned as critical. In the case of cancer 
patients, change in KRAS gene is probably one of the well-known gene changes, 
mainly because mutations in this gene affect anti-EGFR therapy blocking the 
proliferative pathways in general. KRAS gene mutations varies between not only 
patients but also patient itself. (Alix-Panabieres and Pantel, 2016; Mostert et al., 
2013; Casch et al., 2013) BC therapy has often relied on HER2-targeted treatment 
process so activation of PI3K pathway has been also studied in this context. A 
strong heterogeneity in PIK3CA mutational status in CTC has been reported for 
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individual patients. (Ibrahim et al., 2015; Mukohara et al., 2015; Polzer et al., 2014; 
Pestrin et al., 2014) Studies have also focused not only on tumor DNA 
heterogeneity between patients but also on intra-tumor variability. Mutational status 
has been tested also before and after therapy where only few variants were shared 
in samples. (De Luca et al., 2016) Several very interesting and complex 
observations have been published last year in a Nature science journal. This paper 
suggests opportunities of potential for early diagnosis due to mutation timing that 
may occur decades prior to diagnosis. (The ICGC/TCGA Pan-Cancer Analysis of 
Whole Genomes Consortium, 2020)   
Molecular analysis includes also gene expression examination. It is usually tested 
on RNA and/or protein levels. Significance of gene expression analysis has been 
already suggested by various CTC studies. Specific genes have been studied to 
reveal presence and character of CTC and tumor disease itself. Information 
obtained from these analyses can be useful mainly in the terms of drug sensitivity 
and resistance. (Alix-Panabieres and Pantel, 2016)  
Studies of prostate cancer have identified patients with truncated form of AR, 
known as Arv7, whose presence in CTC samples could predict failure of 
antiandrogen therapy with enzalutamide and abiraterone treatment. (Steinestel et 
al., 2015; Antonarakis et al., 2014) In the case of lung cancer, aberrant expression 
of EGFR can be result of numerous mechanisms such as epigenetic modifications 
or increase in copy number variations. EGFR overexpression has been described in 
40-80% of NSCLC patients and is correlated with disease progression, decreased 
survival, lymph node metastasis and poor chemosensitivity. Patients with high 
EGFR expression have taken an advantage of clinical benefit and increased overall 
survival from monoclonal anti-EGFR antibodies, such as cetuximab, receiving. 
(Hopper-Borge and Wangari-Talbot, 2013; Pirker et al., 2012)  
1.8.5 Circulating tumor cells testing during therapy 
Monitoring of CTC has been found as a useful tool in various parts of treatment 
process. Surgery still belongs to the most common treatment procedures of cancer 
diseases if diagnosed in early stages. This type of procedure is the most ordinary 
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strategy in majority of early-stage NSCLC patients, the primary treatment of 
patients with melanomas or the first choice, in most thyroid cancers. Despite it’s 
relatively often uses in tumor diseases, many unwelcome consequences may occur. 
(DeSantis et al., 2014) In addition to surgery, other therapies have been widely used 
in various tumor diseases. This treatment usually includes receiving of 
chemotherapeutics, radiotherapy, immunotherapy, hormone or targeted therapies 
which can be administered individually or in combination with surgery or each 
other. (National Cancer Institute, 2017) 
Detection of CTC before and after surgery procedure has been usually associated 
with poor outcome. (Van Dalum et al., 2015) Recent studies have connected 
chemotherapy and targeted therapies with higher impact on CTC numbers in 
comparison to surgical treatments. Reduction of CTC-positive rates could be likely 
after neoadjuvant, adjuvant, palliative or combination treatment but not after 
surgery regardless of CTC detection method used. Long-term studies suggested 
shorter recurrence-free survival (RFS) and OS of patients with CTC presence in 
pre-surgery, one and two years after surgery but not in 1 week after surgery samples. 
Based on these results, it has been concluded chemotherapy treatment should be 
highly recommended for patients with initially CTC positive status after surgery to 
increase a chance of more favourable outcome. (Yan et al., 2017; Van Dalum et al., 
2015) 
Numbers of studies monitoring therapy efficiency using CTC have been performed 
in BC. Study of Coumans et al., have concluded that the aim of cancer treatment 
should be the elimination of all CTC; while reduction to zero CTC can be seen after 
4 to 6 weeks. To reach this aim, 10 to 12 weeks of therapy may be needed for some 
patients; and if the number does not decrease within this time span, treatment is not 
effective. (Coumans et al., 2012) CTC status has been monitored also after start of 
treatment. It has been found out in the persistently increased CTC after 21 days of 
first-line chemotherapy; more effective treatment should be highly recommended. 
Research has suggested CTC which are determined shortly before the second cycle 
of chemotherapy have been found as early predictor of treatment outcome. 
(Smerage et al., 2014; Martin et al., 2013; Rack et al., 2012) 
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Molecular testing of CTC in regular intervals can also reveal important information. 
(Figure 14) Correct timing may be useful in mainly in therapy efficiency 
monitoring. Current studies have been discussing new markers to distinguish 
patients between responders and non-responders. This information is crucial mainly 
in the term of disease cure, cancer slowdown and cancer progression. Numbers of 
markers have to be known for their contribution to disease progression. (Bobek and 
Kolostova, 2018; Leong et al., 2015) 
 
Figure 14: Schematic presentation of circulating tumor cells (CTC) response patterns in cancer 
patients during therapy courses. A) Hypothetical CTC count options in cancer patients during 
therapy. Light green cycles represent frequent sampling times, dark green cycles represent 
infrequent sampling times. B) Representation of potencial responses interpretations, simulation of 
sampling frequency when is halved from 6 to 3 sampling points. (adapted from Leong et al., 2015) 
There is no right or wrong frequency of CTC sampling. It is necessary to keep in 
mind the consequences of inappropriate timing of CTC testing. (Figure 14) 
Although low frequency of CTC testing can result from wrong assumption or 
delayed diagnosis, opposite situations have usually no more advantages. Too 
frequent withdrawals and CTC examination can lead to CTC oscillation because 
of their usually endless changing dynamics which can cause misleading trend. 
(Figure 14) Numbers of studies should be done for the most appropriate CTC 
analysis frequency determination by the highest possible withdrawals number to 




1.8.6 Circulating tumor cells in breast cancer 
For better understanding of metastatic process and spread of disease, biological 
features of CTC should be revealed as accurate as possible. Since detection of 
CTC has been usually correlated with tumor burden, it has been believed they are 
more frequent in the cases of mBC. (Bidard et al., 2016) Studies have also 
suggested CTC release starts early during progression of BC. These cells are shed 
from primary tumor and are distributed to other organs which results in metastatic 
lesion formation. (Gkountela et al., 2016; Hüsemann et al., 2008) 
Breast tumor characterization according to HR status and HER2 status has become 
a standard part of BC evaluation. Based on these results, patients can receive 
targeted therapy. Although these examinations of primary tumor can be helpful in 
therapy selection, CTC and primary tumor consistency are rare. CTC are also 
unusually very heterogeneous not just between patients but also within the 
patients’ themselves. This diversity is manifested in various characteristics such 
as higher tumor-associated markers expression or difference in tumor-seeding 
potential. Variability between both CTC and primary tumor and CTC themselves 
can results from very dangerous consequences for patients. One of the most urgent 
is their unresponsiveness to therapy. (Paoletti et al., 2018; Polasik et al., 2017; 
Reinhardt et al., 2017; Gkountela et al., 2016) 
Researchers who study these issues in BC are often focused on ordinarily tested HR 
characteristics. The reason for this approach is the evidence of endocrine therapy 
effectivness as of a leading treatment choice in HR-positive BC of all stages. One 
of the examples is the analysis of ESR expression in BC patients with ESR-positive 
BC diagnosis. Most of the studies have revealed lack of ESR expression in CTC 
which may be a mechanism explaining their resistance to endocrine therapy such 
as tamoxifen or raloxifene. (Kabel, 2017; Reinhardt et al., 2017; Paoletti et al., 
2016; Babayan et al., 2013) Then as well, HER2 expression between primary tumor 
and CTC has been studied and compared. The results revealed inconsistency 
between tissue and liquid biopsies.  
Unpredictable behaviour of HER2-positive and HER2-negative CTC has been 
proved by number of studies. Jordan et al., has confirmed HER2-positive/HER2-
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negative spontaneous interconversion in BC CTC but the work has proved this CTC 
feature at the level of a single CTC. Surprisingly, single HER2-negative CTC firstly 
proliferated slowly but after acquired HER2-positive daughter cells rapid 
interconversion thereafter. Similarly, single HER2-positive CTC with rapid 
proliferation generated HER2-negative CTC progeny which rose slowlier. (Jordan 
et al., 2016) Examination of HER2 status is important mainly because of its linkage 
to more aggressive disease behaviour and significantly decreased survival rate of 
patients. Paper of Jordan et al. also highlighted the importance of CTC molecular 
testing in real-time. Targeted therapeutics such as trastuzumab or lapatinib can 
improve patients’ outcome. (Kabel, 2017; Gkountela et al., 2016; Jordan et al., 
2016; Gutierrez and Schiff, 2011; Pestrin et al., 2009)  
Other phenotypic characteristics to be significant in CTC include mesenchymal 
features, stem-cell like features or clusters presence in peripheral blood. Although 
CTC that undergo EMT usually represents a small fraction of cells which 
disseminated from tumor tissue, this step is critical for metastatic cascade. CTC 
with EMT markers have been detected in BC patients often during disease 
progression. In most of these studies, detection of EMT markers shorter PFS and 
their presence have been usually connected with patients who do not respond to 
therapy. (Krawczyk; et al., 2014; Mego et al., 2012; Yu et al., 2011; Aktas et al., 
2009) Surprisingly, CTC monitoring during treatment and disease progression has 
revealed reversible shifts between these two features which may suggest EMT 
occurrence as result of therapy failure. Other explanation has suggested interesting 
individual cell diversity in mesenchymal and epithelial markers. It has been 
confirmed co-expression of both types of markers in the same cell in BC patients. 
(Gkountela et al., 2016; Yu et al., 2013; Kallergi et al., 2011; Armstrong et al., 
2011) Reversibility of EMT process has been suggested by detecting CTC in BC 
patient who was positive for vimentin (VIM) but this marker was not detected in 
metastasis. (Krawczyk; et al., 2014; Armstrong et al., 2011) 
Presence of cells with stem-cell like properties has been proven in patients with BC. 
They have been associated with aggressive behaviour of tumor. Confirmation of 
their responsibility in the process of tumor cells dissemination and metastasis has 
been presented by researchers. (Giordano et al., 2012; Barrière et al., 2012; Mego 
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et al., 2012; Raimondi et al., 2011) CTC with higher expression of not only stem 
cell-like but also EMT markers have been found in peripheral blood of patients with 
both early and mBC. Studies have indicated population of CTC with stem-cell 
characteristics is produced by EMT. (Mego et al., 2012; Giordano et al., 2012; 
Morel et al., 2008) According to multiple studies, CTC with proven expression of 
stem cells markers have been considered as one of the possible explanations for 
therapy resistance and failure in BC. (Krawczyk; et al., 2014; Monteiro and Fodde, 
2010)  
CTC clusters belong to other typical characteristics of CTC in patients with BC. 
There are two or more CTC which are bound together and may be displaying from 
23- to 50- fold higher potential of metastasis forming than a single CTC. (Gkountela 
et al., 2016; Aceto et al., 2014) Presence of CTC clusters in peripheral blood of 
patients has been clearly associated with shorter PFS, metastatic-free survival 
(MFS) and OS in various types of BC compared with individual CTC. (Mu et al., 
2015; Paoletti et al., 2015; Aceto et al., 2014) Possible hypothesis about their origin 
has been tested and results from surprising suggestions. These cells have been rather 
derived from tumor tissue or raised from oligoclonal expansions of cancer cells 
assembles than aggregation of single CTC or individual CTC proliferation. 
(Gkountela et al., 2016; Lu et al., 2015) Further analysis of single and clustered 
CTC has revealed difference in expression of protein called plakoglobin which has 
been responsible for holding cancer cells together and also has been significantly 
increased in CTC clusters. (Figure 15) Indeed, analysis of single and clustered CTC 
from the same BC patient showed negative and positive result for plakoglobin, 
respectively. (Aceto et al., 2014) Elevated expression of this biological 
macromolecule in primary tumors of BC patients was also associated with 
decreased MFS which leads researchers to conclude heterogeneity of plakoglobin 
expression in primary tumors results in different types of CTC production. 





Figure 15: Presumed model of plakoglobin location, CTC types, metastatic capabilities. Cancer cells 
that extensively express plakoglobin escape from tumor tissues, enter and circulate in clusters in the 
bloodstream. These clusters promote metastasis to other sites which can lead to worse patients 
survival. CTC, circulating tumor cell; CTCs, circulating tumor cells. (adapted from Lu et al., 2015) 
Plakoglobin has been considered also as oncogenic or tumor-suppresive molecule 
but this hypothesis has never been confirmed. Although plakoglobin expression was 
negatively associated with prognosis in the mean of BC progression, increased 
expression of this protein enables CTC to circulate in clusters which raise a chance 
of distant metastasis formation and often results from worse survival. (Figure 15) 
(Lu et al., 2015) On the other hand, other research study has also revealed 
cytokeratine 14 (KRT14) as a key regulator of metastasis through CTC clusters. 
They have found cells positive and negative for KRT14 were usually enriched 
during metastasis phases associated with systemic spread and proliferation in BC 
patients, respectively. (Cheung et al., 2016) Results of these studies have indicated 
analysis of CTC clusters has an independent prognostic value and CTC are 
remarkably effective precursors of metastasis in BC. Information from this analysis 
may be obtained at the same time as CTC examination without any extra additional 
tools or experiments. Although liquid biopsies in BC have been promising for 
patients’ individualized treatment it has been found that clinical value of CTC 
varies between early and mBC. (Banys-Paluchowski et al., 2016; Gkountela et al., 
2016; Mu et al., 2015) 
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1.8.6.1 CTC in early BC 
Most patients with early BC (eBC) have usually good prognosis and survival has 
been significantly improved nowadays. For continuation of this trend, novel 
markers have been discovered and investigated to help with treatment process 
determination. Methods which are used are often based on clinical, pathological 
and molecular genetics features of tumor and patient. Despite of great improvement, 
significant cases of problems, such as relapses have been documented in patients 
with this diagnosis thus new tools for long-term and regular disease monitoring are 
essential. One of the promising biomarkers is CTC which can add detailed 
information about patients’ real-time disease behaviour and increase chance for 
cure. Although plenty of studies have been performed to research their potential 
benefit, some of the CTC eBC-related issues have still remained inconsistent. 
(Ramos-Medina et al., 2016; Banys-Paluchowski et al., 2016)  
 
Studies regarding the CTC in eBC have mostly reported CTC positivity from 7.9 to 
55% of these patients. (Thery et al., 2019; Bidard et al., 2018; Pierga et al., 2017; 
Hall  et al., 2015; Banys et al, 2012; Georgoulias et al., 2012; Molloy et al.,2011; 
Sandri et al., 2010; Krishnamurthy et al., 2010; Ferro et al., 2010; Riethdorf et al., 
2010; Apostolaki et al., 2009) Their presence has been usually connected with 
decreased of progression-free and overall survival regardless of detection method 
or blood sampling timing. (Maltoni et al., 2016; Schindlbeck et al., 2013; Lucci et 
al., 2012; Zhang et al., 2012; Graves and Czerniecki, 2011; Bidard et al., 2010) 
Researchers have also tried to find a relationship between other clinic-pathological 
characteristics of disease and CTC but the results are quite inconsistent in the 
moment. A significant connection between CTC presence and both lymph node and 
receptors status has brought attention for detailed investigation. On the one hand it 
has been found that CTC presence was independent of either lymph node status or 
receptor status. (Krishnamurthy et al., 2010) On the other hand positive correlation 
between lymph node status and CTC positivity was reported. This was an evidence 
for prognostic relevancy of CTC presence in the HR positive eBC tumors’ patients 
but not in the ones with HER2-positive and TNBC types. (Rack et al., 2014; Rack 
et al., 2010) Association between CTC prognostic character and both TNBC and 
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HER2-positive patients was described, but not confirmed for CTC status and 
luminal BC tumors. (Hwang et al., 2012) Other papers have also suggested HER2 
status of primary tumor can be a trustworthy predictor of CTC presence but this has 
not been approved by other researchers. (Lang et al., 2009) Several studies have 
also confirmed CTC as strong independent prognostic factor of lymph node, 
receptor status and tumor grade and size. (Pierga et al., 2015; Mego et al., 2015; 
Graves and Czerniecki, 2011; Krishnamurthy et al., 2010) 
Discrepancy between features of primary tumor and CTC may seriously affect 
patients’ survival. Several studies have been performed to clarify different HER2 
status of CTC and primary tumor in eBC patients. Elevated expression of KRT19 
or MGB in CTC has been associated with poorer prognosis. (Graves and 
Czerniecki, 2011; Ferro et al., 2010) Other studies focusing on this prognostic 
relationship have suggested certain time limitation - during the first 36 and 48 
months CTC positivity may act as a survival predictor, more studies should be 
performed to clarify this issue. (Banys-Paluchowski et al., 2016; Bidard et al., 2013) 
Innovatively, CTC enabled to monitor minimal residual disease in patients with 
early stages of BC and without obvious metastasis evidence. (Maltoni et al., 2016) 
Despite an initial examination of tumor characteristics may be usually complex, 
development and evolution of eBC in the meaning of long-term prognosis may not 
be estimated precisely. Patients with the same primary tumor features have rarely 
the same or similar diseases’ progress. Promising potential of CTC is to get as much 
information as possible through CTC profiles at all steps of disease progression to 
decide as accurate targeting strategy as possible during treatment process. (Ramos-
Medina et al., 2016; Maltoni et al., 2016) 
Regarding significant number of eBC patients suffering from treatment resistance 
or relapses, new challenge for CTC in future during treatment monitoring is 
pending. Most of the studies have agreed on that CTC persistence has meaningful 
impact on eBC patients’ survival. They have been usually connected with shorter 
DFS, PFS and OS. Although results suggest CTC detection is associated with worse 
clinical outcome, key time point of blood withdrawal during treatment process is 
still not clear. (Banys-Paluchowski et al., 2016; Ramos-Medina et al., 2016; Hall et 
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al., 2015; Rack et al., 2014; Graves and Czerniecki, 2011) Results of studies which 
have performed real-time CTC monitoring during therapy differ significantly. 
Associations between pre- and post- treatment CTC results with DFS, PFS and OS 
have been investigated. A part of studies suggested both pre- and post- treatment 
CTC analysis is associated with DFS and OS. (Pachmann et al., 2011; Xenidis et 
al., 2009) Opposite, a part of the publications reported inconsistent results in pre- 
or post- treatment withdrawals in relationship with patients’ outcome. Both shorter 
DFS and OS were associated with pre-therapy CTC detection while post-treatment 
CTC observation was connected with reduced DFS. (Rack et al., 2014; Pierga et 
al., 2008) Different studies have claimed that single one of the pre- or post-therapy 
sampling is a better predictor of DFS and OS. (Bidard et al., 2014; Rack et al., 2014; 
Bidard et al., 2010) Additionally, Xenidis et al. have used CTC analysis to evaluate 
survival benefit between taxane-based and taxane-free group. More favourable DFS 
was observed in taxane-based patients. This survival advantage was also showed 
by shifting from CTC-positive to CTC-negative status of significant fraction of 
taxane-based patients’ group. (Banys-Paluchowski et al., 2016; Xenidis et al., 2013) 
Achieving of pCR after neoadjuvant chemotherapy (NACT) is usually associated 
with favourable clinical outcome although it is not an evidence of a complete cure. 
(Ramos-Medina et al., 2016; Symmans et al., 2007) Both pCR and CTC detection 
have been investigated for their mutual relationship. Although one part of the 
studies reported pCR and CTC-negative status for patients with an increased DFS, 
other researchers reported no correlation between CTC detection and treatment 
response. (Ramos-Medina et al., 2016; Pierga et al., 2015; Riethdorf et al., 2010)  
Discrepancies between CTC presence and pCR have seemed to originate in primary 
tumor properties which correspond to neither CTC nor possible metastasis 
characteristics. Although in eBC patient treatment choice is usually selected based 
on primary tumor features an incredible diversity between primary tumor and CTC 
is reported nowadays. (Maltoni et al., 2016; Banys-Paluchowski et al., 2016; 
Ramos-Medina et al., 2016; Graves and Czerniecki, 2011) 
Changes in ESR or HER2 status can contribute to endocrine or anti-HER2 therapy 
resistance, respectively. Particularly, HER2 status has been taken place to detailed 
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studies. Although numerous publications have showed HER2-positive CTC status 
in HER2-negative primary tumor which is not rare event in eBC patients, these 
people are not eligible to treatment targeted against HER2 resulting into higher 
relapse risk. (Banys-Paluchowski et al., 2016; Riethdorf et al., 2010; Fehm et al., 
2009) Studies also associated anti-HER2 therapy receiving with longer DFS and 
smaller danger of relapses. Anti-HER2 therapy was demonstrated to eliminate 
HER2-positive CTC regardless of the eBC tumor type. (Georgoulias et al., 2012; 
Rack et al., 2012) This fact has been currently evaluated in clinical study TREAT 
CTC Trial (NCT0158677). Patients with HER2-negative primary BC who had 
detectable CTC after completing both (neo) adjuvant chemotherapy and surgery are 
eligible. They were randomized in 1:1 ratio to trastuzumab or observation group 
and treatment response was assessed after 18 weeks of treatment/observation. 
(ClinicalTrials.gov) Trastuzumab did not decrease the detection rate of CTC in 
HER2 non-amplified, nonmetastatic BC (Ignatiadis et al., 2018) 
Treatment process of eBC requires real-time information on actual disease status. 
It is necessary to keep in mind potential danger, such as discordance between 
primary tumors and both CTC and possible metastasis may occure. CTC may be a 
useful tool to help with real-time monitoring and possibly minimalize consequences 
of unpredictable cancer behaviour. Moreover, with growing suggestions of early 
metastasis theory in eBC it is necessary to start disease monitoring from as early 
point as possible. CTC analysis may allow clinicians not only to recognize patients’ 
disease progression but also to identify those with higher risk of recurrence. 
Additionally, molecular and genetic characterization of these cells allows 
evaluation of chemoresistance profiles and therapeutics targets which can enable 
more efficient and individualized curative regimens. (Maltoni et al., 2016; Banys-
Paluchowski et al., 2016; Ramos-Medina et al., 2016; Bidard et al., 2014; 





1.8.6.2 Circulating tumor cells in metastatic breast cancer 
CTC studies related to mBC have been provided more often than in eBC. The main 
purposes of mBC research are to improve patients’ life quality and prolong their 
survival expectance. For fulfilling these ambitions, it is necessary to develop 
approaches which would be able to abort or at least to slow down tumor progression 
and reduce side effects of receiving treatments. Despite the confirmed fact of not 
only phenotypic but also genotypic discrepancies between primary tumor and 
metastasis occur, most of the treatment choices have been still performed based on 
primary tumor characteristics. (Banys-Paluchowski et al., 2016; Banys et al., 2012) 
CTC are usually detected in the 40-80% of patients with mBC and belong to 
relatively new tools for monitoring metastatic cancer development. Initial CTC 
analysis performed before beginning of the palliative therapy demonstrated that 
CTC presence was a prognosticator of shorter PFS and OS of mBC patients. 
Subsequently studies have revealed very poor outcome, reduced PFS, OS of mBC 
patients with persistently elevated CTC number at any point during therapy 
regimens. (Banys-Paluchowski et al., 2016; Smerage et al., 2014; Graves and 
Czerniecki, 2011) Moreover, expression analysis of CTC has connected shorter 
PFS of mBC patients with greater than two multidrug-resistance proteins (MRPs) 
elevated in comparison with those without. (Gradilone et al., 2011) 
Regular tracking of disease evolution belongs to the most important parts of 
treatment process mainly because of endlessly possible illness changes during 
therapy process. Moreover, phenotype and genotype of primary tumor, isolated 
tumor cells in secondary homing sites and metastatic tissue may differ therefore 
most of the primary tumor biopsies tissues usually do not reflect metastatic sites 
character. This problem is often seen in the mBC cases regarding hormone receptors 
and HER2 status which have been intensively studied. (Agelaki et al., 2015; Rack 
et al., 2012) Determining HER2 status, 31% and 26% discrepancies were found 
between CTC in comparison with primary tumor and metastasis, respectively. 
(Wallwiener et al., 2015) Fehm et al., detected HER2-positive CTC in significant 
number of patients with HER2-negative primary tumors. (Fehm et al., 2010) 
Moreover, a research focused on anti-HER2 therapy reported promising effects of 
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this treatment which have been found to significantly contribute to persistent 
HER2-positive CTC regardless of primary tumor status in mBC patients. (Banys-
Paluchowski et al., 2016; Agelaki et al., 2015; Rack et al., 2012) 
Studies have also investigated CTC as strong and early predictive marker of 
chemotherapy response. Not only CTC enumeration but also their genetic profiling 
seems to become a useful tool to determine real-time status of individual patients’ 
disease progression, treatment efficiency and outcome prediction. Researchers see 
a big potential of CTC in their contribution to reduce treatment adverse reactions. 
(Gkountela et al., 2016; Fina et al., 2015; Graves and Czerniecki, 2011) Wide 
ranges of not just short- but also long-term side effects have been reported during 
and after receiving of anti-cancer drugs. (Institute for Quality and Efficiency in 
Health Care, 2016; DeSantis et al., 2014) Early information about ineffective and 
moreover potentially harmful treatment can significantly contribute to 
improvement of patients’ life quality. This CTC potential can be used to reduce 
toxic exposure caused by the treatment with little or no effect which can be followed 
by switching to alternative therapy receiving. (Ramos-Medina et al., 2016) 
There are several other biomarkers and imaging techniques used by clinicians that 
are helpful in disease monitoring and in specifying therapy continuation. In 
comparison with other markers, CTC have been confirmed as prognostic in mBC 
regardless of molecular BC subtype, serum markers such as CEA or cancer antigen 
15-3 (CA 15-3) have been shown not to improve prognostication in mBC. (Banys-
Paluchowski et al., 2016; Bidard et al., 2014) Moreover, interesting experiment has 
been performed to compare correlation of treatment response by CTC presence and 
radiologic assessment and also in relationship with OS. Patients without radiologic 
progression and elevated CTC number had significantly shorter OS than patients 
with radiological progression and decreased CTC number. Most of the studies have 
agreed on using CTC as trustworthy alternative biomarker of therapy response. 
CTC are identifying not only patients with poor prognosis but also those with little 




1.9 Resistance to anticancer drugs  
Even though researchers have made a significant progress in new treatment 
combinations and mechanisms, therapy failure has been still the consequence of 
chemotherapy resistance. Resistance strategies have been naturally evolved as 
protection to prolong survival of living cells by adapting to environmental changes 
with offensive conditions which is true for chemotherapy, too. The cells are able to 
achieve this adaptation by either intrinsic or acquired mechanisms. To reach 
effectiveness, anticancer drugs, also like other medication, need to be absorbed 
through lipophilic membranes, distributed to cells and tissues through the blood, to 
target the wanted site. (El-Awady et al., 2017; Blair et al., 2014; Binkhathlan and 
Lavasanifar, 2013; Holohan et al, 2013; Swanton, 2012; Tiwari et al., 2011) 
The most common anticancer multidrug resistance (MDR) mechanisms have been 
classified into three categories: target-dependent, drug/target-independent and 
drug-dependent. Factors which are able to influence drug targeting (target 
translocation, mutation, deletion or amplification) are responsible for target-
dependent MDR. On the contrary, drug/target-independent MDR has occurred in 
the case of drug targeting desensitization by genetical or epigenetical modification 
of cell signalling pathways. Moreover, MDR dependent on drug has been caused 
by numerous mechanisms to decrease intracellular drug concentration, including 
efflux drugs transporters or detoxifying enzymes overexpression which results from 
decreased uptake or elevated drugs efflux withing cancer cells. (Figure 16) Despite 
numerous possibilities of MDR which have been already clarified, overexpression 
of adenosine triphosphate (ATP)-binding cassette (ABC) super-family of 
transporters has been considered as the most prominent mechanisms among 
organisms. (El-Awady et al., 2017; Chen et al., 2016; Holmes et al., 2016; Ye et al., 






Figure 16: General overview of resistance mechanisms to chemotherapy. (adapted and modified 
from El-Awady et al., 2017) 
Although anticancer treatment includes variety of chemotherapeutics used for 
specific tumors, cancer resistance mechanisms are usually common. (Li et al., 2016; 
Akhdar et al., 2012) The ABC transporters are the most abundant superfamily of 
protein transporters present in all organisms. They are playing an important role not 
just in efflux but also in drug metabolism. Convetional drug metabolism process is 
consisting of Phase I (exogenous compounds oxidation/reduction to pro-drugs or 
inactive actives activation) and Phase II (partially detoxified metabolites 
conjugation), Phase 0 (entry and exit control) and Phase III (total eradication of the 
metabolized molecules assurance). All of the phases are responsible for cellular 
entry and exit of exogenous compounds alteration. (El-Awady et al., 2017) 
The ABC transporters present in human are complexes which are categorized based 
on their sequenced similarities into seven subfamilies, from ABC subfamily A 
(ABCA) to ABC subfamily G (ABCG) and are consisting of 48 members. Although 
these transporters are mostly settled on the plasma membrane, their subfamily, ABC 
subfamily C (MRP/ABCC), are able to provide intracytoplasmic drugs capture and 
pump them out. The systems are able to decrease various toxins concentration 
which can cause the chemotherapy failure and cancer progression in the term of 





















and ABCC subfamily, are the most associated with MDR in various cancer types. 
(Tang et al., 2016; Chen et al., 2016; Ween et al., 2015; Alakhova and Kabanov, 
2014)  
Structure of ABC transporters are composed of transmembrane (TMDs) and 
nucleotide binding domains (NBDs). (Figure 17) Structurally diverse TMDs are 
hydrophobic and are alternatively able to recognize and translocate different 
substrates upon conformational changes. NBDs are highly conserved proteins that 
contain Walker A and B motifs and the signature (C) motif which joins the Walker 
A and B motifs. These two motifs play crucial role in ATP hydrolysis and energy 
coupling. (Figure 17) Moreover, ABC transporters can be categorized based on 
their structure and sequence of the NBDs domain, also known as ABC domains. 
(Kathawala et al., 2015; Choi and Yu, 2014; Rice et al., 2014; ter Beek et al., 2014; 
Kunjachan et al., 2013) 
 
Figure 17: Schematic description of ABC transporters function. TMD, transmembrane domain; 
NBD, nucleotide binding domain; ATP, adenosine triphosphate; ADP, adenosine diphosphate; Pi, 
phosphate. (adapted from Chen et al., 2016) 
The prominent function of the ABC transporters, efflux, has been summarized into 
several steps which lead to complex conformational modifications (Weismanova et 
al., 2012): 
1. At the beginning, ABC transporter is in the open form and has high afinity to 
the substrate. Transmembrane domain (TMD) associates with substrate in both 
inside the cell or in the cytoplasmatic membrame which results from 
conformation change and ATP molecule binding. 
2. Walker A in the first nucleotide binding domain (NBD) forms a bond with ATP 
molecule which is stabilized by C motif from the second NBD. This „sandwich“ 
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bond (Walker A – ATP molecule – C motif) facilitates the second ATP 
molecule binding to Walker A from the second NBD which is stabilized by C 
motif from the first NBD. These „sandwich“ bonds cause getting the both NDBs 
closer followed by conformational change of TMDs with substrate from open 
to closed position. Cavity between TMDs is created. (Figure 17) 
3. Energy obtained from ATP hydrolysis is used for rotation of cavity with 
substrate. Cytoplasmic region is rotating into extracellular environment which 
is accompanied substrate release into extracellular environment. (Figure 17) 
4. Energy obtained from second ATP hydrolysis is used for transporter original 
returning.  
1.9.1 Genes associated with chemoresistance 
Despite the fact ABC transporters have performed useful tasks in the cells, they 
have found to be involved in drug efflux out of the cells. As a consequence, there 
are more cancer cells with higher expression of multidrug-resistant genes which 
support intrinsic chemoresistance. (Table 9) Although chemotherapy failure is often 
a multifactorial process, overexpression of ABC transporters plays very an 
important role. The activation of ABC transporters has found to be the first and 
limiting event of the acquired resistance. This event can be a consequence of several 
mechanisms such as higher amplification of the genes, increased transcription by 
novel transcription factors, changes in translational efficiency, genes mutations or 
chromosomal rearrangements. Moreover, treatment options such as radiotherapy or 
chemotherapy have been found to cause multi-drug resistance efflux tranporters 
over expression. (El-Awady et al., 2017; Tang et al., 2016; Kathawala et al., 2015; 
Gazzaniga et al., 2010a) Many studies regardless of cancer types have demonstrated 
that elevated expression of the ABC transporters in cancer cells causes poor clinical 
outcome. (Housman et al., 2014; Yanase et al., 2004) Their association with 
prognosis, prediction, clinicopathological characteristics and tumors behaviour 




1.9.2 Resistance and circulating tumor cells 
Transporters contributing to the chemoresistance were also analysed in CTC of 
various cancer diagnoses. Despite the great progress in tumor treatment options, the 
major causes of death are still both cancer progression and metastasis. Detailed 
research of this area is focused on question, if the right cancer cell has been targeted. 
It has been suggested CTC population is heterogenous and consists of resistant 
subpopulations which are able to cause distant metastasis. Moreover, the results of 
resistant markers in CTC have confirmed CTC testing as promising. (Abdallah et 




Table 9: List of selected genes associated with chemoresistance and their characteristics. Table contains localisation of selected genes in healthy cells/tissues, type of 
cancer disease that association with selected genes was studied and particular references.  
Gene  Occurence Type of cancer Reference 
MDR1 / 
ABCB1 
liver, placenta, intestine, kidneys, 
adrenal gland, colon and blood-
brain barrier 
pancreatic, breast, ovarian, lung, bladder, 
sarcoma, glioblastoma, colon, leukemia, 
gastrointestinal tumors, hepatocellular 
carcinoma, colorectal, liver, osteosarcoma, 
thyroid tumor, esophageal tumor, testicular germ 
cell tumors 
Kassem et al., 2019; Briz et al., 2019; Cornelison et al., 
2017; El-Awady et al., 2017;  Sun et al., 2016; Fan et al., 
2016; Balaji et al., 2016; Borel et al., 2012; Lu et al., 2012; 
Nakai et al., 2009; Duan et al., 2008; Lhomme et al., 2008; 
Lu et al., 2007; Roy et al., 2007; Warmann et al., 2005; 
Diestra et al., 2003; Sun et al., 2000; Tidefelt et al., 2000; 
Abolhoda et al., 1999; Del Vecchio et al., 1997; Trock et 
al., 1997; Mizoguchi et al., 1990 
MRP1 / 
ABCC1 
testis, prostate, lung, thyroid, 
urinary bladder, liver, kidney, 
regions of the gastrointestinal 
system, such as pancreas, 
esophagus and stomach 
lung, ovarian, colorectal, esophageal, leukemia, 
lung, breast, colon, prostate, hepatocellular 
carcinoma (localized in intracellular membranes 
of tumor cells-minor) 
Briz et al., 2019; Fan et al., 2016; Lu et al., 2015; Zhang et 
al., 2015; Bagnoli et al., 2013; Yamada et al., 2013; Hlaváč 
et al., 2013; Zhang et al., 2015; Hlavata et al., 2012; Sodani 
et al., 2012; Chen and Tiwari, 2011; Roy et al., 2007; Nies 
et al., 2001; Nooter et al., 1997 
MRP2 / 
ABCC2 
hepatocytes membrane, peripheral 
nerves, gallbladder, CD4+ 
lymphocytes and in the intestine, 
apical membrane of epithelial 
cells of the biliary system and 
proximal renal tubules 
breast, colon, ovarian, lung, hepatocellular 
carcinoma, renal carcinoma, colorectal, skin 
melanoma, liver, cholangiocarcinoma, testicular 
germ cell tumors, leukemia 
Briz et al., 2019; Lacy et al., 2015; Zhang et al., 2015; Chen 
and Tiwari, 2011; Shibayama et al., 2011; Tiwari et al., 
2011; Korita et al., 2010; Zimmermann et al., 2008; Gillet 
et al., 2007; nies et al., 2007; Huisman et al., 2005; 





highly expressed in the liver, 
gastrointestinal system, kidney, 
colon, biliary system, pancrease 
adrenal glands tract or gallbladder 
and less in the spleen, tonsils, 
stomach or lungs 
ovarian, hepatocellular carcinoma, colorectal 
tumor, kidney carcinoma, breast, colon, bladder, 
lung, testicular tumors, thymomas and gliomas 
Briz et al., 2019; Tomonari et al., 2016; Balaji et al., 2016; 
Lacy et al., 2015; Zhang et al., 2015; Hlavata et al., 2012; 
Sun et al., 2012; Tiwari et al., 2011; Lagas et al., 2010; 
Scheffer et al., 2002; Zelcer et al., 2001; Kool et al., 1999; 
Ortiz et al., 1999 
MRP4 / 
ABCC4 
prostate, kidney, urinary 
bladder, pancreas, thyroid, testis, 
pancreas and colon cancer, 
hepatocytes, gastric cells 
prostate, renal, gastric, tumors derived from the 
digestive tract, kidney, pancreatic, ovarian, 
breast, bladder, lung  
Briz et al., 2019; Kochel and Fulton, 2015; Wen et al., 
2015; Zhang et al., 2015; Hlaváč et al., 2013; Chandra and 
Liddle, 2012; Kleberg et al., 2012; Chen and Tiwari, 2011; 
Tiwari et al., 2011; Russel et al., 2008; Kruh et al., 2007; 
Tian et al., 2005; Leggas et al., 2004; Lee et al., 2000 
MRP5 / 
ABCC5 
cornea, skeletal muscle, heart, 
brain, stomach, testis, lung, many 
healthy tissues 
breast, breast cancer with bone metastasis, 
pancreatic, colon, lung, head and neck, ovarian, 
bladder, thyroid, esophageal, stomach, kidney, 
colorectal, cholangiocarcinoma, leukemia 
Briz et al., 2019; Lal et al., 2017; Krajinovic et al., 2016; 
Chen et al., 2015; Wang et al., 2014; Hlaváč et al., 2013; 
Sodani et al., 2012; Partanen et al., 2012; Zhang et al., 
2011; Karla et al., 2009; Hagmann et al., 2009; Calatozzolo 
et al., 2005; Dazert et al., 2003; Oguri et al., 2000 
MRP6 / 
ABCC6 
liver, kidney, pancreas, lung, 
thyroid, salivary gland, intestine 
hepatocellular carcinoma, cholangiocarcinoma, 
lung, colorectal, kidney cancer, thyroid 
carcinomas, renal cancer 
Briz et al., 2019; Eadie et al., 2019; Zhang et al., 2015; 
Beck et al., 2005; Belinsky et al., 2002 
MRP7 / 
ABCC10 
skin, colon, testes, pancreas, ovary, 
salivary glands 
lung, colon, leukemia, hepatocellular, 
esophageal, colorectal, thyroid, breast 
Briz et al., 2019; Balaji et al., 2016; Hlaváč et al., 2013; 
Borel et al., 2012; Tiwari et al., 2011; Bessho et al., 2009; 
Hopper-Borge et al., 2009; Wang et al., 2009; Oguri et al., 
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2008; Hopper-Borge et al., 2004; Dabrowska and Sirotnak, 
2004; Hopper et al., 2001 
MRP8 / 
ABCC11 
liver, testes, breast, brain, placenta, 
mammary gland, prostate 
breast, melanoma, lung, pancreatic, prostate, 
colorectal 
Briz et al., 2019; Oba et al., 2016; Tsuchiya et al., 2016; 
Zhang et al., 2015; Wang et al., 2014; Yamada et al., 2013; 
Hlaváč et al., 2013; Toyoda and Ishikawa, 2010; Zhou et 
al., 2008; Oguri et al., 2007, Chen et al., 2005 
ERCC1 Cells: nucleotide excision and 
repair pathway, a part of the 
cellular response to DNA damage 
lung, bladder, breast, ovarian, cervical, 
esophageal, pancreatic, gastrointerstinal, 
colorectal  
Anuja et al., 2019; Piljić Burazer et al., 2019; Dai et al., 
2019; Lin et al., 2019; Mesquita et al., 2019; Takemoto et 
al., 2019; El Baiomy and El Kashef, 2017; Ryu et al., 2017; 
Kim et al., 2017; Du et al., 2016; Choueiri et al., 2015;  
Deng et al., 2014; Muallem et al., 2014; Steffensen et al., 
2009; Wei et al., 2008; Kim et al., 2008; Bellmunt et al., 
2007; Cobo et al., 2007; Kwon et al., 2007; Moore Joshi et 
al., 2005; Reed, 2005; Shirota et al., 2001; Metzger et al., 
1998 
MDR1/ABCB1, Adenosine Triphosphate - Binding Cassette Subfamily B Member 1; MRP1 / ABCC1, Adenosine Triphosphate - Binding Cassette Subfamily C Member 
1; MRP2 / ABCC2, Adenosine Triphosphate - Binding Cassette Subfamily C Member 2; MRP3 / ABCC3, Adenosine Triphosphate - Binding Cassette Subfamily C 
Member 3; MRP4 / ABCC4, Adenosine Triphosphate - Binding Cassette Subfamily C Member 4; MRP5 / ABCC5, Adenosine Triphosphate - Binding Cassette Subfamily 
C Member 6; MRP6 / ABCC6, Adenosine Triphosphate - Binding Cassette Subfamily C Member 6; MRP7 / ABCC10, Adenosine Triphosphate - Binding Cassette 





Gazzaniga et al., have divided patients with bladder, CRC, BC, NSCLC, gatric, 
urothelial, ovarian, esophageal and head and neck tumors into “resistant” and 
“sensitive” groups based on their CTC chemoresistance-profile. Resistance 
prediction was reached in 95% of patients in progressive disease based on 
molecular sensitivity assay. They had also found the correlation between molecular 
test and chemotherapy response prediction in 98% of patients. In this publication 
Adenosine Triphosphate - Binding Cassette Subfamily C Member 4 (MRP4), 
Adenosine Triphosphate - Binding Cassette Subfamily C Member 5 (MRP5) and 
Adenosine Triphosphate - Binding Cassette Subfamily C Member 7 (MRP7) 
expression revealed resistence to anthracyclines and other ordinarily used 
chemotherapeutics. This publication had determined molecular CTC profile of drug 
resistance and chemotherapy response forecasting regardless of tumor type or 
disease stage. (Gazzaniga et al., 2010a) Moreover, the same group published 
another article about molecular markers in CTC from metastatic CRC patients in 
the same year. The analysis showed patients receiving oxaliplatin and 5-fluorouracil 
(as specific MRP5 substrates) who expressed MRP5 had shorter PFS and higher 
progression rate. (Gazzaniga et al., 2010b) 
MRP transporters have been tested in CTC of metastatic BC patients, too 
(Gradilone et al., 2011). These patients have been divided into “drug sensitive“ and 
“drug resistant“ group based on specific MRP transporters expression profile. This 
paper agreed with previous results, shorter PFS had been observed in “drug 
resistant“ in comparison with “drug sensitive“ patients. Furthermore, detailed 
analysis of different MRPs expression and survival was provided. This examination 
showed patients who expressed two or more MRPs in CTC had shorter PFS than 
the ones who’s expressed one or none MRPs. This publication has supported the 
opinion that MRPs overexpression in CTC may be a poor response predictor and it 
is associated to shorter PFS. (Gradilone et al., 2011) 
In a work published by Abdallah et al. metastatic CRC patients receiving irinotecan-
based therapy underwent Adenosine Triphosphate - Binding Cassette Subfamily C 
Member 1 (MRP1) and MRP4 expression analysis in CTC, primary tumor and 
metastasis. This publication proposed CTC as the best tumor compartment for 
gathering reliable information on resistance to anticancer drugs in metastatic CRC. 
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Several examinations have been performed in this study showing interesting results 
for CTC. In the survival analysis, patients with MRP1 expression in CTC had 
shorter PFS and less median number of days for disease progression than those who 
did not. MRP1 positive CTC were then associated with KRAS mutation. It has been 
found that 75% of patients whose CTC expressed MRP1 had also KRAS mutation 
whereas patients with CTC without MRP1 expression had mostly wild-type KRAS. 
Another interesting analysis was performed in the case of MRP4 expression in 
CTC, primary tumor and metastasis. Although PFS was longer in the case of 
patients who expressed MRP4 in CTC and metastasis, inverse results were obtained 
in the case of primary tumor. From these data, CTC - MRP4 in the relation to PFS 
was a statistically significant result. This study recommended CTC as a marker for 
therapy selection. (Abdallah et al., 2016) 
Except the ABC transporters, excision repair cross-complementation group 1 
(ERCC1) gene expression has been measured in CTC in various tumor types 
including BC, lung or ovarian cancer. Das et al. measured expression level of 
ERCC1 in CTC of metastatic NSCLC patients who were treated with platinum-
based therapy. Results of this analysis showed longer PFS was associated with lack 
of ERCC1 expression and vice versa. The study also revealed decreased PFS in 
CTC of patients who displayed increased expression of cytokeratin. This study 
concluded expression of ERCC1 in CTC correlates with PFS of these patients. (Das 
et al., 2012) 
One of the most important studies has been published by Kuhlmann et al. who tested 
ERCC1 expression in CTC and PT of patients with ovarian carcinoma. This paper 
constituted CTC with ERCC1 expression as an independent predictor for OS and 
PFS. It had been discovered CTC with expression of ERCC1 at primary diagnosis 
may be considered as independent predictor of platinum resistance whereas its 
expression in analogous primary tumors predicted neither platinum resistance nor 
prognosis. CTC have become even more promising marker for patients with ovarian 
cancer. (Kuhlmann et al., 2014) 
Ovarian cancer study of Chebouti et al. continued on previous publication by 
ERCC1 expression analysis of CTC in patients with ovarian cancer. They have 
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found a correlation between CTC expressing ERCC1 after chemotherapy and 
platinum resistance, shorter PFS and OS. It has been also observed that CTC 
positive for ERCC1, persisting in the circulation, indicated a poor post-
chemotherapeutic outcome. CTC have been advocated as useful marker for 
platinum-based therapy monitoring and outcome. (Chebouti et al., 2017) 
CTC of BC patients were also tested for several chemoresistance associated 
markers, including ERCC1 before and also after neoadjuvant therapy. A ratio of 
patients who expressed ERCC1 was lower before therapy in comparison to post- 
therapy samples, 63% and 72%, respectively. Surprisingly, 50% of the ERCC1 
positive CTC post- therapy samples were positive for ALDH1 and at least for one 
another EMT marker. Additionally, Bredemeier et al., has revealed association 
between expression of ERCC1 alone or in combination with aurora kinase A 
(AURKA) gene and therapy failure. These results indicate ERCC1 positive CTC 
are able to survive treatment regimens and may represent therapy-resistant 
population of cancer cells. They may be a valuable source of information for 




2. Thesis Aims: 
 
Doctoral thesis is focused on liquid biopsy – CTC examination and its translational 
research in oncological therapy personalization.  
The aims of this thesis were CTC enrichment and molecular characterization and 
can be summarized into following points:   
 To set- up size- based enriched CTC in vitro cultures of cancer patients CTC 
in various treatment process stages; before therapy, undergoing 
chemotherapy, radiotherapy and biological treatment (e.g. anti – HER2), 
which is the prerequisite of successful molecular characterization of CTC in 
different solid tumor cancer types  
 
 To evaluate cytomorphology of CTC with focus on cytomorphological 
changes of CTC during ongoing therapy (e.g. chemotherapy, radiotherapy, 
anti- HER2 treatment) in different cancer types  
 
 To analyse gene expression profile of tumor-associated, stem cell-like and 
chemoresistance-associated genes in CTC in early and metastatic BC 
patients undergoing NACT with respect of CTC population heterogeneity 
under the chemotherapy pressure  
 
 To assess prognostic and predictive potential of CTC based on molecular 
data correlated to the observed clinicopathological criteria in eBC patients 
 
 To compare characteristics of primary tumor and CTC in BC patients 






3. Materials and Methods: 
3.1. Patients 
 
All of the patients’ subsets are described in the corresponding articles, but in short: 
Publication I (page 212) – 20 eBC patients; Publication II (page 238) - 167 BC 
patients; Publication III (page 244) – 8 patients with various cancer diagnosis (4 
patients BC, 2 CRC, 1 CRC + prostate and 1 lung cancer patient); Publication IV 
(page 261) – 40 ovarian cancer (CaOV) patients; and Publication V (page 269) – 
118 CaOV patients were included into the studies. 
All of the studies were performed in accordance with Declaration of Helsinki. 
Signed informed consent form had been obtained from each patient before start of 
any clinical procedure and patients’ clinical data collection related to particular 
study.  
 
Group 1 – Publication I (page 212) 
Article: Characterization of circulating tumor cells in early breast cancer patients 
receiving neoadjuvant chemotherapy (study of eBC patients) 
 
The second paper studied 20 eBC patients. Patients underwent peripheral blood 
withdrawals for CTC analysis in regular intervals at 4 main time points: before 
NACT, during NACT and/or before and after surgery; and CTC monitoring 
continued for several patients also in long-term period after operation. In the cases 
NACT consisted of anthracyclines (AC) and/or taxanes (TAX) administration, CTC 
analysis were usually performed before the first AC cycle, before the first TAX 
cycle and before the last TAX cycle.  
Other clinicopathological characteristics of patients who were enrolled into this 
study are described in Table 10. 
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ER0, PR0, HER2- 3xFEC-
9xT  
  pCR     
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Group 2 – Publication II (page 238) 
Article: Molecular characterization and heterogeneity of circulating tumor cells in 
breast cancer (study of BC patients with various disease stages) 
The published research studied 167 patients who were diagnosed with BC. Patients 
included in this study were in different stage of the disease and were candidates for 
surgery, surgical diagnostics, or with planned or applied chemotherapy regimens. 
Clinicopathological characteristics of patients who were enrolled into this study are 
presented in Table 11. While most of the patients took part single blood withdrawal, 
regular monitoring was performed on 20 patients with respect on HER2 and ESR 
CTC status.  
 
Table 11: Clinicopathological characteristics of BC patients included in the Publication II.  







0 3 2 Benign 2 01.7 G1 7 11.8 
IA 45 30 DCIS 9 07.6 G2 24 40.6 
IIA 64 42.7 LCIS 1 0.85 G3 28 47.4 
IIB 20 13.3 IDC (NST) 76 65.6 Menopausal status 
IIIA 13 08.7 ILC 14 11.86 Premenopausal 65 39.39 
IIIB 1 0.67 Mixed 16 13.6 Menopausal 18 10.9 




Nodal involvement HR+ HER2+ 16 11.7 Tumor size 
N0 56 56.5 HR- HER2+ 7 05.1 T1 63 61.1 
N1 37 37.3 HR+ HER2- 91 66.4 T2 36 34.9 
N2 6 6 HR- HER2- 23 16.8 T3 4 03.8 
 
Group 3 – Publication III (page 244) 
Article:  Circulating tumor cells: what we know, what do we want to know about 
them and are they ready to be used in clinics? (study of case reports) 
 
Publication no. 3 was published as selection of detailed case reports. Eight patients 
diagnosed with BC, CRC, prostate and lung cancer were included in this study for 
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long-term examination of CTC presence and their characteristics. Patients’ tumor 
characteristics are showed in Table 12 which includes also staging and histology 
before and after surgery.  
 
Table 12: Pre- and post- surgery patients’ tumor characteristics included in Publication III 
Cancer type / 
Age in the 
time of 
diagnosis 





BC / 34 b:T2N1M0; a: T2N1aM0 
IDC, G3, TNBC, 
Ki67: 70% 
Metaplastic carcinoma, 
G3, TNBC, Ki67: 70% 
BC / 44 




NST, G1, ESR10, PGR0, 
HER2NA, Ki67: 5% 
BC/ 29 
b: NA; a: pT1c multi(3) pN0 
(0/2) M0 
NA TNBC, G3, Ki67: 60% 
BC / 39 
b: T2N1; a: 
T1cN1mi(2m/8)M0 
IDC, G2, ESR80, 
PGR90, HER2+, 
Ki67: 20% 
G2, ESR70, PGR30, 
HER2+, Ki67: 10%  
CRC / 35 b: NA; a: pT2pN0(0/10)M0 NA 
Tubular adenocarcinoma 
of rectum, G2, RAS? 
CRC / 50 b: NA; a: pT2pN0(0/12)M0 NA 
Adenocarcinoma of 
rectum, G2, RAS? 
Lung / 47 b: NA; a: NA NA NA 
CRC + PC / 57 





Group 4 – Publication IV (page 261) 
Article: Molecular characterization of circulating tumor cells in ovarian cancer. 
(molecular study of CaOV CTC) 
In the last presented study, 40 women patients were involved. All of them were 
diagnosed with ovarian carcinoma in different stages and were also surgery or 
surgical diagnostic candidates.  
 
Group 5 – Publication V (page 269) 
Article: The added value of circulating tumor cells examination in ovarian cancer 
staging. (study of CaOV CTC value) 
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In total 118 women diagnosed with CaOV in various stages were included in the 
study. All patients were candidates for surgery or surgical diagnostics and their 
detailed features are showed in Table 13. 
 
 





stage   
Histology   Grading   
118 
IA 5 Serous 81 1 1  
IC 14 Serous/borderline 4 2 19  
IIA 1 
Non serous (e. g. 
mucinous) 
6 3 52 
 
IIB 2 Clear cell type 3 4 46  
IIC 4 Endometrioid 1    
IIIA 3 Undifferentiated 2    
IIIB 12 NA 21    
IIIC 69      
IV 8      
3.2. Methods  
Patients’ blood withdrawal as a part of liquid biopsy examination was followed by 
blood processing within 24 hours. After CTC enrichment, cytomorphology and 
gene expression analysis were applied for detailed CTC characterization.  
3.2.1. CTC enrichment and cultivation of CTC 
Patients’ blood withdrawal as a part of liquid biopsy examination was followed by 
blood processing within 24 hours. After CTC enrichment, cytomorphology and 
gene expression analysis were applied for detailed CTC characterization.  
Enrichment of CTC was done by size-based separation protocol at room 
temperature. Until the blood was processed, it was kept at 4-8oC (temperature in the 
fridge). Approximately 6-8ml (volume was dependent on each study blood) of 
peripheral blood was filtered using Metacell® device (Metacell s.r.o., Czech 
Republic). (Figure 18) Cells captured on the filter were either cultured in vitro or 
stored for later gene expression studies.   
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After whole peripheral blood filtration, membrane with captured cells was washed 
by RPMI media (SIGMA-ALDRICH, USA) and placed into cultivation plate. 4 ml 
of RPMI media supplemented by fetal bovine serum (FBS) - 10% (SIGMA-
ALDRICH, USA), Amphotericin B (SIGMA-ALDRICH, USA) and penicillin-
streptomycin (SIGMA-ALDRICH, USA) antibiotics to avoid contamination were 
added on the membrane. The cells were cultured in vitro under standard conditions 
(37oC, 5% CO2) for 3-5 days. (Figure 18) Long-term cultivation was performed in 
the cases of massively growing cancer cells.   
In the case of enriched cells storage, the cells with the membrane were directly after 
the filtration put into the 600 µl of Buffer RLT (QIAGEN, Germany) + β-
mercaptoethanol (VWR, USA) and stored at -20oC. 
 
 
Figure 18: The shortened protocol of CTC enrichment by Metacell. Cells which are bigger than 8 
µm are caught on the membrane. After washing (RPMI medium), plastic ring keeping the membrane 
is then separated from tube and placed into the culturing wells. After cultivation (3-5 days), the 
membrane can be moved out of the plastic rings and placed directly on the microscopic slide. Cells 




3.2.2. Cytomorphological analysis 
After 3-5 days of in vitro cultivation, cytomorphological analysis of cells by 
fluorescent microscope was performed. Nucleus and cytoplasm of viable cells were 
stained by vital fluorescent dyes NucBlue® Live ReadyProbes® Reagent (Thermo 
Fisher Scientific, USA) and Celltracker™ Green CMFDA Dye (Thermo Fisher 
Scientific, USA), respectively. Stained cells were captured (magnification x40) by 
C software, Olympus IX51 fluorescent microscope with built in camera (Olympus 
U-RFL-T power supply unit) and identified using standardized cytopathologic 
criteria for CTC, which include: nuclei larger than 10µm, proliferation, presence of 
tridimensional cell-sheets, high nuclear/cytoplasmic ratio, prominent nucleoli, 
irregular nuclear membrane, visible cytoplasm, cells size above 15 µm. After 
cytomorphological analysis, cells captured on the membrane (membrane fraction) 
and meanwhile growing under the membrane (bottom fraction) were both disrupted 
by 600 µl of Buffer RLT + β-mercaptoethanol and stored at -20 oC, respectively. 
3.2.3. Gene expression analysis 
White blood cells enrichment from whole peripheral blood  
In total, 800 µl of Buffer EL (Qiagen, Germany) and 200 µl of peripheral blood 
were mixed together and incubated for 10-15 min on ice. After centrifugation of 
this suspension at 400 x g for 10 min at 4oC supernatant was removed and discarded. 
Pellet of the cells was resuspended with 400 µl of Buffer EL by pipetting and this 
mixture was centrifuged at 400 x g for 10 min at 4oC. Supernatant was completely 
removed and discarded. This procedure was completed by adding 600 µl of Buffer 
RLT supplemented by β-mercaptoethanol to the cells pellet. This suspension was 
mixed by pipetting and stored at -20oC until RNA/DNA was isolated.  
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RNA isolation and reverse transcription reaction 
All of the samples for RNA isolation were stored in Buffer RLT + β-
mercaptoethanol solution. After defrosting (if there were stored in freezer, at -
20oC), RNeasy Mini Kit (Qiagen, Germany) was used for RNA isolation. Particular 
fractions of cells were analysed (1. white blood cells (WBC), 2. enriched cells 
(virgin CTC), 3. cultured cells on the membrane (membrane fraction CTC) and 4. 
cultured cells invading the membrane and setting up a colony under the membrane 
(bottom fractions).  
Sample types differed in studies. Concentration of RNA was measured by 
NanoDrop™ 2000 Spectrophotometer (Thermo Fisher Scientific, USA). 
High-Capacity RNA-to-cDNA™ Kit (Thermo Fisher Scientific, USA) was used for 
cDNA synthesis. Reaction components were added according to manufacturing 
instructions as showed in Table 14. 
Table 14: Instructions for preparing reverse transcription reaction mix (per 20 µl reaction) 
Component Volume/Reaction (µl) 
2X RT Buffer 10 
20X RT Enzyme Mix 1 
Sample Up to 9  
Nuclease-free H2O To 20  
Total per Reaction 20 
 
Tubes with reaction mix were centrifuged and placed to the thermal cycler 
(ELISABETH PHARMACON, spol. s r.o., The Czech Republic). Conditions in the 





Table 15: Instructions of optimized conditions for High-Capacity RNA-to-cDNA™ Kit 
Step Temperature (oC) Time (min) 
Step 1 37 60 
Step 2 95 5 
Step 3 4 ∞ 
 
Analysis of gene expression 
After the reverse transcription reaction, differences between particular fractions 
were detected by qPCR analysis of tumor- and/or stem-cells like- and/or resistance-
associated genes. For gene expression monitoring in the samples TaqMan™ Gene 
Expression Assays (Thermo Fisher Scientific, USA) were used. Conditions in the 
cycler were set according to manufacturing instructions as shown in Table 16 and 
monitored genes are listed in Table 17. 
Table 16: Instrutions to program the thermal-cycling conditions for the real-time PCR 
Step Temperature (oC) Time (sec) Number of cycles 
UNG Incubation* 50 60 1 
Enzyma activation 95 20** 1 
Denature 95 1 40 
Anneal/Extend 60 20 
*Optional, for optimal UNG activity 




Table 17: List of Taqman assay codes for gene expression profiling of tumor associated genes and 
genes associated with chemoresistance.   
Name Assay Hs number 
MDR1 ABCB1 Hs00184500_m1 
MRP1 ABCC1 Hs01561502_m1 
MRP2 ABCC2 Hs00166123_m1 
MRP4 ABCC4 Hs00988717_m1 
MRP5 ABCC5 Hs00981087_m1 
MRP7 ABCC10 Hs00375701_m1 
ActB ACTB Hs01060665_g1 
CD24 CD24 Hs02379687_s1 
CD44 CD44 Hs01075861_m1 
CD68 CD68 Hs02836816_g1 
EpCAM EPCAM Hs00158980_m1 
Her2 ERBB2 Hs01001580_m1 
ERCC1 ERCC1 Hs01012158_m1 
ESR ESR1 Hs00174860_m1 
KRT18 KRT18 Hs01920599_gH 
KRT19 KRT19 Hs01051611_gH 
MUC1 MUC1 Hs00159357_m1 
PGR PGR Hs01556702_m1 
CD45 PTPRC Hs04189704_m1 
MGB SCGB2A2 Hs00935948_m1 
 
Results of genes expression were processed, evaluated and charted by GenEx 
software (MultiD Analyses AB). Several groups had been set in measured data 
which were based on patients, fraction type (WBC, virgin CTC, membrane fraction 
CTC and bottom CTC fraction), HR and HER2+ primary tumor status, results of 
cytomorphology and genes expression analysis and monitored genes. Beta-actin 
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(ActB) gene was selected as reference gene due to its stability and enough amount 
presence in all of the tested samples. Normalization to this reference genes was 
performed which corresponds to ΔCq calculation. Relative quantities process was 
the next step of pre-processing. Quantity our samples were given to relation with 
WBC fraction of corresponding withdrawal. This step corresponds to ∆∆Cq 
calculation. Relative RNA amounts are showed in log2 values. Data in particular 
groups were compared visually in bar graphs by Mann-Whitney test (2-tailed). 
Hierarchical clustering of samples and genes was combined displaying the 




4. Results and comments 
The research accompanying this PhD thesis was aimed to CTC in various cancer 
diagnoses with main focus on breast cancer. Peripheral blood samples were 
withdrawn from cancer patients and CTC were enriched by size-based separation. 
Further processing of CTC included their microscopic and molecular analyses that 
confirm their presence and provide detailed characterisation. 
4.1. Breast cancer 
The published data of Publication I (page 212) report the dynamics of CTC 
changes in 20 patients diagnosed with early BC. This CTC status was monitored 
for a period of the 6-24 months. Enrolled patients had received neoadjuvant 
chemotherapy (NACT) before surgery and their detailed clinicopathological 
characteristics are showed in Table 10. CTC were analysed cytomorphologically 
and by gene expression. Gene expression analysis was provided for tumor- and 
chemoresistance-associated genes and stem cell-like markers. All together 20 genes 
were tested per CTC-positive sample. Individual long-term monitoring of medical 
treatment and CTC status was performed in all of the 20 patients. 
Tumor response for NACT was monitored by bimanual palpation and ultrasound 
examination approximately at the time of blood withdrawal for CTC examination. 
According to these results tumor regression / progression were observed and 
responders / non-responders were identified. Tumor mass regression was assessed 
as very significant (response rate 3, more than 50% regression), moderate (response 
rate 2, 50% regression), minimal (response rate 1, less than 50% regression) and no 
regression observed (response rate 0).  
Subsequently, correlation between tumor regression and CTC was studied. 
Significant effect of AC and TAX was reported in 40% and 23% of patients where 
CTC positivity was detected in 87.5% and 75% of patients, respectively. Among 
non-responders, 85%-100% CTC positivity was detected. (Table 18) Based on the 
data on tumor volume regression, we may assume that tumor regression was not 
associated with CTC positivity in our patients’ sample receiving NACT.  
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Table 18: Overview of tumor volume regression during NACT in Publication I 
  CTC  Regression of tumor volume (Response rate - RR)  
  












group              













group              







- - - - - - - - 
After  
AC 
16/18                  
(88) 
1/20           
(5) 
1/1              
(100) 
7/20                
(35) 




3/4                        
(75) 
8/20      
(40) 






)    
13/18             
(72) 
3/17                 
(18) 
3/3                     
(100) 
9/17           
(53) 




1/1               
(100) 
4/17            
(23) 
3/4                  
(75) 
 
The Publication II (page 238) is focused on CTC - testing in 167 BC patients. They 
were divided into several groups based on their disease status and 
clinicopathological criteria. These parameters were detected by standard medical 
examination of primary tumor.  
Four BC case reports in the context of CTC are described in Publication III (page 
244). CTC presence and character have been monitored for long-term (6-24 
months). Most of the blood withdrawals were evaluated as CTC-positive. CTC 
results were evaluated in relation to the clinical status of each individual and their 
future perspectives. 
Following questions were asked regarding CTC studies in BC patients 
Does CTC character differ from primary tumor features? 
Does the cancer cells morphology and molecular profile develop in the course of 
disease?  
Are the molecular markers of the disease changing during treatment process?  
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Is the evolution of BC primary tumor molecular heterogeneity detectable by CTC 
molecular characterization?  
Do CTC reflect real-time disease status?  
Could CTC contribute to assess disease prognosis? 
Does expression of chemoresistance associated genes on CTC indicate worse 
therapy response during NACT?   
Results of BC research are described below for each scientific paper 
Publication I (page 212) 
CTC positivity was also evaluated in relation to particular tumor types. We had 
found the highest CTC positivity in the peripheral blood of patients with ESR+ and 
HER2+ tumors corresponding to 90% and 91%, respectively. The lowest, 76% was 
detected in patients with TNBC primary tumors. (Table 19)  





CTC + samples 
at all 
CTC + during 
NACT 
CTC +  at 
any time  
ESR+ 5/20 27/30 (90 %) 1/13 (8 %) 1/27 (4 %) 
HER2+ 6/20 38/42 (91 %) 12/15 (80 %) 18/38 (47 %) 
TNBC 9/20 28/37 (76 %) 12/18 (67 %) 19/28 (68 %) 
plus (+) represents positive 
 
Consistence of ESR+, HER2+ and TNBC expression was also studied. Our results 
showed relatively low concordance between primary and CTC, 1/13 and 1/27 in the 
ESR+ tumor type throughout the whole monitoring type. Higher accordance 
between primary tumor and CTC was observed in HER2+ and TNBC tumors not 





Table 20: Status of primary tumor and CTC in relation to tumor types and neoadjuvant 
chemotherapy 
Primary tumor  
CTC  
ESR+ ESR- HER2+ HER2- 
NACT - any time NACT - any time NACT - any time NACT - any time 
ESR+ HER2- 
1/13 (8 %) - 1/27 
(4 %) 
12/13 (92 %) - 
26/27 (96 %) 
4/13 (31 %) - 7/27 
(26 %) 
9/13 (69 % ) - 
20/27 (74 %) 
ESR- HER2- 0/18 - 0/28 
18/18 (100 %) - 
28/28 (100 %) 
6/18 (33 %) - 9/28 
(32 %) 
12/18 (67 %) - 
19/28 (68 %) 
ESR+ HER2+ 
0/10 - 5/26 (19 
%) 
10/10 (100 %) - 
21/26 (81 %) 
9/10 (90 %) - 
13/26 (50 %) 
1/10 (10 %) - 
13/26 (50 %) 
ESR- HER2+ 
3/5 (60 %) - 3/12 
(25 %) 
2/5 (40 %) - 9/12 
(75 %) 
3/5 (60 %) - 5/12 
(42%) 
2/5 (40 %) - 7/12 
(58 %) 
plus (+) represents positive; minus (-) represents negative 
Monitoring of CTC was performed in a regular manner from diagnosis through 
NACT to post-surgery follow-up period. As part of this process, real-time CTC 
characteristics were examined by gene expression analysis. It had been showed 
CTC features were changing not only in the case of tumor-specific characteristics 
but also in chemoresistance-associated features. Our results indicated that several 
epithelial markers and chemoresistance-associated genes expression during NACT 
had seemed to be linked with positive clinical effect of treatment. Surprisingly, 
CTC negativity was detected only in the cases of relevant clinical response 
(response rate as set by ultrasound) (RR=2 or 3), after AC (patient no. 2, 8 and 14) 
or TAX (patient no. 2, 5, 7, 13 and 17) therapy. On the contrary, CTC of patients 
with poor clinical response (RR=0 or 1) had usually higher expression of two or 
more chemoresistance-associated genes detected and number of these genes was 
increased throughout treatment. (Table 21)  
Except chemoresistance-associated markers, other characteristics of CTC had been 
monitored. Changes of ESR and HER2 expression status during NACT were 
dynamic. Several different scenarios occurred. Higher HER2 gene expression level 
was detected only before NACT (patient no. 16), during therapy (patient no.12), in 
several peripheral blood withdrawals (patient no. 3, 4, 5, 6, 8, 9, 10) or in none 
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(patient no. 13, 14, 15, 17, 18, 19, 20) of them. (Table 21) On the other hand, ESR 
was detected in 4 CTC samples of 3 eBC patients (patient no. 7, 8, 12) in our 




Table 21: Overview of status of CTC presence and characteristics and clinical effect of neoadjuvant chemotherapy.  
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Changes in epithelial and stem-cells like features were detected. Most of the 
patients exhibited exclusively CTC with higher levels of epithelial markers before 
NACT (KRT19, EpCAM, mucin 1 (MUC1), etc.). Increased stem cells-like (CD44, 
CD24) characteristics expression was observed in CTC during or after NACT 
therapy. There were patients with elevated stem cells-like markers expression also 
before NACT. (Table 21)  
After NACT, the surgery had taken place and status of both disease and CTC was 
monitored in several patients. CTC were observed in 100% at different time points. 
Regarding CTC characteristics, in patients with ESR+ tumor type CTC with 
epithelial features were detected more frequently in comparison with stem cells-
like. Although certain trends in disease behaviour were observed, development of 
both CTC and tumor tissue(s) was individual in each patient monitored. (Table 21) 
Publication II (Page 238) 
Overall result of CTC positivity examination in this study was 76% from the 
patients with BC. (Figure 19) Patients were the divided into groups based on their 
stage, histopatological characteristics, menopausal status, tumor size, nodal 
involvement, grade, hormonal receptors and HER2 status of primary tumor and 
therapy state.  
 
Figure 19: CTC enriched from peripheral blood of breast cancer patients after cultivation on the 
membrane after vital fluorescent staining with NucBlue™ and CellTracker™. Bar represents 10 µm 




Regarding histopathological characteristics we had identified the lowest CTC 
positivity, 44.4%, in ductal carcinoma in situ (DCIS) patients’ group. The highest 
percentage, 82%, was showed within grade 3 (G3) patients’ group. The menopausal 
and premenopausal group showed 55.5% and 78.4% of CTC - positive samples, 
respectively. Impact of therapy on CTC presence had been also studied. We found 
high CTC occurrence in the groups before therapy and surgery which were 82.3% 
and 86.6%, respectively. Group of patients who were undergoing hormonal therapy 
showed 52.9% CTC positivity. CTC had been examined also in the relationship 
with primary tumor and HR and HER2 status. The highest CTC positivity was 
detected in HR- HER2+ and the lowest in patients with HR+ HER2- primary tumors 
corresponding 100% and 70.3%, respectively. In patients’ groups with primary 
tumors characteristics as ESR+ PGR- and ESR+ PGR+, CTC were identified in 
60% (9/15) and 73% (68/93) of tested samples, respectively. In ESR+ tumors CTC 
occurred in 96.7% (30/31) of samples. 
The second part of this study was a regular long-term monitoring of 20 BC patients 
during the course of the disease. CTC samples were analysed by both 
cytomorphological and molecular examination. Gene expression tests have been 
focused on ESR and HER2 status of CTC. This analysis had revealed difference 
between primary tumor and CTC in ESR and HER2 expression. Although 12 of 
these patients had been diagnosed with TNBC, HER2 status changed from HER2- 
to HER2+ in at least four cases (33.3%). Similarly, 50% (3/6) of patients who had 
been initially HER2+ changed to HER2-. In the case of ESR status; it had been 
changed only from ESR+ to ESR- (3/3) in our patients’ sample.  
Publication III (page 244) 
The results of the research in reported paper is processed in the form of case study 
reports. Patients’ no. 1, 2, 3 and 4have been diagnosed with BC and their monitoring 
outcomes are dscribed below. 
Patient No. 1 (TNBC; 34 years old, woman) underwent 3 blood withdrawals 
presented in this study. There were 2 CTC examinations during neoadjuvant 
treatment and 1 CTC analysis after primary tumor surgery. At the time of diagnosis 
gene expression of KRT18, KRT19, MUC1 and MRP1 increased in CTC. After AC 
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(doxorubicin + cyclophosphamide) treatment KRT18, KRT19, VIM, ALDH and 
MRP1, MRP7 and ERCC1 were elevated. Primary tumor grew from 28 mm to 32 
mm (35 mm according to final histology) during neoadjuvant therapy. The last 
withdrawal was performed 1 month after surgery, increased level of CD44 and 
MRP1 was reported. None of the CTC examination had confirmed increased 
expression level of HER2 or HR. 
Patient No. 2 (TNBC; 44 years old, woman) underwent long-term CTC monitoring. 
Before start of NACT following genes were increased in enriched CTC-fraction: 
KRT18, KRT19, MUC1 and MRP1. Surprisingly, elevated level of HER2 in CTC 
was also confirmed. Although after surgery there were still CTC detected, after 
radiotherapy treatment CTC were no longer present in peripheral blood of this 
patient. During adjuvant chemotherapy (capecitabine) treatment, patient was 
evaluated as CTC-positive again. This withdrawal had revealed CTC clustering and 
increased expression of mesenchymal markers, such as VIM and ALDH. 
Expression of HER2 was confirmed in CTC only before the therapy.  
Patient No. 3 (TNBC; 29 years old, woman) was tested for CTC presence 
exclusively in the postoperative period (adjuvant setting (AS)). During AS the 
doxorubicin + cyclophosphamide – docetaxel (AC-D) treatment, CTC have 
expressed epithelial characteristics; in the follow-up period mesenchymal features 
were in prevalence. First withdrawal was provided at the start of AS (AC-D 
treatment) and EpCAM, KRT19, ESR and MRP1 gene expression was increased in 
the CTC fraction. During therapy, CTC expressed MUC1, KRT19, HER2 (not ESR 
anymore), MGB, MRP1 and MRP7, at the end of treatment epithelial characteristics 
and MRP1 with ERCC1 were increased. None of the HR or HER2 showed elevated 
expression. In the follow-up period, expression of mesenchymal genes started to be 
increased even though number of CTC had a decreasing tendency. 
Patient No. 4 (BC - ESR+, PGR+, HER2+; 39 years old, woman) underwent 6 blood 
withdrawals for the purpose of CTC examination and all of them were evaluated as 
CTC positive. Although at the time of diagnosis two genes, HER2 and KRT19 were 
increased, after NACT (AC therapy) epithelial (EpCAM, KRT19, MUC1), 
mesenchymal (CD44), HER2 and chemoresistance-associated (MRP1, MRP5, 
118 
 
ERCC1) genes were increased. After another therapy with docetaxel + herceptin 
(DH), genes CD24, CD44, KRT19, ESR and MRP1 expressed elevated expression 
levels. Although CTC features were changing, size of the primary tumor diminished 
from 31x25 mm to 12x15 mm. During another treatment, firstly with tamoxifen + 
herceptin and later with tamoxifen alone, the patient generalized into central 
nervous system (CNS) and CTC expressed KRT18, KRT19, CD24, CD44, MRP1, 
Adenosine Triphosphate - Binding Cassette Subfamily C Member 2 (MRP2) and 
MRP5. Shortly after CNS metastasis diagnosis the patient died.  
Comments and conclusion of BC research are described below 
Several important aspects of CTC were taken into notice in this research. 
Microscopical evaluations, expression analysis of genes and detailed 
personalization had been studied to better understand their potential for early, 
advanced or metastatic BC patients. 
Some of the researches had confirmed that CTC are an independent prognostic 
factor in BC. On the contrary several of them have found correlation between CTC 
count and positive lymph nodes or HER2 status of the primary tumor. (Bauer et al., 
2018; Cherdyntseva et al., 2017; Riethdorf et al., 2017; Mego et al., 2017; Bidard 
et al., 2016; Van Dalum et al., 2016; Usiakova et al., 2014) Our study presented as 
Publication II (page 238) reported the lowest CTC positivity in DCIS carcinoma 
and in menopausal women. The highest CTC positive patients were observed in 
grade 3 of primary BC tumors and premenopausal BC patients.  
Since the first step of CTC analysis is cytomorphogical evaluation, changes in CTC 
number and morphology may be the useful indicator of actual disease status and 
therapy efficiency. Previous studies have already confirmed CTC enumeration and 
morphological character in various part of treatment can be independent prognostic 
factor. They may help with patients’ stratification and predictive biomarker for 
therapy selection in numerous cancer types. (Sundling and Lowe, 2018; Li et al., 
2018; Riethdorf et al., 2017; Yan et al., 2017; Potdar and Lotey, 2015) In the 
Publication III (page 244) morphological dynamics of CTC was monitored and 
several individual cases were observed. CTC numbers have been decreasing 
(patient no. 3) or increasing (patient no. 2) throughout therapy. Other situation 
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occurred in the case of CTC - clustering and aggressive growth at the membrane 
(patient no. 1) which was supposed to unfavourable as the CTC in cluster have 
greater ability to metastasize compared with single CTC. (Cherdyntseva et al., 
2017) 
Our study that is reported as Publication I (page 212) is focused on patients treated 
with NACT. Several researches have confirmed CTC as an independent prognostic 
biomarker for these patients and it was also in accordance with our study. (Bidard 
et al., 2018; Riethdorf et al., 2017) During monitoring period we found CTC 
presence in all sampling points (not only during NACT but also after surgery and/or 
following therapy). These samples revealed persisting CTC (patient no. 8 and 17) 
or CTC-negative blood withdrawal (patient no. 6, 10 and 11) despite pCR 
achievement followed by NACT (patient no. 6 and 17). Indeed, CTC positivity after 
several months or years after primary diagnosis is not a rare event. Similar studies 
have confirmed their occurrence in blood 2 years after chemotherapy or 5 years 
after primary eBC diagnosis even without any clinical signs of disease recurrence. 
(Trapp et al., 2018; Bauer et al., 2018; Sparano et al., 2018) 
Other important results had been obtained regarding HR and HER2 status of 
primary tumor presented in Publication II (page 238). These parameters are linked 
closely to the treatment choice based on primary tumor status. (Al-Mahmood et al., 
2018; Hortobagyi et al., 2018; Bøttcher et al., 2018; Loibl and Gianni, 2017) In our 
patients samples the highest CTC positivity was detected in blood samples before 
surgery and/ or before therapy. The lowest CTC numbers were observed in patients 
during hormonal therapy. Although studies had confirmed lower CTC count after 
therapy in most cases, a decrease in CTC number is not clearly associated with 
TNBC type. (Cabel et al., 2017; Yan et al., 2017; Van Dalum et al., 2015) This 
attitude is consistent with our results as CTC positivity after neoadjuvant therapy 
was 77.7% 
Apart from CTC presence examination, gene expression analysis of ESR and HER2 
in CTC was performed. These results were then compared with primary tumor 
status. We found the lowest concordance status in patients with ESR+ BC diagnosis 
whereas higher concordance rate was observed in TNBC and HER2+ in our 
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patients’ sample presented in Publication I (page 212). Our study reported as 
Publication III (page 244) also confirmed that the concordance between CTC and 
primary tumor is not always the case. There were several different situations that 
occurred; CTC of patients with TNBC had expressed neither HER2 nor receptors 
through all long term-monitoring (patient no. 1); partial accordance CTC and 
primary tumor at the time of diagnosis (patient no. 4) or discordance of CTC and 
primary tumor at the time of primary tumor characteristics determination (patient 
no. 3). Researchers from other groups demonstrated different concordance rates and 
found CTC were often negative or HER2 positive in their studies. Occurrence of 
HER2+ CTC in TNBC patients was not occasional. They had also revealed the 
highest discordance in ESR between CTC and primary tumor in various stage of 
BC. (Bittner et al., 2018; Brown et al., 2019; Jaeger et al, 2017; Aktas et al., 2017) 
It was found HER2+ CTC had usually prevailed during disease evolution. They 
were also detected in peripheral blood of patients who had been previously 
classified into HER2- CTC group. (Pierga et al., 2018; Agelaki et al., 2017) 
Gene expression analysis in our study presented in Publication II (page 238) 
revealed that CTC status changed from HER2- to HER2+. This discordance 
between primary tumor tissue and CTC is not rare event. Frequency of discordance 
rates has not been clearly identified in bigger cohorts and remained individual. 
Routine long-term monitoring of BC heterogeneity from diagnosis through therapy 
and follow-up phase could be promising strategy for better outcomes achievement. 
(Aktas et al., 2018; Agelaki et al., 2017; Ellsworth et al., 2 
CTC usually represent a heterogeneous sub-population of cells with different 
biological behaviour or ability to metastasize. CTC population undergoes changes 
during therapy. (Kaigorodova et al., 2018; Cherdyntseva et al., 2017) During long-
term monitoring we found CTC character in terms of other genes expression had 
changed through therapy. Markers KRT18, KRT19, EpCAM, MUC1, CD24 and 
CD44 genes expression was monitored in CTC obtained from our patients enrolled 
into studies presented in Publication I (page 212) and Publication III (page 244). 
However, these changes were highly individual. Since at least one of the keratins 
was expressed in majority of our patients’samples, other important markers were 
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expressed differently in certain sampling points. Expression of EpCAM marker was 
evaluated as it is essential molecule for enrichment and detection process of CTC 
by several methods. (Sharma et al., 2018; Pugia et al., 2017) Whereas CTC of 
patients no. 6 and 18 showed higher EpCAM expression only in the first withdrawal 
or exclusively during NACT (patient no. 1), patient no. 10 demonstrated increased 
expression of this marker entirely in the fifth blood withdrawal (24 months after 
diagnosis) in Publication I (page 212). Another study confirmed that although CTC 
expressed epithelial features at the start of therapy, they changed to mesenchymal 
or stem cell-like markers till the next withdrawals (patients’ no. 1, 3, and. 4) as 
presented in Publication III (page 244). Other researches had also supported the 
hypothesis of variable EpCAM expression in CTC and its loss had been considered 
as a result of dynamic changes during EMT. (Aaltonen et al., 2017; Bredemeier et 
al., 2017; Wang et al., 2017) 
In regard to stem cells markers, CD24 and CD44 genes, expression on CTC we 
report differences between the different sampling times in Publication I (page 
212). It has been found that undifferentiated tumor cells with CD44+/CD24-/low gene 
expression profile play important role in cell proliferation, tumorigenesis, relapse 
and metastasis in BC patients. Approximately one-third out of all circulating cells 
shows this character. (Bai et al, 2018; Li et al, 2017; Zarzynska, 2017) Identification 
of these cells has been determined to circulate in the body throughout whole disease 
and may be helpful in metastasis recognition from early stages. (Dasgupta et al., 
2017; Mansoori et al., 2017) 
Regular examination of chemoresistance-associated markers in CTC-positive 
samples was provided as part of the Publication I (page 212). Based on this 
research, we could observe differences between responders and non-responders via 
CTC character. A minimum of chemoresistance-associated genes was expressed on 
CTC of responders. In the group of non-responders usually two or more of these 
markers were overexpressed. Detailed research also revealed that elevated MRP1 
expression corresponded to the after - AC effect. We also detected significant 
progression-free survival rate difference between groups of patients with higher 
expression of more and less than four increased chemoresistance-associated 
markers in CTC. Studies published by other groups had showed similar results. 
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Increased expression of resistance-associated markers may be helpful in various 
aspects of disease monitoring. Whereas patients with drug resistant CTC profiles 
exhibited progressive disease, those with drug sensitive CTC characteristics had 
partial/complete response or stable disease. Moreover, chemoresistant CTC 
indicated significantly shorter PFS in comparison with the other group. Their 
predictive value has been also examined. CTC with higher expression of 
chemoresistance-associated genes were predictive of chemotherapy resistance. 
(Adamska et al., 2018; Ween et al., 2015; Eroglu et al., 2013) 
4.2. Ovarian cancer 
CaOV belongs to the most common and serious malignancies of the women 
reproductive system. In most cases, it is diagnosed in the advanced stage because 
early-stage disease is often asymptomatic and late-stage disease symptoms are 
nonspecific. This fact has seemed to be the cause of its high mortality. It had been 
found that only around 25% of these tumors are diagnosed by the time when tumor 
is still present in the ovary. The cure probability in the CaOV is getting worse with 
the disease spreads. (Smith, 2017; Doubeni et al, 2016) 
In the studies of CTC in CaOV patients, cytomorphological together with gene 
expression analysis were provided. Together 56 and 118 CaOV patients in different 
stages were enrolled into this research presented as Publication IV (page 261) and 
Publication V (page 269), respectively.  
Following questions were asked regarding CTC studies in CaOV patients 
Is enrichment of CTC by MetaCell® effective enough for obtaining of viable CTC 
and representative heterogeneous CTC sample? 
Could CTC examination significantly enhance in the CaOV staging process in 
patients with recurrent disease?  
Is there a difference in molecular character of CTC developing under different 
environment conditions (e.g. chemotherapy, radiotherapy, in vitro culture)? 
Results of CaOV research are described below for each scientific paper 
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In our patients’ sample in Publication IV (page 261), 32 (58%) of them were 
assessed as CTC-positive and 24 (42%) were included in CTC-negative group 
based on cytomorphological examination. (Figure 20) 
 
Figure 20: Cultivated CTC on the membrane from ovarian cancer patients after enrichment and 
short-term cultivation in publication IV. Cells were stained by NucBlue™ and CellTracker™ and 
captured by fluorescent microscope. The bar represents 10µm. (adapted from Kolostova et al., 2016) 
 
Our results in Publication V (page 269) showed that 77 out of 118 (65.2%) CaOV 
patients, enrolled into our study, were evaluated as CTC-positive based on 
cytomorphological evaluation (Figure 21). Although no significant correlation 
between CTC and lymph nodes involvement was found in this study, in the case of 
more severe disease status (higher grade, worse FIGO stage) CTC were detected in 
more than 2/3 of the cases.  
Out interest in Publication V (page 269) had been also focused on correlation of 
CTC presence with other patients‘clinicopathological characteristics. Patients with 
ascites, peritoneal carcinomatosis and residual disease had been evaluated as CTC 
positive in 73.6% (39 out of 53), 70.5% (43 out of 61) and 75.0% (42 out of 56) in 
our study.  
Another important CaOV marker CA125 had been studied in the context of CTC 
presence in Publication V (page 269). We concluded elevated level of CA125 
could be a reliable marker of peritoneal spread and CTC presence could be a 





Figure 21: CTC of CaOV patient on the membrane after enrichment and cultivation in publication 
V. Cells were stained by NucBlue™ (nucleus, blue colour) and CellTracker™ (cytoplasm, green 
colour) and displayed by fluorescent microscope (pictures A-D). The bar symbolizes 10µm. CaOV, 
ovarian cancer (adapted from Kolostova et al., 2015) 
 
Information on real time disease development in cancer patients can be obtained 
not only from CTC presence but also from their characteristics. One of the 
mechanisms of shedding the CTC from tumor tissue is EMT. Subpopulations of 
CTC with various morphological features and molecular character have been found. 
Moreover, CTC have been circulating in early tumor patient, too. (Chang et al., 
2019; Guo et al., 2018; Zhang et al., 2018) 
After cytomorphological analysis, genes expression analysis was performed in 
samples of 40 CaOV patients in Publication IV (page 261). Four fractions for every 
patient have been tested: peripheral blood leukocytes (fraction 1 sample type 1), 
CTC fraction stored immediately after enrichment procedure (fraction 2 sample 
type 2), cultured CTC fraction grown on the membrane (fraction 3 sample type 3) 
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and CTC fraction which pass through the membrane and grew at the bottom of 
cultivation plate (fraction 4 sample type 4). Relative gene expression for monitored 
markers regarding different sample types is shown on the figures below. (Figure 22 
and Figure 23) 
 
Figure 22: Relative gene expression of monitored markers regarding each sample types in 
publication IV. Sample type-1, whole peripheral blood; sample type-2, CTC fraction stored 
immediately after enrichment procedure; sample type-3, cultured CTC fraction grown on the 
membrane; sample type-4, CTC fraction which pass through the membrane and grew at the bottom 
of cultivation plate. (adapted from Kolostova et al., 2016) 
 
The results of gene expression analyses showed noticeable increase of tumor-
associated genes in both CTC - enriched and also CTC - cultivated fractions. Single 
CTC enrichment by size-based MetaCell® device had resulted in higher level of 
cytokeratin-7 (KRT7), KRT18, KRT19, EpCAM, wilms tumor 1 (WT1) and mucin 
16 (MUC16) in CTC fraction if compared to peripheral blood samples (sample type 
1). (Figure 22) Results had become more powerful in the case of enriched CTC 
fraction after short-term in vitro cultivation. Gene expression analyses revealed 
elevated level of KRT7, KRT18, KRT19, EpCAM, MUC1 and MUC16 in fraction 
3 in comparison with peripheral blood with statistically significant differences (p < 
0.02). (Figure 22 and Figure 23) These results had strongly indicated not only 




In the next step, gene expression analysis of chemoresistance-associated genes was 
performed. The analysis included following genes: MRP1, MRP2, MRP4, MRP5, 
MRP7, ATP binding cassette subfamily B member 1 (MDR1) and ERCC1. 
According to the findings, all of these genes were expressed in excess if compared 
to peripheral blood. (Figure 23) 
 
Figure 23: Relative gene expression of all of the monitored markers considering two sample types 
in publication  - whole peripheral blood and cultured CTC fraction grown on the membrane. Sample 
type-1, whole peripheral blood; sample type-3, cultured CTC fraction grown on the membrane. 
(adapted from Kolostova et al., 2016) 
Comments and conclusion of CaOV research are described below 
This research has been focused on CTC examination by the means of CTC 
enrichment, cytomorphological and molecular analysis in patients with different 
stages of CaOV. Since this disease is known for its aggressiveness and usually later 
stages diagnosis, biomarkers for recognition and monitoring have been studied for 
decades. Although the progress in this field was remarkable and initial therapy 
(surgery, chemotherapy) is usually successful, recurrence and treatment failure 
occurs in most of the patients. New biomarkers are still essentially needed for better 
outcome of CaOV patients’ achievement. (Markowska et al., 2018; El Bairi et al., 
2017) 
One of the most challenging parts within CTC analysis process is enrichment 
mainly because of their rarity and heterogeneity. (Ma et al., 2018) Enriched sub-
population of cells should represent actual situation of cancer cells in peripheral 
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blood of the individual patient which is not the case of one or several specific 
markers-based isolation. (Muinao et al., 2018; Markowska et al., 2018) In our study 
size-based enrichment by MetaCell® was used and vital cytomorphological analysis 
revealed 58% and 65.2% as CTC-positive in Publication IV (page 261) and 
Publication V (page 269), respectively. These results were in agreement with gene 
expression analysis in 92% of samples. Based on the results, we can conclude size-
based enrichment by MetaCell® is appropriate method for viable CTC enrichment 
in CaOV. CTC are able to grow and divide under the laboratory conditions for both 
short- and long-term (not a part of presented CaOV publications) cultivation.  
Significant correlation had been confirmed between CTC presence and ascites, 
peritoneal carcinomatosis and residual disease. Our results had out performed the 
hypothesis that CA125 levels and CTC are two independent CaOV markers, which 
has been confirmed in other studies, too (Cheng et al., 2017) 
Microscopic analysis was followed by multimarker genes expression examination. 
Since CTC population is not homogenous, tumor- and chemoresistance-associated 
markers were tested for deeper revealing of CTC character in our samples. Our 
heterogeneous genes expression results suggest our enrichment method is effective 
enough to obtain representative CTC patients sample. Increased expression not only 
tumor-associated but also chemoresistance-associated genes in our patients’ 
samples were detected. Features of CTC have been also developing through time 
based on current environment (f.e. chemotherapy) which can result from therapy 
failure. (Chebouti et al., 2017) Moreover, CTC may be useful biomarker of minimal 
residual disease detection after surgery removal of tumor in CaOV patients. 
(Obermayr et al., 2017) Real-time monitoring can be helpful in early detection and 
therapy response prediction. (Zhang et al., 2018; Cheng et al., 2017)  
4.3. Other cancer diagnosis 
Patients diagnosed with another cancer(s) were monitored during their treatment 
process in the form of individual case studies. The Publication III (page 244) has 
been issued as a report of 8 cancer patients with CTC dynamics long-term 
monitoring in time. Patients were diagnosed with BC (case studies of patients’ no. 
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1-4 are presented under “Breast cancer” section of Results and comments), CRC, 
prostate and lung cancer.  
Following questions were asked regarding CTC study in various cancer diagnoses 
The study should answer the question, how to use CTC in clinical practice based 
on the data with obtained in time following the dynamics of the cancer disease.  
Do CTC reflect whole cancer disease heterogeneity? 
Are CTC ready to be used in clinical practice at all?  
Could be a personalized therapy implemented at all? 
Results of research are described below 
Publication III (page 244) 
Patient No. 5 (CRC; 35 years old, man) underwent CTC examination after primary 
surgery and two relapses. This withdrawal was evaluated as CTC positive where 
KRT18, KRT19, MUC1 and MRP4 genes showed increased expression. After 
FOLFIRI (leucovorin + fluorouracil + irinotecan) chemotherapy regimen and after 
the third relapse, another CTC analysis revealed higher expression of KRT18, 
KRT19, MUC1, VIM, Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) 
and MRP1 genes. RAS status was examined with negative results for liver 
metastasis and CTC. 
Patient No. 6 (Rectal adenocarcinoma, 50 years old, man) started with CTC 
examination after surgery and lungs generalization. All of the CTC analyses were 
evaluated as CTC positive. The cells expressed epithelial characteristics, 
chemoresistance profile showed MRP1 and ERCC1 in the first blood withdrawal 
and two additional genes (RRM1, Ribonucleotide Reductase Regulatory Subunit 
M2 (RRM2)) were elevated in the second withdrawal. The third CTC analysis was 
provided by means of cytomorphology only, the last CTC test revealed increased 
expression of KRT18, thyroid transcription factor 1 (TTF1), MRP1 and MRP4 
genes in CTC fraction. The disease progressed and new lesions in bones were 
detected. This patient died because of new lesions in CNS. 
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Patient No. 7 (Lung cancer, 47 years old, man) who’s first CTC analysis was 
provided during carboplatin and pemetrexed therapy resulted in detection of 
elevated gene expression for: KRT18, KRT19, EpCAM, MUC1, MRP1 and 
ERCC1. Later on, CTC examination revealed not only mesenchymal 
characteristics, VIM expression, but also more chemoresistance-associated 
markers, such as MRP1, MRP2, MRP4, MRP7 and ERCC1.  
Patient No. 8 (Duplicate tumor CRC and PC; 57 years old, man) monitoring CTC 
analysis revealed there are cells expression epithelial (KRT18, KRT19), stem cells-
like (VIM, ALDH), prostate (AMACR) and vascular endothelial growth factor 
(VEGF) markers in the patient peripheral blood. 
Comments and conclusion of research are described below 
The Publication III (page 244) reports long-term monitoring of cancer patients, for 
whom the CTC examination might bring unique treatment management option. 
Their status in aspects of CTC-count and CTC-character has been changing 
dynamically through treatment process. 
Another step in presented CTC examination is gene expression analysis. Results of 
our study have supported the opinion of CTC dynamic changes during therapy. 
Changes of chemoresistance-associated markers expression have occurred 
frequently. Increasing levels of these markers can also reduce therapy efficiency 
(patient no. 1, 6). These dynamics of CTC can allow real-time monitoring of 
individual patients disease status. 
The heterogeneous nature of tumor disease has been confirmed in various cancer 
types. Researchers have revealed this character at the multiple levels; between 
primary tumor and metastasis, between metastasis themselves and also within 
tumor tissue. (Sokolenko and Imyanitov, 2018; Zhang et al., 2016) Moreover, 
primary tumor and CTC have not always shared the same characteristic. (De Kruijff 
et al., 2018; Liu et al., 2017; De Gregorio et al., 2017; Kulemann et al., 2017) 
This publication had demonstrated individual development of cancer disease for 





Cancer is a systemic disease and its initial prognosis and predictions are not always 
consistent with the current disease development. Patients can experience increase 
in tumor volume or metastasis forming despite complete surgical removal of the 
primary tumor, receiving targeted medicinal products or general improvements in 
medical care.  
For sure, a regular monitoring of the disease status is a necessary part of the 
treatment schedule and tumor biopsies and imaging methods are considerably 
involved in. These procedures have often an invasive character, especially in cases 
where tumor is not easily accessible due to its location. (Schaffner et al., 2020; 
Liikanen et al., 2018; Dasgupta et al., 2017; Tang et al., 2017; Wu et al.,2017; 
Zhang et al., 2017; Shiozawa et al., 2015; Tu et al., 2014; Pantel and Alix-
Panabieres, 2014) 
Cancer cells released from primary or metastatic tumor mass reaching 
patients’blood seem to be a useful marker for real-time tumor disease monitoring. 
However, their occurrence is very rare and their fate in circulation rather unclear. 
Although it has been suggested that CTC half-life in bloodstream is about 1-2 hours, 
these cells can be detected 8-22 years after mastectomy in BC patients. (Cote and 
Datar, 2016) 
In fact, CTC examination relies on peripheral blood withdrawal which is a 
minimally invasive procedure. Peripheral blood, seen as a source of CTC for LB 
analysis, is the only prerequisite of the regular CTC-monitoring during whole 
treatment process. (Yamada et al., 2019; Zapatero et al., 2017; Potdar and Lotey, 
2015; Karachaliou, et al., 2015) There are usually several treatment options 
considered for a patient before the final decision of the therapeutic schedule is 
agreed. Biomarkers are significant help within this decision processes. (Coates et 
al., 2015; Burstein et al., 2014) A biomarker has been defined as a characteristic 
that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or biological responses to a therapeutic 
intervention. (Kessler et al., 2015)  
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Enrichment of viable CTC is believed to play a significant role in experimental 
functional assays. CTC present a great challenge due to their natural characteristics 
such as incidence, heterogeneity or adaptability. Occurrence of CTC in patients’ 
blood has been estimated to be 1 - 10 CTC in 106-108 WBC or 1-100 CTC may be 
found in 1 ml of whole blood. (Ecke and Thomas, 2019; Gard et al., 2018; Liu and 
Hu, 2017; Shen et al., 2017) Also, CTC are highly heterogeneous population 
considering both biological and physical properties. Enrichment strategies relying 
on a single CTC-feature has not obtained reproducibility and clinical relevance so 
far. A significant ratio of CTC is able to survive in unfavourable environment in 
circulation by several mechanisms such as phenotype alteration which avoids them 
from immune system attack. (Luo et al, 2018; Yang et al., 2017; Meyer et al., 2016) 
Numerous methods have been developed for CTC enrichment and detection in the 
last decade. A size-based enrichment protocol (Metacell®) has been implemented 
in clinical studies of various cancer types. This technology allows obtaining of 
viable and unmodified CTC without implementation of pre-processing procedures 
or any physical force during enrichment. The artificial overpressure or vacuum 
which are used in the most of the size-based enrichment methods to regulate the 
filtration flow, can result in cells damage, too. (Bhagwat et al., 2018; Kang et al., 
2017; Song et al., 2017; Gabriel et al., 2016) The size-based captured cells are 
heterogeneous, vivacious and contain both single cells and clusters that enable 
further downstream cellular and molecular analysis including set up of both short- 
and long-term in vitro cultures as has been discussed in presented publications I-
V. 
Research of CaOV CTC (Publication V, page 269) evaluated 118 patients with 
CaOV who were candidates for surgery or surgical diagnostics. 77 out of 118 
(65.2%) patients were evaluated as CTC positive and short-term in vitro CTC 
cultures were established. Gene expression analysis confirmed heterogeneous 
expression profile of captured cells. The results confirmed that CA125 level and 
CTC may behave as two independent biomarkers for lymphogenic and 
haematogenous dissemination in CaOV patients, respectively.  
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In the study of Rao et al., CTC positivity was detected in 87% of patients with 
CaOV if CTC were captured by microfluidic system with immunomagnetic beads. 
(Rao et al., 2017) Other results have been reported by Obermayr et al. who observed 
CTC positivity at the time of diagnosis and 6 months after completion of adjuvant 
therapy in 26.5% and 7.7% of CaOV patients, respectively. CTC enrichment was 
provided by density gradient centrifugation and followed by multi-marker 
immunostaining. (Obermayr et al., 2017) Gebauer et al. reported CTC positivity in 
32.3% of CaOV patients using CellSearch system and confirmed presence of CTC 
was not correlated with FIGO stage, nodal status or grading factors in CaOV 
patients. (Gebauer et al., 2017)  
In the molecular study of CTC in patients with CaOV (Publication IV, page 261) 
cytomorphological and molecular analysis of enriched cells was performed. 56 
patients with CaOV were enrolled into this study and 32 out of 56 (58%) were 
evaluated as CTC positive. Gene-expression analysis confirmed heterogeneity of 
the population of CTC enriched and cultured by size-based Metacell® protocol 
examinating tumor-associated genes expression. We found increased expression of 
EpCAM, KRT7, KRT18, MUC16 and WT1 genes in CTC-enriched fraction and 
elevation in EpCAM, KRT7, KRT18, KRT19, MUC1, MUC16 and WT1 genes 
expression after 3 days of CTC - in vitro culture. This study has also supported the 
idea of multi-marker instead of single-marker analysis. In the recent paper of 
Balakrishnan et al. enriched CTC were used to set up a short-term cluster culture. 
This study had confirmed that captured cells were cytokeratines positive and CD45-
negative after 14 days of in vitro culture. (Balakrishnan et al., 2019) Outcomes of 
these studies support the hypothesis of immune cells depletion during in vitro 
culture. 
Similar analysis was also performed in the study of 167 patients with various BC 
stages (Publication II, page 238). CTC examination revealed CTC positivity in 127 
patients. Further cytomorphological and tumor-associated gene expression analysis 
revealed the highest CTC occurrence was identified in the group undergoing 
surgery and before the start of neoadjuvant treatment. In this study HER2 and ESR 
receptors, routinely examined in primary tumor, were evaluated in CTC. These 
markers are being used to stratify BC patients with early disease and are used as 
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predictive markers for targeted therapies, too. (Schaffner et al., 2020) It has been 
widely accepted that expression status of these key receptors differs between 
primary tumor and metastasis. (Aaltonen et al., 2017) Our testing also found that 
status of these markers can differ between primary tumor and CTC. Research 
in this area is still not delivering consistent results. Although some of the studies 
demonstrated significant discordances in receptors status on CTC and in primary 
tumor tissue, other studies reported similarities between them. (Braun et al., 2019; 
Wang et al., 2017; Beije et al., 2016; Wallwiener et al., 2015; Kalinsky et al., 2015; 
Onstenk et al., 2015) One of the possible explanations could be coexistence of cells 
that display different phenotypic characteristics. (Castro-Giner and Aceto, 2020; 
Jordan et al., 2016) In any case, this discordance can significantly affect treatment 
response of BC patients. 
Long-term CTC monitoring was performed in the study presented as collection of 
case reports (Publication III, page 244) where patients with BC, CRC, prostate and 
lung cancer were involved. Individual cases were analysed for CTC and clinical 
perspective of the CTC test results. In this publication, several aspects of CTC 
monitoring are described. Cytomorhological evaluation was concentrated on 
showing CTC numbers in responders and non-responders. The CTC numbers 
differed in the patients with the same disease type undergoing the same treatment. 
Size-based label-free enrichment was used and heterogeneous CTC population was 
obtained. In total, 24 out of 34 (70.6%) samples were evaluated as CTC-positive. 
Molecular analysis revealed that EpCAM, KRT18/19 and MUC1 gene expression 
was increased in 2, 23 and 7 out of 34 samples, respectively. This study supports 
the idea of the long-term cancer patients monitoring. Continuous CTC-monitoring 
after primary treatment is a tool how to follow the CTC-persistence in the blood. 
Persistence of CTC after primary treatment significantly increases relapse risk. 
Recent study of Trapp et al. published that CTC presence 2 years after 
chemotherapy significantly increased a risk of relapse in eBC patients. (Trapp et 
al., 2019) Similar outcomes have been reported by Sparano et al. who studied 
association of CTC with late recurrence of ESR+ BC patients. They reported that 
CTC positivity 5 years after diagnosis had provided independent prognostic 
information for clinical recurrence. (Sparano et al., 2018) 
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The last presented study of eBC patients (Publication I, page 212) included a long-
term monitoring for both cytopathological and molecular CTC character of 20 
patients diagnosed with eBC. These patients underwent CTC examination in the 
time of diagnosis, during NACT (after AC therapy, after TAX treatment), after 
surgery and in the next follow-up period. We monitored CTC during the course of 
treatment and found that CTC-positivity is not associated with tumor volume. The 
study confirmed that receptors status is not always the same in primary tumor and 
CTC. According to our results, during NACT, the highest concordancy rate in 
receptor expression was observed in patients with TNBC and HER2+ primary 
tumors. On the other hand, CTC of patients with ESR+ primary tumors showed the 
lowest concordancy rate regardless of their HER2 status. Long-term monitoring 
revealed each of the patients monitored experienced an individual disease 
development. Our publications emphasize importance of personalized treatment. 
Although chemotherapy regimens are often an essential part of the cancer 
treatment, its success rate can be low due to intrinsic or acquired chemoresistance 
mechanisms. (Briz et al., 2019) Monitoring of genes associated with 
chemoresistance has become an important part of our CTC studies. We monitored 
gene-expression of chemoresistance-associated genes in different cancer case 
studies and in the study of early BC patients (Publications II and III, pages 238 
and 244). In the Publication III (page 244) a prolonged CTC-monitoring revealed 
an expression of different chemoresistance-associated genes for various diagnoses. 
The development of chemoresistance has been confirmed also in eBC patients 
(Publication I, page 212). Despite importance of individual features of the disease 
progress, some of the findings were significant and common for several patients. In 
non-responders group, two or more chemoresistance-associated genes often 
showed increased expression and these CTC characteristics changed dynamically 
during treatment process. Worse therapy outcome was observed in patients with 
CTC that expressed chemoresistance markers. Frequent overexpression of MRP1, 
MRP2 or MRP7 was observed in our patients although another 9 patients with TAX 
chemoresistance showed elevated expression of MRP2, MRP7 or MDR1 before or 
during TAX therapy. Based on our observations, resistance patients expressed 
elevated levels of MRP1 during AC and MRP1 and MRP7 during TAX treatment. 
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ERCC1 overexpression was detected in 4, 3 and 2 patients before, during and after 
NACT, respectively and MRP1 was co-expressed in 8 of the 9 cases. We have also 
observed epithelial signs of CTC and minimal chemoresistance-associated genes 
expression during NACT correlated with positive clinical effect of AC or TAX. 
Recent research of Shlyakhtunou et al. confirmed CTC heterogeneity in primary 
non-mBC patients. This study has also revealed elevated expression of MRP7, 
MRP1, MDR1 and MRP5 in 37/69 (54%), 37/69 (54%), 24/69 (35%) and 14/69 
(21%) of BC patients included in this study, respectively. (Shlyakhtunou, 2018) 
Gradilone et al. classified patients into “drug sensitive” and “drug resistant” groups 
based on MRPs expression and found that the resistant group has significantly 
shorter PFS than the sensitive patients. Detailed analysis also confirmed that 
patients whose CTC expressed two or more MPRs were having shorter PFS than 
those who expressed zero or one of the MRPs. Furthermore, this research had 
clearly connected MRP1 and MRP7 with resistance to AC and TAX, respectively, 
which is in concordance with our results. (Gradilone et al., 2010) In another study 
Kasimir-Bauer et al analysed ERCC1 in CTC. 72% of residual CTC obtained from 
peripheral blood of BC patients after NACT expressed ERCC1 which indicated 
them as therapy resistant population. Awareness of this information may help 
clinicians with decision of further therapy. (Kasimir-Bauer et al., 2016) Approaches 
which would be able to pair treatment targeting the predominant, drug-sensitive 
population in addition to various subsets of drug-resistant and drug-tolerant cells 
may lead to the most-durable responses achievement. (Dagogo-Jack and Shaw, 
2017) 
 
EMT and stem cell-like characteristics of cancer cells have been also considered as 
major importance in metastatic progression. (Schaffner et al., 2020) Previous 
studies confirmed presence of tumor cells which survive in the blood, pass through 
EMT and can exist in intermediate stages expressing both epithelial and 
mesenchymal markers. This cell phenotype has been found to contribute to 
resistance of anti-cancer therapies including AC and TAX. Part of this 
heterogeneous CTC population may manifest stem cells character. The stem cell 
character promotes therapy resistance, survival facilitation or metastases. (McInnes 
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et al., 2015; Yu et al.,2013; Bonnomet et al.,2012; Lecharpentier et al., 2011; 
Raimondi et al., 2011) Although CTC with elevated expression level of EMT or 
intermediate phenotype occured more frequently in patients with metastatic in 
comparison with early-stage disease, their presence is not rare so their significance 
should not be underestimated. (Lowes and Allan, 2018; Pal et al., 2015; Papadaki 
et al., 2014)  
Markers that characterize these features were included into our testing. We have 
identified these types of cells by CD24, CD44 in study of eBC patients (Publication 
I, page 212) and together with ALDH1 and VIM genes-expression analysis in study 
of case reports (Publication III, page 244). We observed differences in stem cells 
markers expression in ESR+ and other BC subtypes in study of eBC patients 
(Publication I, page 212). Although in the cases of ESR+ primary tumor CTC with 
CD24/CD44 characteristics were detected more often after surgery in comparison 
with epithelial features (patient no. 1, 2, 7, 14 or 15), patients with more aggressive 
tumor types (HER2+ primary tumor diagnosis) showed CTC with these markers 
overexpressed from the beginning of disease (patient no 9, or 12). However in study 
of eBC patients (Publication I, page 212) most of the TNBC patients overexpressed 
CD24 and/or CD44 markers in their CTC from the time of diagnosis (patient no. 
10, 11, 13, 16, 17, 19, 20), study of case reports (Publication III, page 244) showed 
3 TNBC case reports each with different EMT and stem cell-like features during 
CTC development. In the patient no.1 we observed changes in CTC regarding EMT 
and stem cells-like characteristics. None of these markers was overexpressed in the 
CTC from the first blood withdrawal, VIM, ALDH1 and CD44 gene expression 
was elevated in the second, third and fourth blood collection, respectively. The 
expression level of CD24 and CD44 elevated from the diagnosis time point and 
during the most of her blood withdrawals in the CTC of patient no. 2. As next, VIM 
and ALDH1 markers were overexpressed later during the monitoring, after 15 
months. Recent study of Akkiprik et al. reported CTC with stem-cells properties 
were found in most HR+, HER2- cases and their high incidence was also observed 
in the cases of early metastasis. (Akkiprik et al., 2020) 
Our studies declare patients individual CTC development in time considering the 
different markers monitored. Most of the BC patients included in our studies 
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overexpressed EMT and stem cells-like markers in the corresponding CTC. 
Presented studies have also contributed to the hypothesis that circulating cancer 
cells may become a helpful tool for individual patients‘disease characterization and 
provide benefit for early detection and therapy personalization as transition status 
between epithelial and mesenchymal cells subpopulation changed dynamically. 
(Mansoori et al., 2017; Grosse-Wilde et al., 2015; Liu et al., 2014) 
Despite all efforts, metastasis may take place after a long period after surgical tumor 
removal without any symptoms’ appearance. Metastasis has been major cause of 
cancer-related death. Understanding and proper monitoring of this process may 
bring disease treatment process improvement. (Chitty et al., 2018; Gomis and 
Gawrzak, 2017; Liu et al., 2017) 
CTC showed to reflect cancer disease more accurately than biopsies, they are highly 
heterogeneous and more affortable in comparison with classical biopsies. 
Additional studies are needed to explore their use and potential in cancer disease 
monitoring, treatment and patients’ life quality improvement. (Brown et al., 2019; 






The presented PhD thesis was focused on CTC, their isolation, in vitro culture, 
cytomorphological description and molecular characterization. Based on our 
results, following could be concluded: 
1. Size-based enrichment (MetaCell®) of CTC in patients diagnosed with solid 
tumor diagnoses was performed and successfully implemented into the 
diagnostic processes, reflecting purposes of special timing for CTC-tests in 
different cancer treatment periods (neoadjuvancy, adjuvancy, palliative). 
Patients with BC, CaOV, lung, CRC and prostate cancer were included into 
the testing. The enriched CTC (bigger than 8µm) were captured in a viable 
stage and were in the good fitness cultured for both, short and long time 
period in vitro.  
2. Enriched and cultivated cells were observed using vital fluorescent 
microscopy. Following cytomorphological criteria were applied and 
evaluated to identify tumor cells in CTC samples: nuclei larger than 24µm, 
cell size at least 1.5 times larger than white blood cells, irregular nuclei and 
nuclear membrane, anisonucleosis, high nuclear/cytoplasmic ratio, presence 
of 3-dimensional cell sheets, presence of prominent nucleolus or several 
nucleoli. Significant differencies in CTC morphology of BC patients during 
treatment included also prevalent changes in CTC number and increased 
frequency of CTC clusters formation.  
3. Gene expression profiling of both tumor- and chemoresistance-associated 
genes was provided in CTC collected during NACT, surgery and in follow-
up period in BC patients. CTC expression profile has been analyzed 
reflecting disease and treatment dynamics. In patients who did not respond 
to NACT, two or more chemoresistance-associated genes showed elevated 
expression. The molecular characteristics of CTC were changing 
dynamically during treatment process.  
4. It was confirmed that molecular characteristics of tumor and CTC in BC 
patients may not be always concordant either in the time of diagnosis or 
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during treatment period. This has been confirmed in every of the presented 
publications (I-V). In the Publication III (page 244), CTC of TNBC 
patients have been HR and/ or HER2 negative in 78.5% of tested cases. In 
the Publication V (page 269), the change from HER2 negative to HER2 
positive status and vice versa was shown for 33.3% and 50% of BC patients, 
respectively. Status of HR (ESR) changed from ESR+ to ESR- in all of the 
patients monitored (3/3). Based on the results from Publication IV (page 
261) a high concordance rate of CTC and primary tumor was confirmed for 
TNBC and HER2+ BC patients. The highest discordance was revealed in 
tumors with ESR+ status independent of HER2 status.  
We can conclude that majority of CTC showed ESR- and HER2-negativity 
in HER2-negative primary tumors. On the other hand, in HER2-positive 
primary tumors, discordance of HER2 was detected in 50% of tested CTC 
samples.  
5. Gene expression analysis of CTC identified several CTC subpopulations in 
BC patients’ samples. We were able to identify CTC with epithelial, 
mesenchymal, stem cell-like and chemoresistance features during long-term 
monitoring of CTC (up to 36 months in total).  
6. Long-term monitoring in combination with real-time clinical assessment 
(ultrasonography) had allowed us to conclude that CTC of NACT 
responders overexpressed epithelial genes. In the case of the NACT non-
responders, increased expression of chemoresistance-associated genes in 




7. Prospective studies 
 
The intensive research of CTC has been conducted for the last sixteen years despite 
the fact CTC were first described in 1869 by Thomas Ashworth. The milestone for 
the increased interest was the work of Cristofanilli et al. that suggested CTC as 
potential prediction marker of OS and PFS. (Cristofanilli et al., 2004) Although 
during this period significant progress has been done in CTC characterization, more 
studies and investigation are necessary to reach and use full potential of CTC.   
In future, two main challenges of CTC need to be overcome: rarity and 
heterogeneity. These features cause their problematic enrichment and raise question 
regarding ability to obtain representative CTC sample from cancer patient. 
Numerous techniques based on different principles have been developed for CTC 
enrichment and detection; new approaches are still currently tested. Time necessary 
for processing or procedure types may cause damage to CTC and accurate CTC 
identification has remained challenge for researchers. (Yang et al., 2021; Cote and 
Datar, 2016) 
The other approach that could help with CTC enrichment is to increase the volume 
of the tested blood. The preliminary results suggested large volumes of blood from 
patient could significantly improve CTC enrichment efficiacy. It has been found 
that detection rate difference in 7.5 and 30 ml of blood sample is 13% and 47%, 
respectively. Practical outcome for the patients in the future could be either large 
sample volume or multiple blood withdrawals. (Eifler et al., 2011, Lalmahomed et 
al., 2010) Another question is setting up the correct CTC withdrawals frequency. 
Whereas low frequency could cause incorrect assumption or delayed diagnosis, too 
high frequency can result from misleading trend due to CTC oscilation. Number of 
studies need to be performed to set up the correct blood withdrawal frequency. 
(Leong et al., 2015) The fourth approach how to obtain representative CTC sample 
is to stabilize blood where CTC are enriched from. The fitness and vitality of the 
cancer cells in the collected blood is an important factor for their enrichment, 
characterisation and downstream analysis. (Yang et al., 2021) 
141 
 
The current effort is to use information obtained from CTC to help with cancer 
management and patients’ treatment process. Techniques of molecular analysis 
could be applied in personalized therapy and may help with cancer patients’ 
assignment into high- or low- risk group. Another approach could be applied in 
therapy regimens selection. Due to the fact that CTC are living and also sometimes 
proliferating, their characterisation could make us an advantage to be one step ahead 
– ability to identify prominent genetic feature in the disease relapse. 
(Diamantopoulou et al., 2020, Chemi et al., 2019) 
Future approach for treatment decision could also include ex vivo culture and drug 
screening. In the case of cancer patients therapy failure events are not rare 
particularly in advanced stages of disease when multiple therapeutics failures were 
observed. In these cases, small-scale model of the patients’ disease could help with 
identification of effective treatment combination. The limitation of this approach is 
time as cells need to be cultivated and following testing will take place in weeks or 
months period after blood withdrawal that can not reflect the current situation. 
(Diamantopoulou et al., 2020) 
The current idea of future CTC management is to obtain real-time information 
about disease status in individual patients. Potential of using cancer cells from blood 
is to identify aggressive CTC, new targets for therapies, discover cellular markers 





Circulating tumor cells (CTC) have showed great potential to become both 
prognostic and predictive biomarker in various types of oncological diseases. CTC 
can help detect patients in higher risk of shorter overall survival, progression-free 
survival or relapse. They can be also helpful in therapy selection as in current 
clinical practice treatment is chosen based on primary tumor characteristics. 
Regular CTC counts and features monitoring can be real-time indication of therapy 
response and can be used to guide-targeted treatment. This information can be 
implemented to personalized medicine and each cancer patient can be treated based 
on individual profile.  
However, patients’ sample with CTC is easily accessible, their detection has 
remained challenge due to low CTC number in the circulation and heterogeneous 
nature. CTC can circulate in blood in the form of single cells or in clusters that 
usually represent minority in comparison with single CTC but their metastatic 
potential is significantly greater than of single CTC. Apart from CTC count, the 
molecular character showed dynamic development and heterogeneous nature not 
only between patients but also within the individual patient’s tumor tissue itself. 
Character of primary tumor, CTC and metastasis are not always consistent and has 
been changing during treatment process which can significantly impact response to 
therapy. 
In this work, we used size-based CTC enrichment in various cancer diagnoses and 
monitored both CTC count and molecular character in regular intervals during 
treatment process. Cytomorphological and genes-expression analyses revealed 
dynamic disease development through whole treatment process. Fluorescent 
microscopy found count changes not only single CTC but also in CTC clusters 
presence. CTC behaviour also varied during withdrawals. While some of the CTC 
were able to survive only days during cultivation, there were enriched CTC 
fractions with aggressive growth and long-term cultures were established from 
them. Gene-expression CTC analyses of genes associated with tumor, epithelial-
mesenchymal transition, stem cells-like features and chemoresistence revealed their 
presence and dynamic change in expression levels. We found CTC character does 
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not correlated to corresponding primary tumor features. The outcomes of the CTC 





Cirkulující nádorové buňky (CTC) prokázaly velký potenciál stát se prognostickým 
a prediktivním biomarkerem u různých typů onkologických onemocnění. CTC by 
mohly pomoci detekovat pacienty s vyšším rizikem kratšího celkového přežití, 
přežití bez progrese nebo relapsu. Mohou být také užitečné při výběru terapie, 
protože v současné klinické praxi je léčba volena na základě charakteristik 
primárního nádoru. Pravidelné sledování počtu a charakteru CTC by mohlo být 
indikátorem terapeutické odpovědi v reálném čase a bylo by možné jej použít k 
cílené léčbě. Tyto informace by bylo možné implementovat do personalizované 
medicíny a každého pacienta s rakovinou léčit na základě individuálního profilu. 
Ačkoli vzorek pacientů s CTC je snadno dostupný, jejich detekce CTC zůstává 
výzvou zejména kvůli jejich nízkému počtu v krevním oběhu a jejich heterogenní 
povaze. CTC mohou cirkulovat v krvi ve formě samostatných buněk nebo ve 
shlucích, které se obvykle nevyskytují tak často jako jednotlivé CTC, ale jejich 
metastatický potenciál je významně větší než u samostatných CTC. Kromě počtu 
CTC, taky molekulární charakter vykazoval dynamický vývoj a heterogenní 
povahu nejen mezi pacienty, ale také v rámci nádorové tkáně pacienta. Charakter 
primárního nádoru, CTC a metastáz není vždy konzistentní a během procesu léčby 
se mění, což může významně ovlivnit reakci na léčbu. 
V této práci jsme použili metodu izolace CTC založenou na jejich velikosti u 
různých nádorových diagnóz a sledovali jsme počet a molekulární charakter CTC 
v pravidelných intervalech v průběhu léčby. Analýza cytomorfologie a genové 
exprese odhalila dynamický vývoj onemocnění v průběhu celého procesu léčby. 
Pomocí fluorescenční mikroskopie jsme pozorovali změny počtu nejen 
jednotlivých CTC, ale také CTC shluků. Vlastnosti CTC se také měnily mezi 
jednotlivými odběry krve. Zatímco některé CTC dokázaly během kultivace přežít 
jen několik dní, u jiných izolovaných CTC byl pozorován agresivní růst a založili 
jsme z nich dlouhodobé kultury. Analýzy genové exprese genů spojených s 
nádorem, epiteliálně-mezenchymálním přechodem, vlastnostmi podobnými 
kmenovým buňkám a chemorezistencí u CTC odhalily jejich přítomnost a 
dynamické změny v expresi markerů. Zjistili jsme, že charakter CTC nekoreluje 
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s charakteristikami odpovídajícího primárního nádoru. Výsledky výzkumu CTC 
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Characterization of circulating tumor cells in early breast cancer 
patients receiving neoadjuvant chemotherapy 
 
Abstract 
Aim/Background: The aim of this study was to characterize circulating tumor cells 
(CTCs) during neoadjuvant chemotherapy (NACT) in early locally advanced breast 
cancer (LABC) patients. Using ultrasound, tumor volume measurement was 
compared to the presence and the molecular nature of CTCs over multiple time 
intervals corresponding to treatment periods.  
Methods: Twenty patients diagnosed with breast cancer (BC) of different 
histotypes were monitored during the NACT period and in the follow-up period 
(~5years). Peripheral blood for CTCs (n= 115) was taken prior to NACT, after 2-3 
chemotherapy cycles, after the completion of NACT (before surgery) and at some 
time points during adjuvant therapy. CTCs were enriched using a size-based 
filtration method (MetaCell®) capturing viable cells, which enabled vital 
fluorescence microscopy.  A set of tumor-associated (TA) genes and 
chemoresistance-associated (CA) genes was analyzed by qPCR in the enriched 
CTCs fractions.  
 
Results: The analysis of tumor volume reduction after administration of 
anthracyclines (AC) and taxanes (TAX) during NACT showed that AC therapy was 
responsive in 60% (12/20) of tumors compared to TAX therapy which was 
responsive in 30% (6/20; n.s.). After NACT, CTCs were still present in 70.5% 
(12/17) of patients (responders vs non-responders, 61.5% vs.100%; n.s.).  
In triple-negative BC (TNBC) patients (n=8), tumor volume reduction was 
observed in  75% cases. CTCs were significantly reduced in 42.9 % of all HER2-
negative BC patients. In HER2+ tumors, CTC reduction was reported in 16.6% 
only. Relapses were also more prevalent in the HER2-positive patient group  (28.5 
vs. 66.6%). 
During NACT, the presence of CTCs (3 tests for each patient) identified patients 
with relapses and indicated significantly shorter progression-free survival (PFS) 
rates (p=0.03). Differentiation between progressive disease and non-progressive 
disease was obtained when the occurrence of excessive expression for CA genes in 
CTCs was compared (p=0.024). Tumor volume reduction was also significantly 
indicative for progressive disease (p = 0. 0224).   
Disseminated CTCs in HER2-negative tumors expressed HER2 in 29% of samples 
collected during the overall follow-up period (16/55), and in 32% of samples during 
the follow-up of NACT (10/31). The change accounted for 78.5% of HER2-
negative patients (11/14) in total. 63.6% of the conversion cases occurred during 
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NACT (7/11). For the remaining 4 patients (36.3%), conversion to HER2+ CTCs 
occurred later during adjuvant therapy. We believe there is a possibility to prevent 
further progression by identifying less responsive tumors during NACT using CTC 






Neoadjuvant chemotherapy (NACT) is mainly indicated for locally advanced breast 
cancer (LABC), which involves stage IIB (T2N1, T3N0) and stage III, including 
inflammatory breast cancer (IBC). NACT is implemented to reduce tumor volume 
to convert inoperable to operable tumors or to replace mastectomy with breast-
conserving surgery (BCS). NSABP B-18 and EORTC 1092 trials reported that 
application of NACT was connected mainly to downstaging of the disease (1-3).  
However, subgroup analysis of both trials showed the trend towards better outcome 
in patients under 50 years of age (1). The same benefit of adjuvant chemotherapy 
was reported in young premenopausal women (4) and women under 50 years of age 
(5). Moreover, early indication of NACT and response to doxorubicin (A) and 
cyclophosphamide (C) regimen yielded better disease-free survival (DFS) and 
overall survival (OS) compared to patients undergoing adjuvant treatment with 
docetaxel (D) in the B27 study (6). 
The current indication for NACT is based on tumor biology and is considered a 
treatment option in BC patients with a high risk of tumor dissemination and worse 
prognosis (7). The most important finding in neoadjuvant studies is the association 
between pathological complete response (pCR) and long-term clinical outcomes. 
pCR occurs mainly in patients with aggressive BC subtypes (8). Tumors showing 
high proliferation (Luminal B [HR+, HER2+], HER2+, TNBC) have higher rates 
of pCR compared to Luminal A (HR+, HER2-) (9). Post-treatment residual disease 
and Ki67 levels also seem to have prognostic significance (10,11). It is reported that 
particularly patients with extensive residual disease and Ki67 > 35% after NACT 
have significantly worse outcomes. The need for new biomarkers reflects the 
shortcomings of existing therapeutic options. Although AC and TAX regimens in 
NACT are considered standard clinical practice, recurrence due to clonal expansion 
and/or resistance of residual tumor cells due to treatment selection pressure occurs.  
The metastatic potential of BC could be stratified not only by primary disease 
subtype, but also could be measured by the presence of CTCs. Although their 
occurrence in the blood is very rare, CTCs have a significant prognostic value in 
patients with primary BC (PBC) and metastatic BC (MBC) (21-23). However, the 
clinical utility based on the predictive value of CTC enumeration remains uncertain. 
The genomic characteristics of CTCs may indeed be more important for therapy 
recommendation as suggested by the SWOG S0500 trial (24) as well as 
enhancement of patient outcomes (25,26).  
Clusters are one of the typical CTC characteristics that can be present in patients 
with BC. CTCs that are bound together may exhibit 23- to 50-fold higher metastatic 
potential than single CTCs (27,28). The presence of these clusters in peripheral 
blood of patients has been clearly associated with shorter progression-free survival 
(PFS), metastatic-free survival (MFS) and overall survival (OS) in various types of 
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BC compared to individual CTCs (28,29). 
Many enrichment methods have been successfully implemented into laboratory 
practice to enrich, detect and isolate CTCs from a simple blood draw. 
Immunomagnetic and size-based isolation techniques are the most commonly used 
(30-33). CTCs can be detected by immunofluorescence staining (34), laser scanning 
cytometry (35) or quantitative polymerase chain reaction (qPCR) (36).  
In the case of BC, several markers are known to have different expression ratios 
when non-malignant normal cells are compared to tumor cells, such as cytokeratin 
19 (KRT19), human epidermal growth factor receptor 2 (HER2), epithelial cell 
adhesion molecule (EpCAM), mucin 1 (MUC1), epidermal growth factor receptor 
(EGFR), mammaglobin (MGB), and maspin.  
Another promising marker that can be potentially used for BC diagnostics and 
therapy is the disialoganglioside GD2 subtype (GD2) due to its overexpression in 
tumors (37,38). A high prevalence of GD2 in aggressive BC subtypes such as MBC 
and TNBC was observed (39,40).  
A new targeted therapy with glembatumumab vedotin (CDX-011) is currently 
under evaluation in clinical trials. Its aim is to attack the glycoprotein non-
metastatic b (GPNMB) (41-43). Similarly, clinical trials confirmed the efficacy of 
sacituzumab govitecan-hziy, which is a trophoblast cell surface antigen 2 (TROP2)-
directed antibody-drug conjugate. Other clinical trials in TNBC and other MBC 
forms are currently ongoing (42, 44).  
 
Individually, these markers could be used for CTC identification at the molecular 
level. However, even greater specificity can be achieved by using a multi-marker 
assay to profile each marker simultaneously (45-48). In previous studies, the size-
based filtration system (MetaCell®) was found to reliably recover viable CTCs from 
BC patients for cytomorphologic evaluation. It also permitted CTC downstream 
molecular characterization.  
Despite clinical advances, in some patients, minimal residual disease (MRD) can 
persist and give rise to clonally advanced and resistant disease. Although it is known 
that phenotypic differences between primary tumor and CTCs exist (49-53), 
patients are still treated according to primary tumor characteristics. Recent 
therapeutic indications do not reflect the dynamic changes that occur in tumor cells, 
which are the target of chemotherapy. In this study, we compared tumor response 
during NACT with anthracyclines (AC) and/or taxanes (TAX) as measured by 
tumor volume with the presence and characterization of CTCs over multiple time 
intervals corresponding to standard treatment cycles. We reported the use of real-
time molecular characterization of chemoresistance and tumor-related genes 
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following size-based enrichment (MetaCell®) of CTCs in predicting therapeutic 
decisions and PFS.   
Patients and methods 
Study design 
In total, 20 BC patients undergoing NACT were enrolled in the study. The analysis 
was comprised of 115 blood samples obtained during regular medical examinations 
between 2014 and 2016. CTC assessment was performed prior to NACT, during 
NACT and/or before and after surgery. If NACT included sequential administration 
of AC and TAX, blood collection was usually performed before the first AC cycle, 
before the first TAX cycle and before the last TAX cycle. CTCs were enriched from 
peripheral blood (8 ml) by size-based filtration (MetaCell®, Czech Republic) (54). 
To provide more detailed study protocols, the figure is given to show a treatment 
plan for each patient in the Supplementary file SF1 Patient Follow-up. Figure 1 is 
an example and is related to patient no.7.  
Patient characteristics  
Table 1 and Supplementary File ST1 show patient characteristics. The median age 
of the group was 39 years. In the study, only one patient was postmenopausal (aged 
71 at diagnosis). Of NACT-indicated patients, 16 subjects were treated for LABC 
with lymph node involvement. Negative lymph nodes (N0) were reported in 4 of 
20 patients.  
Based on histological evaluation, BC was classified as invasive carcinoma of no 
special type (NST) in 5 cases, invasive ductal carcinoma (IDC) in 14 cases, or 
medullary carcinoma in 1 case. Most cancers (16/20) were poorly differentiated 
(grade 3; G3), 3/20 carcinomas were graded G2 and 1/20 carcinoma was well 
differentiated (G1). 
All patients presented with very aggressive disease based on proliferation 
parameters (Ki67) of tumor cells. 19/20 primary tumors exhibited Ki67 expression 
of at least 40%. Altogether, 12/20 tumors were estrogen receptor positive (ER+) 
and/or progesterone receptor positive (PR+), 6/20 patients were HER2 positive 
(HER2+). 9/20 patients were classified as TNBC. Patient no 7 was also classified 
as TNBC given that postoperative ER and PR status was negative. According to the 
subtype classification, 5 of 20 patients were HR+/HER2- (luminal A), 4 of 20 
patients were HR+/HER2+ (luminal B, HER2+), 2 of 20 patients were HR-/HER2+ 
(HER2-amplified/overexpressed), and 9 of 20 patients were TNBC (ER-, PR- and 
HER2-).  
Clinicopathologic features of each patient enrolled in the study (N=20) are reported 
in detail in Supplementary Table ST1, including details on individual risk 
(mutation, pregnancy etc.). NACT regimens and chemotherapeutic dosing are 
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reported in Supplementary file SF2 Methods. 
CTC examination  
CTCs were enriched from peripheral blood (EDTA/6-8 ml) by a size-based 
filtration method (MetaCell®, Czech Republic) (54). The enriched cells were 
incubated for 3-5 days in vitro (37oC, 5% CO2) and assessed in a two-step manner. 
Cytomorphologic evaluation of the viable cells by vital fluorescence microscopy 
(NucBlue®, Celltracker®, Mitotracker®, ThermoFisherScientific, U.S.) was 
followed by qPCR analysis of RNA isolated from CTC fraction. qPCR analysis 
included tumor-associated (TA) and chemoresistance-associated (CA) genes. For 
more details, please see Supplementary file SF2 Methods. 
Patient blood samples were classified as CTC-positive by combined microscopic 
evaluation and molecular analysis. In the cytomorphological analysis, fluorescently 
stained viable cells were scored according to the following criteria: nucleus size, 
nuclear membrane irregularity, prominent nucleoli, nucleoli count, cell size, and 
the presence of 2D and 3D cell sheets, etc. The recovered size-enriched fractions of 
cells captured on the membrane were lysed in RLT+ β-mercaptoethanol buffer and 
stored at -20oC for subsequent RNA analysis. 
The qPCR analysis was based on analyzing differences between the whole blood 
leukocyte fraction (white blood cell; WBC) and enriched CTC fractions (with and 
without in vitro incubation). The following TaqMan™ Gene Expression Assays 
(Thermo Fisher Scientific, U.S.) were used for gene expression monitoring in all 
samples: TA genes, including ACTB (control), CD24, CD44, CD45, CD68, 
KRT19, EpCAM, MUC1, MGB, HER2, ESR, and PGR, as well as CA genes, 
including MRP1, MRP2, MRP4, MRP5, MRP7, MDR1, and ERCC1. 
Based on gene expression analysis, CTC-enriched samples with elevated relative 
expression levels in two or more TA genes were considered CTC-positive when 
compared to their matched WBC samples. 
Statistical analysis 
The data were compared by standard tests using GraphPad Prism software vs. 9.1:0 
(GraphPad Prism, U.S.). The evaluation of qPCR data was based on the standard 
ddCT method (55). qPCR results were analyzed using GenEx Professional software 
(MultiD, SE), which enabled multifactorial comparisons between the involved 
groups. Relative RNA levels are shown graphically in clusters (Supplementary files 
SF2 Methods). The differences between the samples were compared by the U 





CTCs and tumor volume regression during NACT  
The effects of NACT were clinically evaluated by bimanual breast palpation and 
ultrasound examination at the time of blood collection for CTC tests. Regression of 
the tumor mass was assessed as significant (response rate - 3, RR=3) if the tumor 
volume was reduced by more than 50%, as moderate (RR=2) if the degree of 
regression was 50%, and as minimal (RR=1) if the degree of regression was less 
than 50%. For non-significant tumor regression or even progression, a response rate 
equal to zero (RR=0) was applied. Patients with RR= 2 and 3 were assigned as 
responders in the further analyses.  
The analysis of tumor volume reduction following the administration of AC vs. 
TAX during NACT showed that AC therapy was assessed as responsive in 60% 
(12/20) of tumors compared to TAX in 33.3% (6/20) (n.s.). The complex NACT 
effect was significant in 70% of patients in the tested cohort (14/20). Table 2 shows 
more details. The response rate was slightly higher in HER2-negative tumors when 
compared to HER2-positive tumors (64.2% vs. 50%; n.s.). 75% responsiveness was 
reported for TNBC (Table 3). 
CTCs were detected in 85% of patients (17/20) prior to NACT, in 88% of patients 
after AC therapy (16/18), in 72% of subjects after TAX therapy (12/18). No 
significant difference was found between the groups in terms of the presence of 
CTCs when the group of non-responders was compared to the group of responders. 
However, 100% CTC positivity was found for the non-responder group after NACT 
as compared to 61.5% CTC positivity in the responder group (Table 2).  
After completing NACT, reduction in CTCs was observed in more HER2-negative 
tumors compared to HER2-positive tumors (42.9% vs. 16.6 %) (n.s.) (Table 3).  
During the follow-up period (185-2455 days, mean 1862 days), 8/20 patients 
progressed (40%). During NACT, all of these patients were positive for CTC in all 
tests. The CTCs obtained from these samplings expressed an excessive number of 
CA genes (≤ 4). There was a significant difference in comparison of PFS rates 
between the group with the expression of more than four CA genes and the 
group with the expression of fewer than four CA genes during NACT 
(p=0.024). 
During NACT, the presence of CTCs (3 consecutive tests for each patient) 
identified patients with relapses and indicated significantly shorter PFS rates (p= 
0.03). Tumor volume reduction was also significantly indicative for progressive 
disease (p = 0. 0224).   
Overall, NACT did not significantly affect CTC positivity in the samples.  
After NACT, CTCs were still present in 70.5% (12/17) of patients (responders vs. 
non-responders, 100% vs. 61.5%; n.s.).  
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CTCs released from the HER2-negative tumors expressed HER2 in 29% of all 
samples collected during the whole follow-up period (16/55) and in 32% of samples 
from NACT follow-up (10/31). The change accounted for 78.5% of HER2-negative 
patients (11/14) in total. 63.6% of the conversion cases occurred during NACT 
(7/11). For the remaining 4 patients (36.3%), conversion to HER2+ CTCs occurred 
later during adjuvant therapy.  
During NACT, CTC reduction was observed in 42.9% of the HER2-negative 
patients, but only in 16.6% of the HER2-positive BC patients. Relapses were also 
more prevalent  in the HER2-positive patient group (28.5 vs. 66.6% n.s.) 
Complex information on NACT effects reflected in captured CTCs is shown in 
detail in Table 5 and Supplementary File ST1. Development of chemoresistance 
during NACT and adjuvant treatment is given in detail in Table 5 and 
Supplementary file SF Patient Follow-ups. The proportion of chemoresistant CTCs 
in the CTC fraction was related to worse therapy outcome. Resistant patients had 
elevated MRP1 gene during AC therapy and MRP1 and MRP7 genes during and 
after TAX therapy (Table 5). 
 
Changes in primary tumor characteristics and CTCs during NACT 
After completing NACT and surgery, definitive histology was compared with the 
pre-treatment biopsy (Supplementary file ST1). In most cases, the effect of NACT 
was linked to a significant decrease in Ki67. Only in 2 cases, the decrease in Ki67 
was very small or there was no decrease in Ki67 (patients no 9 and 14). The BC 
phenotype changed significantly in one patient (no 9; pregnancy during NACT). 
We hypothesize that the loss of ER and PR expression could be caused by 
termination of pregnancy. Insufficient duration of NACT and AC monotherapy 
could be the cause of a small decrease in Ki67.  
The loss of ER/PR+ expression under the influence of NACT is reported in the 
Supplementary file ST1. The distribution of primary tumors i.e., ER+, HER2+ and 
TNBC was as follows: 25%, 30% and 45%, respectively. The discordance in ER 
and HER2 expression in primary tumors and CTCs is given in Tables 4.1 and 4.2.   
The distribution of CTCs during NACT was discordant in patients with ER-positive 
primary tumors (only 8 % CTCs were ER+). During NACT, 80% of samples from 
HER2+ patients showed increased HER2-negative expression. Interestingly, the 
phenotypic evaluation of CTCs during NACT showed HER2+ CTCs in TNBC in 
32% and in 29% of samples during the follow-up. In HER2+ primary BC, 
discordance in HER2 status in CTCs was observed in nearly 50% cases. Therefore, 
in these patients, CTCs predominantly retained more aggressive properties. Tables 




Monitoring of BC treatment during NACT and after the surgical period 
During the follow-up (1-5.5 years), we observed relapse in 8 patients, 6 of whom 
died.  In our group of patients, the 1-year OS was 95 % (1/20 died), the 2-year OS 
was 78 % (3/20 died) and the 5-year OS was 70% (6/20 died).      
The follow-up of all patients enrolled in the study is shown in Supplementary File 
SF1 Patient Follow-ups. The follow-up protocols include reports on the presence 
and characterization of CTCs during disease monitoring. Specific attention was 
paid to patients who achieved pCR after NACT.  
Figure 1 shows the case of a young patient (no. 7) with LABC (medullary 
character). She underwent standard AC and TAX therapy with very good clinical 
effect (RR= 3), which was reported after TAX therapy. Although CTCs displayed 
no markers of chemoresistance before therapy, the expression was present during 
and after AC (the former with multi-resistant and the latter with AC-resistant CTC 
phenotype).  Interestingly, HER2+ and ESR1 (ER) expressing CTCs were present 
in either both or one of the later blood draws, respectively.  
The effect of TAX was confirmed both during the histological examination and 
MRD and the results showed pCR and CTCs negativity. As the primary tumor was 
ER-positive and PR-positive, the patient was still on adjuvant hormonal therapy. 
The first follow-up blood analysis conducted 5 months after surgery did not show 
CTCs, but the tests performed later (12 months and 15 months postoperatively) 
revealed MRD based on the presence of CTCs. Our data suggest that CTCs were 
not sensitive to hormonal therapy given by their increased expression of 
chemoresistance markers. Although the patient remained in clinical remission, the 




NACT is a standard approach in therapy of LABC and CTCs are believed to be 
associated with tumor aggressiveness. Studies have reported a lower prevalence of 
CTCs in PBC compared to MBC with positivity rates ranging from 22 to 23 % 
before NACT, from 10 to 17 % after NACT (56-58) and from 19 to 43 % in the 
adjuvant setting (59-62). Lavrov et al. detected CTCs in 38% of patients with early 
triple-negative disease and 42% of triple-negative LABC (63). By using multi-
cytokeratin-specific antibodies to detect CTCs, Serrano et al. observed CTCs in 70 
% of patients before NACT and in 54% of subjects after NACT (64).  Camara et al. 
reported an even higher frequency of 83% in patients prior to NACT (65).  
Pierga et al. detected CTCs in 39% of patients before the start of therapy and a rapid 
decrease to 9% after four cycles of chemotherapy (66). CTC analysis conducted by 
Sabatier et al. revealed 25 % and 8.9 % of CTCs-positive patients at inclusion and 
after one cycle of therapy, respectively (67). 
In our study, CTCs were detected in 85 % of patients before NACT and 70.5 % of 
subjects after NACT. The relatively high detection rate of CTCs in our cohort can 
be explained by a high prevalence of clinical risk factors (95% of young 
premenopausal woman, 75% of HER2+ and 45% of TNBC, 100% of tumors with 
high Ki67 and 80% patients with G3, and 75% of patients with LABC with 
lymphatic node involvement).  
Another explanation of high CTC detection rates may be the uniqueness of the CTC 
enrichment method used in the study protocol. The two-step detection protocol 
(MetaCell®) combining size-based filtration with cytomorphological and molecular 
characterization may identify more CTCs that go beyond the limited epithelial 
definition based only on EpCAM and cytokeratin expression (e.g. of 105 CTC 
samples analyzed by qPCR, increased expression of EpCAM was confirmed in only 
16 cases (15.2%), whereas the expression of KRT 18/19 was documented in 90 
(85.7%), HER2 in 34 (32.5%), MUC1 in 31 (29.5%) and MMG in 12 samples 
(11.4%).  
The presence of CTCs before or after chemotherapy was associated with worse 
outcome compared to patients who were persistently CTC-negative in the 
SUCCESS trial (68).  
Similarly, in the phase II AVASTEM trial, CTC detection at baseline was a 
prognostic marker for BC (NACT-bevacizumab combination independently of 
tumor response) (67). Many studies have clearly demonstrated a prognostic impact 
of CTCs not only in MBC but also in early BC (69-71). 
In our study, patients remained CTC-positive during NACT (85 % of CTC+ before 
NACT, 88% of patients after AC, 70.5% of subjects after NACT). It is expected 
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that under the influence of NACT, tumor cell mobilization occurs and the number 
of released proliferating CTCs decreases. On the other hand, CTCs released from 
the primary tumor induced by NACT can lead to an increasing number of CTCs or 
their fragments detected in the circulation. Additionally, it was shown that systemic 
response to treatment was independent of local response (72).  
Our analysis showed that TNBC tumors were more sensitive to NACT and the 
effect of AC was more significant in these tumors than the effect of TAX when 
tumor volume reduction was compared. 
Unfortunately, we cannot confirm the correlation between tumor shrinkage and the 
decrease in the number of CTCs due to the methodological limitations of 
MetaCell®.  
However, NACT responders were found mainly in the group of patients with CTCs 
expressing epithelial markers and CTCs with a minimal CA-gene expression. CTC 
negativity during NACT was found only in patients with the documented clinical 
effect (tumor volume reduction measured by ultrasound). In NACT non-responders, 
two or more CA-genes were usually frequently overexpressed in the CTC fraction.  
To answer the question of how long NACT should be administered in the case of 
permanent presence of CTCs, it needs to be elucidated whether the presence of 
CTCs has a more prognostic or predictive value. 
pCR is usually defined as the absence of invasive and non-invasive carcinoma in 
breast tissue. In the presented study, HER2+ tumors responded in 50% of cases, 
whereas TNBC responded in 75% (6/8) of cases. If we assume that aggressive 
cancer cells and CTCs may exist in these subtypes, we could hypothesize that pCR 
could be explained by the eradication of highly proliferating tumor cells (sometimes 
in significant numbers). In both aspects, the number and the characteristics of tumor 
cells could be equally important. Based on our observations, we conclude that CTC 
characterization could significantly supplement the information on the number of 
CTCs.  
Several neoadjuvant clinical trials in BC assessed the benefit of combining 
additional chemotherapy (e.g. capecitabine) or targeted therapy (e.g. bevacizumab) 
with a standard AC or TAX-based chemotherapy regimen. Although the results of 
combination regimens in HER2-negative tumors are unconvincing (12-14), 
targeted anti-HER2 therapy added to standard NACT improved significantly the 
outcomes for HER2-positive patients (15-17). In these studies, a higher incidence 
of pCR in ER-/HER2+ (HER2-enriched) subtype was also shown compared to 
ER+/HER2+ BC. For patients with TNBC who participated in the CALGB and 
GeparSixto trials, significant improvement in pCR rates in the breast and axilla was 
demonstrated when carboplatin was added to more complex neoadjuvant AC- and 
TAX-based regimens (18,19). In the GeparTrio trial (20), the benefit of switching 
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NACT in non-responding patients was evaluated. Patients with no clinical response 
to neoadjuvant TAC (docetaxel, doxorubicin, cyclophosphamide) were randomized 
to four additional cycles of the same regimen or four cycles of vinorelbine and 
capecitabine. Although the benefit for ER+ patients was outlined (DFS, OS), future 
studies are warranted to specify treatment according to the molecular profile of the 
disease. Thus, the need for new biomarkers reflects the shortcomings of existing 
therapy options. Although AC and TAX regimens in NACT are considered standard 
clinical practice, recurrence due to clonal expansion and/or resistance of residual 
tumor cells due to treatment selection pressure occurs. 
Clinical trials showed that NACT has the same benefit for patient prognosis as 
adjuvant therapy. It can be assumed that the higher volume of MRD in patients 
treated with NACT should have no effect on the risk of disease relapse. On the other 
hand, the prognostic value of CTCs is based on their rate in blood. However, 
detailed studies should be performed to find the connection between primary 
disease and the prevalence of CTCs.  
In our study, pCR after NACT was achieved in 4/9 TNBC patients. Despite pCR in 
the case of TNBC patients, all of their blood samples were assessed as CTC-
positive. The validation of prognostic significance of pCR is needed before we can 
say that the eradication of CTCs could be a new goal of treatment instead of pCR. 
CTCs can survive as non-proliferating, dormant cells, and are associated with 
higher resistance to chemotherapy (73). After the completion of NACT, we found 
a few cases with persistent multi-resistant CTCs refractory to therapy (CTC – 
samples were positive for more than 1 chemoresistance gene in 7/20 cases, 35%). 
Considering the higher significance of CTC characteristics, the question of how to 
treat resistant disease arises. One option could be related to the use of CTC-targeted 
therapy, while another one could be connected with the removal of the primary 
tumor rather than random systemic treatment. 
The significance of the status of CTCs after definitive treatment and their long-term 
persistence was assessed in many studies. The results obtained in the SUCCESS 
trial suggested CTC detection after chemotherapy was associated with shorter DFS 
and OS  (74).  
Van Dalum et al. reported a significantly shorter time to disease recurrence and 
death in women with detectable CTCs 1, 2 or 3 years after the end of adjuvant 
therapy or radiotherapy compared to CTCs-negative patients (75). Similar results 
were also obtained by Trapp et al. (76). Sparano et al. observed a 13-fold higher 
risk of recurrence in patients 5 years after diagnosis and without clinical evidence 
of disease when at least 1 CTC was detected at late time point (77).  
Negative results of the SWOG 0500 study could be based on the lack of CTC 
characterization. We found a significant discordance in ER and HER2 status 
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compared to primary disease and MRD. HER2+ primary tumors retained HER2+ 
CTCs, mainly during NACT, after which they lost sensitivity to anti-HER2 therapy, 
very often during adjuvant trastuzumab therapy. HER2 status changed very 
dynamically and CTCs retained aggressive properties in HER2-negative tumors. 
Up to 23% of the CTCs samples in HER2-negative tumors were confirmed to be 
HER2-positive. This percentage was found in 11 of 14 HER2-negative patients. 
This number should be highly considered in the context of HER2 aggressiveness.  
The comparison of responders and non-responders (patients developing disease 
relapse during adjuvant therapy) at the molecular level could complete our 
knowledge related to the significance of CTCs in the post-operative follow-up of 
patients as documented in the Supplementary file SF1 Patient Follow-ups. 
Prolongation of adjuvant hormonal therapy was shown to have clinical significance, 
confirming that the persistence of MRD exists long after surgery and requires 
longer treatment.  
We hypothesize that simultaneous CTC monitoring could predict the risk of disease 
relapse earlier and more accurately compared to standard tumor markers and 
imaging studies. Therefore, both the number and CTC characteristics can play a 
critical role.  
As CTC-guided therapy is not clinically indicated today, CTCs could be used only 
for  treatment response monitoring. Promising designs of new studies focused on 
the predictive value of CTCs and studies of large numbers of patients are the main 
prerequisite for defining the predictive value of CTCs (78-83).  CTCs could be used 
as a tissue source for testing sensitivity to different drugs in the future, which is 
highly attractive (84). 
Conclusions 
The relationship between CTCs and the response to tumor therapy was analyzed 
from the perspective of different tumor histopathology. We believe that monitoring 
of the presence of CTCs during NACT, including gene expression analysis of TA 
genes and CA genes, could identify patients at continuous risk and predict therapy 
outcomes. CTCs in patients with non-responding tumors expressed an excessive 
number of genes associated with chemoresistance.  
Ultrasound monitoring alone is perhaps insufficient, whereas the combination of 
ultrasound and CTC monitoring could prove to be beneficial and enable earlier 
detection of disease relapse. Therefore, in cases of non-responding tumors based on 
the volume and the presence of chemoresistant CTCs, it may be more effective to 
reconsider the duration of NACT and possibly to switch from AC to TAX or to 
discontinue NACT and proceed to surgery. There are no data on the prolongation 
of NACT beyond the standard duration. The results from adjuvant trials with 
metronomic dosing of chemotherapy or adjuvant systemic treatment during NACT 
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may clarify the connection between persistent MRD and patient outcome. We 
believe that CTC-targeted therapy may improve patient outcome even if used only 
for monitoring therapy response. Until the end of prospective trials targeting the 
predictive value of CTCs, the utility of CTCs and CTC-related information are 
limited to palliative indications or support adjuvant therapy choice (i.e., indication 
for adjuvant chemotherapy in TNBC to treat residual disease after NACT).  
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Figure 1. The schematic study protocol of patient no. 7  
The disease course, therapy administration (neoadjuvant, adjuvant period) and 
circulating tumor cell (CTC) sampling are documented over the follow-up period. 
Gene expression testing was performed for positive CTC samples. Genes listed 
under the CTC+ had higher expression in enriched CTC fraction than in paired 
white blood cell fraction. The figures clearly show the evolution of resistant cancer 
cell clones later during adjuvant therapy (Tamoxifen with Zoladex). Personalized 
graphic protocols for each patient in the study are included in the Supplementary 












































































































13.5. Publication V 
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